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[Abstract] Chen ZHANG, PhD thesis 
Metal-NHC Complexes for Anti-Cancer Applications: Gold(I) 
for Antimitochondrial Activity and Iridium(III) for 
Photodynamic Therapy 
In this work of thesis, several groups of novel NHC-based gold(I) complexes 
containing aliphatic and aromatic amino-side arms with interesting potential in 
biomedical applications have been synthesized and fully characterized. Also, a series 
of iridium(III) complexes containing NHC ligands with pronounced PDT anticancer 
activities has been prepared and fully characterized. 
The first group represents a family of cationic bis(NHC)-gold(I) complexes 
containing aliphatic amino-side arms. These complexes have been synthesized and 
investigated for their antiproliferative activities towards four human cancer cell lines 
and the non-cancerous MDCK cell line. In this series, the lipophilicity correlates 
directly with the cytotoxic activity against cancer cells. 
The second family of compounds concerns cationic gold(I) bis(NHC) complexes 
containing aromatic amino-side arms. The in vitro cytotoxicity of these complexes and 
proligands on the representative PC-3 prostate and T24 bladder cancer cell lines has 
been evaluated. All these complexes show higher Log P values (lipophilicity) than the 
first series of complexes, and in line with this higher cytotoxicity, nevertheless too high 
lipophilicity can also lead to lower selectivity. 
In order to develop a drug candidate with optimized activity and selectivity, we 
designed and synthesized the third family of cationic gold(I) bis(NHC) complexes. The 
Log P values of this series were between the first series and the second series. The lower 
cytotoxicity towards non-cancerous NIH3T3 cells was found for this series of 
complexes whereas they also displayed less activities towards cancer cells than the 
second series. 
The mechanistic studies on two gold complexes by monitoring the cellular uptake 
showed the rapid cellular accumulation of the intact gold bis(NHC) and a good 
bioavailability, in good agreement with the antiproliferative activity of these two 
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complexes. Moreover, both complexes inhibit TrxR, a common target for gold(I) 
complexes. The cell death induced by these two complexes was ROS-dependent. 
Besides anticancer activities, we also tested gold(I) mono-NHC complexes for other 
biomedical applications in parasite disease Leishmaniasis. They were screened in vitro 
against both promastigote and axenic amastigote forms of L. infantum. Moreover, their 
cytotoxicity was evaluated on the murine J774A.1 macrophages in order to determine 
their selectivity of action. 
Another topic of this thesis concerns iridium(III)-NHC complexes. Three families of 
theranostic iridium(III)-NHC complexes were prepared and characterized. The in vitro 
cytotoxicity of all the complexes against PC-3 prostate, T24 bladder cancer cells and 
non-cancerous NIH3T3 cells was evaluated. Moreover, all complexes are theranostic 
agents, and the confocal microscopy experiments of one complex showed that it can be 
quickly and effectively taken up into PC-3 cells and specifically localize into 
mitochondria. Interestingly, these complexes can act as efficient photosensitizers. The 
cytotoxicity of these complexes was increased substantially upon 365 nm light 
irradiation, which suggested the high potential to be mitochondria-targeting theranostic 
anticancer agents for photodynamic therapy. 
[Résumé] Chen ZHANG, thèse PhD 
Complexes métalliques à ligands NHC pour des applications 
anticancer: Or(I) pour l'activité antimitochondriale et 
Iridium(III) pour la thérapie photodynamique 
Dans ce travail de thèse, plusieurs groupes de nouveaux complexes d'or(I) à base de 
carbènes N-hétérocyclique (NHC) contenant des bras amino-aliphatiques et 
aromatiques avec un potentiel intéressant dans des applications biomédicales ont été 
synthétisés et entièrement caractérisés. En outre, une série de complexes d'iridium(III) 
contenant des ligands NHC avec des activités anticancéreuses prononcées pour une 
application en thérapie photodynamique, a été préparée et entièrement caractérisée. 
 Le premier groupe représente une famille de complexes cationiques or(I) bis(NHC) 
contenant des bras latéraux amino-aliphatiques. Ces complexes ont été synthétisés et 
étudiés pour leurs activités antiprolifératives vis-à-vis de quatre lignées cellulaires 
cancéreuses humaines et de la lignée cellulaire non cancéreuse MDCK. Dans cette série, 
la lipophilie est directement liée à l'activité cytotoxique contre les cellules cancéreuses. 
 La deuxième famille de composés concerne les complexes cationiques or(I) 
bis(NHC) contenant des bras latéraux amino-aromatiques. La cytotoxicité in vitro de 
ces complexes et de leurs proligands sur les lignées cellulaires représentatives du cancer 
de la prostate PC-3 et de la vessie T24 a été évaluée. Tous ces complexes présentent 
des valeurs de Log P (lipophilie) supérieures à celles de la première série de complexes 
en accord avec leur cytotoxicité plus élevée, mais une lipophilie trop élevée peut 
également conduire à une sélectivité plus faible. 
 Afin de développer un candidat-médicament avec une activité et une sélectivité 
optimisées, nous avons conçu et synthétisé la troisième famille de complexes 
cationiques or(I) bis(NHC). Les valeurs de log P de cette série se situent entre la 
première série et la deuxième série. Ces complexes moins lipophiles sont moins 
cytotoxiques envers les lignées cellulaires saines (NIH3T3) et montre des activités 
anticancéreuses un peu plus faibles sur les cellules PC-3 que la deuxième série, avec 
néanmoins des valeurs de GI50 dans la gamme du nanomolaire.  
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 Les études mécanistiques sur deux complexes d’or(I) ont été réalisées. Les mesures 
d'absorption cellulaire ont montré une accumulation cellulaire rapide et une bonne 
biodisponibilité des complexes, en accord avec l'activité antiproliférative de ces deux 
complexes. De plus, les deux complexes inhibent la thiorédoxine reductase (TrxR), une 
cible commune pour les complexes d'or(I). La mort cellulaire induite par ces deux 
complexes est dépendante des espèces réactives de l’oxygène.  
 En plus des activités anticancéreuses, nous avons également testé des complexes 
d'or(I) mono-NHC pour une autre application biomédicale, la leishmaniose, maladie 
parsitaire. Ils ont été testés in vitro sur les formes promastigotes et amastigotes 
axéniques de L. infantum. De plus, leur cytotoxicité a été évaluée sur les macrophages 
murins J774A.1 afin de déterminer leur sélectivité d'action.  
 Un autre sujet de cette thèse concerne les complexes d’iridium(III)-NHC. Trois 
familles de complexes ont été préparées et caractérisées. La cytotoxicité in vitro de tous 
les complexes sur les cellules cancéreuses de la prostate PC-3 et de la vessie T24, et les 
cellules non cancéreuses NIH3T3 a été évaluée. De plus, tous les complexes sont des 
agents théranostiques, et les expériences de microscopie confocale d'un complexe ont 
montré qu'il pouvait être rapidement et efficacement absorbé dans les cellules PC-3 et 
se localiser spécifiquement dans les mitochondries. De manière intéressante, ces 
complexes peuvent agir comme des photosensibilisateurs efficaces. La cytotoxicité de 
ces complexes a été augmentée substantiellement après une irradiation lumineuse de 
365 nm, ce qui suggère le potentiel élevé de ces agents anticancéreux théranostiques 
ciblant les mitochondries pour la thérapie photodynamique. 
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MCF-7 = human breast cancer cells 4T1 = mouse breast cancer cells 
MCF-10A = human mammary epithelial 
cells 
U-2 OS = human bone osteosarcoma 
cells 
MDA-MB-231 = human breast cancer 
cells 
U87 = human primary glioblastoma cells 
MDA-MB-468 = human breast cancer 
cells 
U937 = human monocyte-macrophage 
cells 
MDCK = Madin-Darby Canine Kidney 
cells 
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1. Introduction 
1.1. Metals in medicine 
Medicinal inorganic chemistry is a developing field, and novel therapeutic and 
diagnostic metal complexes have a great impact on medical treatment. 
  Metal complexes are very important for our health both endogenously and 
exogenously. Exogenous metal complexes can be administrated to our body in a 
controlled way, as the case of therapeutic agents, or in an uncontrolled way, as by air 
or pollutants. It is remarkable that the therapeutic agents or pollutants are directed 
towards the endogenous metal targets or require metal coordination to act. The 
biological activity of pharmaceuticals depends on the nature and oxidation state of 
metal and its ligands. Two main factors, thermodynamic stability and selectivity, are 
very important in the design of metal complexes for medical applications.1 
 
Fig 1.1.1 Essential elements. 
 
  A wide variety of metal compounds are already in clinical use. These include 
mineral supplements containing metals essential for mammalian life, e.g. Ca, Mg, Cr, 
Mn, Fe, Co, Cu and Zn (Fig 1.1.1). Vitamin B12, which contains colbalt positioned in 
the center of a planar tetra-pyrrole, shows physiological activity. Most of them are 
used as antacids, many of which are simple inorganic salts from group I, II and XIII 
metals, such as sodium bicarbonate, magnesium oxide or carbonate and aluminium 
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hydroxide.2 
  In 1890, the first well-defined metal-based drug potassium dicyanoaurate with 
formula K[Au(CN)2] as antibacterial was discovered. Since 1940, gold complexes 
have been used for the treatment of arthritic disorder in humans. At the end of last 
century, gold complexes such as gold sodium thiomalate and gold thioglucose used to 
treat arthritis were administered by injection. It was discovered, however, that 
orally-administered auranofin (Fig.1.1.2) was equally effective against rheumatoid 
arthritis. It is notable that the coordination of gold by thiolate appears to be a natural 
process in the body.2-3 
Fig 1.1.2 Structures and names of some metal-based drugs. 
 
The cytotoxicity of cisplatin has drastically promoted the development of treatment 
of certain types of cancer.4 Cisplatin and carboplatin (Fig 1.1.2) are used to treat 
various types of cancers such as testicular, ovarian, lung and bladder cancer. 
Oxaliplatin (Fig 1.1.2) was the first drug which could avoid the cisplatin resistance of 
colon carcinoma.5 The ultimate target for Pt(II) drugs is DNA and certain platinated 
DNA adducts trigger conformational change of DNA structure, leading to DNA repair 
response and then to cell death (Fig 1.1.3).6 
 
Fig 1.1.3 Mechanism of cisplatin. 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
3 
 
 
However, the use of cisplatin in clinic trials is limited by 1) the resistance observed 
in several types of cancer cells, 2) the increase of resistance after continuous treatment 
and 3) the high toxicity against normal cells, which means strong side effects.7 
Therefore, there are more interests in the development of platinum drugs against a 
wide range of types of cancer cells, especially cisplatin-resistant cancer cells. 
Although platinum complexes have been the most detailedly investigated, research 
has been extended to other metal-based drugs, such as gold, silver, copper, palladium, 
rhodium, iridium and ruthenium. 
 
1.2. N-heterocyclic carbene metal complexes in medicine 
The last decade has witnessed the dramatic development in the field of metal 
complexes of N-heterocyclic carbenes (NHCs).8 NHCs are a class of electron 
donating ligand, which form strong σ bonds to metal ions in both high and low 
oxidation states. Some similarities between NHC and phosphine ligands have been 
noted and NHCs have been used to replace phosphines, which are sensitive to oxygen, 
to prepare catalysts.9 Nowadays, metal-NHC complexes appear to be a more and more 
popular field of research in the development of metal-based drugs because of their 
high stability and the ease of NHC derivatization (Fig 1.2.1).8b, 8d, 10 At the beginning, 
most of the researchers focused on the 1,3-nitrogen substituents to do modulations.11 
Then substituents at 4- and 5-positions started to draw the attention of some 
researchers. Recently, benzimidazole, pyrazole, triazole, tetrazole and caffeine-based 
NHC gold complexes were designed and synthesized to enlarge the families of NHC 
ligands for biomedical applications.10 
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Fig 1.2.1 Scheme of different types of NHC ligands. 
 
Various metal-NHC complexes have been shown to possess biological activities 
like anti-infective, anti-bacterial and anti-cancer. The main results reported in the 
literature for biomedical NHC compounds are related to Au, Ag, Ru, Rh and Cu 
complexes.8b, 12 
Here, we will talk about Ag, Ru, Rh and Cu complexes bearing NHC ligands, and 
then introduction of gold NHC complexes will be presented in a special section. 
 
Silver complexes: Silver complexes have been noted as antimicrobial agents for 
many years and nowadays they also display anti-cancer activity.13 The first 
Ag(I)-NHC complexes with antimicrobial activity was published by Youngs’ group. 
In this report by Youngs and co-workers,14 the synthesis of two pyridine-linked pincer 
silver NHC complexes 1a and 1b (Fig 1.2.2) is presented. 1a and 1b were active 
against E. coli, S. aureus and P. aeruginosa, showing minimum inhibitor 
concentration (MIC) values much lower than that of silver nitrate, which is the 
appropriate reference for this type of application. 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
5 
 
 
Fig 1.2.2 NHC-Ag(I) silver complexes as antimicrobial (1a and 1b) and anticancer 
(2a-2e) agents reported by Youngs and co-workers. 
 
Besides the antimicrobial activity of silver, these years more and more attentions 
are focused on the research of anticancer activity of silver complexes.8d Youngs’ 
group reported the anticancer activity of several monomeric and dimeric 
imidazol-2-ylidene and 4,5-dichloroimidazol-2-ylidene silver acetate complexes 
(2a-2e, Fig 1.2.2). Complex 2a is not stable enough to study its activity, but the IC50 
values of complexes 2b and 2c were in the same range as cisplatin against ovarian 
(OVCAR-3) and breast (MB157) cancer cell in vitro.15 On the other hand, dimeric 
complexes 2d and 2e just showed 10-fold less activity than cisplatin against lung 
(H460) cancer cell and no significant effect against cervical (HeLa) cancer cell.16 
 
Ruthenium complexes: Group 8 metal complexes based on ruthenium have arisen 
interest in the research of metal-based anticancer agents. Two ruthenium complexes 
NAMI-A and KP1019 (Fig 1.2.3) have entered phase II clinical trials, and the former 
as an antimetastatic agent.17 They are less toxic than platinum-based drugs and 
capable of overcoming the resistance of cisplatin-resistant cancer cells. 
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Fig 1.2.3 Chemical structure of NAMI-A and KP1019. 
 
Ott and co-workers reported a series of ruthenium complexes (3a-3d, Fig 1.2.4) of 
the type (p-cymene)(NHC)RuCl2 and studied their behavior in biological tests.
18 
These compounds interact with biologically relevant thiols and selenols, which lead to 
the inhibition of enzymes like thioredoxin reductase (TrxR) and cathepsin B (catB). 
One of the complexes (3d) showed pronounced antiproliferative effects with low IC50 
values against breast cancer cells (MCF-7, 2.07 μM) and colon adenocarcinoma cells 
(HT-29, 2.40 μM). The inhibition of tumor cell growth was accompanied by a 
perturbation of metabolic parameters such as cellular respiration. 
 
Fig 1.2.4 Structure of NHC-Ru complexes as anticancer agents. 
 
Similarly, five Ru(II)-NHC complexes 4a-4e (Fig 1.2.4) were synthesized, 
characterized and tested by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
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tetrazolium bromide) assay on four different human cancer cell lines by Qiu, Lin and 
co-workers.19 The cytotoxicity of these complexes enhanced with the increase of the 
lipophilicity. The most lipophilic complex 4e (Log P = 2.62) showed the best activity 
with IC50 values of 10.3 μM for SKOV-3 (ovarian), 2.9 μM for PC-3 (prostate), 8.2 
μM for MDA-MB (breast) and 6.4 μM for EC109 (esophagus) cancer cell lines. 
Moreover, 4e can inhibit PC-3 cell lines by inducing cell cycle arrest at G2/M phase. 
 
Rhodium complexes: With the development of ruthenium complexes as potential 
chemotherapeutic agents, the neighboring group 9 rhodium complexes have drawn 
lots of attention. Because of the controllable reactivity, good solubility and relative 
accessibility, rhodium complexes have become potential alternatives to palladium and 
ruthenium metallodrugs. 
Ott and co-workers developed a series of Rd(I)-NHC complexes 5a-5h (Fig 1.2.5) 
with cyclooctadiene (COD) as secondary ligands with pronounced antiproliferative 
effects against HT-29 (colon carcinoma) and MDA-MB-231 (human breast 
adenocarcinoma) cells.20 The most active complex 5g triggered IC50 values of 1.5 μM 
in both cancer cell lines. Structure-activity relationship for cytotoxicity indicated that 
the biological properties of rhodium complexes could be modulated by changing the 
substituents on the NHC ligands and the nature of the secondary halide ligand. In 
terms of their mode of action, effects on cellular signal of certain targets such as p38 
(a class of mitogen activated protein kinases) and ERK1/2 (extracellular 
signal-regulated kinases) have to be taken into account. 
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Fig 1.2.5 Structure of NHC-Rh complexes as anticancer (5a-5h) and antimicrobial 
(6-9) agents. 
 
Besides anticancer activity, rhodium complexes can also be taken as antimicrobial 
agents. Cetinkaya and co-workers were the first to investigate the in vitro 
antimicrobial activities of Rh(I)-NHC complexes. 21 The rhodium complexes 6-9 (Fig 
1.2.5) were evaluated against E. coli, S. aureus, Enterococcus faecalis and P. 
aeruginosa. Of all these compounds, 6a and 6c were found to be the most effective 
against both Gram-positive bacteria with MIC values of 5 μg/ml. No significant 
inhibition was observed against Gram-negative bacteria. 
 
Copper complexes: Copper is an essential element for most aerobic organisms, and 
it has a long history for medical applications. Copper, which is important for the 
function of several enzymes and proteins and is involved in many biological pathways, 
is maybe less toxic than non-essential elements.22 
Two types of novel NHC-copper(I) bromide derivatives 10a-10j (Fig 1.2.6) have 
been synthesized via silver oxide pathway by Tacke and co-workers.23 The 
copper(I)-NHC complexes 10a-10e showed high cytotoxicity against breast 
carcinoma (MCF-7) and renal cell carcinoma (Caki-1) with low IC50 values in the 
micromolar and sub-micromolar range. With IC50 value of 0.60 μM against MCF-7 
and 0.65 μM against Caki-1, the most active compound 10c has been selected as a 
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promising candidate for future biological studies. 
Fig 1.2.6 Structure of NHC-Cu complexes as anticancer agents. 
 
The newly-designed Cu(I) 1,2,4-triazole based NHC complex 11 (Fig 1.2.6) was 
synthesized and assessed for its cytotoxic properties in various human cancer cell 
lines, including cisplatin sensitive and resistant cells.24 Compared with corresponding 
Ag(I)-NHC and Au(I)-NHC complexes, Cu(I)-NHC complex 11 was the most 
efficacious antiproliferative compound, and it was able to promote a growth inhibitory 
effect up to 7-times higher than that triggered by cisplatin. It was shown that copper 
complexes can enter and accumulate into cancer cells leading to cell death through the 
impairment of ubiquitin-proteasome degradation pathway (ubiquitin-proteasome 
pathway is the principle catabolism in the mammalian cytosol and nucleus). 
 
1.3. N-heterocyclic carbene gold complexes as potential anticancer 
metallodrugs 
Among the non-platinum anti-cancer drugs, gold complexes with metal center in 
the oxidation states +1 and +3 have drawn considerable attentions because of their 
strong cytotoxic activity in various cancer cells.8d  Based on the great structural 
variety of the ligands, the detailed mechanisms of action of gold complexes remain 
unclear. Among the numerous hypothesis in terms of mechanism of action, inhibition 
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of enzyme TrxR seems to play an important role in pharmacology of gold complexes 
as gold displays a high affinity to selenol group.8d 
 
Thioredoxin reductase targeting mode of action:  
Thioredoxin reductase (TrxR), a homodimeric protein containing one 
selenocysteine and one FAD, catalyses the NADPH-dependent reduction of 
thioredoxin disulfide and numerous other oxidized cell constituents (Fig 1.3.1). As a 
general reducing enzyme with little substrate specificity, it also contributes to redox 
homeostasis and is involved in prevention, intervention and repair of damage caused 
by H2O2-based oxidative stress.
25 
 
Fig 1.3.1 The thioredoxin reductase/thioredoxin system. 
 
In cancer cells, although many different targets are available for gold complexes, 
the observed inhibition of TrxR seems to play a main role. Humans express mainly 
two TrxR isoenzymes: TrxR1 (cytosolic) and TrxR2 (mitochondrial). The mechanism 
of action of cell death induced by gold complexes is shown below in Fig 1.3.2.26 The 
mitochondrial respiratory chain produces superoxide anion that becomes hydrogen 
peroxide and oxidizes thioredoxin in a reaction mediated by peroxiredoxin (Prx). 
However, TrxR, inhibited by gold complexes, is no longer able to reduce back the 
oxidized thioredoxin that accumulates together with hydrogen peroxide and both act 
on several different mitochondrial targets leading to the opening of the mitochondrial 
permeability transition pore or an increase of the permeability of outer membrane, and 
therefore causing the release of proapoptotic factors. 
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Fig 1.3.2 Model depicting the mechanism of action of cell death induced by gold 
complexes as proposed by Bindoli and co-workers.26 
 
Mitochondria targeting mode of action:  
Mitochondria play a major role in the regulation of apoptosis (cell death) and in 
diseases characterized by abnormal apoptotic responses such as cancer. Apoptosis is a 
form of cell death characterized by activation of caspases that cleave multiple targets 
in the cell.27 In vertebrate cells, the main form of apoptosis proceeds through the 
mitochondrial pathway, and the critical event in the process is mitochondrial outer 
membrane permeabilization (MOMP), which represents the “point of no return” of 
cell death.28 The mechanisms responsible for MOMP during apoptosis remain 
controversial, but there are two classes of mechanism that have been described, and 
each of them may function under different circumstances (Fig 1.3.3).29 On one hand, 
MOMP can occur as a consequence of the mitochondrial permeability transition 
(MPT).30 The opening of MPT involves the adenosine nuclear transporter (ANT) in 
the inner mitochondrial membrane, and the voltage-dependent anion channels 
(VDACs) in the outer membrane. On the other hand, MOMP appears to be mediated 
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by members of the Bcl-2 family of apoptosis-regulating proteins acting directly on the 
outer mitochondrial membrane.31 The proapoptotic multidomain member Bax or Bak, 
leading to the release of cytochrome c from mitochondria, are vital for MOMP to 
occur during apoptosis. 
 
Fig 1.3.3 Mechanism for MOMP during apoptosis.27  
 
Chen and co-workers found that compared with living cells, carcinoma cells have 
higher mitochondrial membrane potential (ΔΨm).32 Recent researches in 
mitochondria result in the elevated interest in the development of delocalized 
lipophilic cations (DLCs). They can readily pass through the lipid bilayer and 
selectively accumulate in mitochondria of carcinoma cells as the consequence of 
elevated ΔΨm in tumor cells. A huge variety of DLCs have shown pronounced 
anti-tumor activities, and the selectivity of cancer cells over normal cells can be 
modulated by changing the lipophilicity of DLCs.33 
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Fig 1.3.4 Number of articles (left) and citations (right) per year on the topic of “gold + 
anticancer + NHC or carbene”. Data were obtained from Web of Science. 
 
As shown in Fig 1.3.4, which reports the number of articles and citations in Web of 
science on the topics “gold, anticancer, NHC or carbene” from 2004 to May 2018, the 
field has rapidly grown in the past few years. This introduction will focus on 
Au(III)-NHC and Au(I)-NHC complexes, highlighting the potential of using gold 
NHC complexes in the development of new anticancer drugs. 
 
1.3.1.  Gold(III)-NHC complexes as anticancer agents 
Organometallic complexes of gold are found increasing usage in biomedical 
application. Many complexes with anticancer activity use the metal gold in the 
oxidation state +1 or +3, which can be stabilized by NHC-based ligands.8d, 10 While 
majority of researches focus on the NHC complexes of gold in +1 oxidation state, the 
gold(III)-NHC complexes have drawn lots of attention recently. 
It has been previously reported that gold(III) complexes are not very stable under 
physiological environments, and Au(III) can be reduced to Au(I) by thiols and 
thioethers containing cysteine residues in proteins and peptides.34 However, by taking 
advantage of the donating property of NHC ligands and the ease of 
pharmaco-modulation, Che’s group previously reported a panel of stable 
cyclometalated gold(III) complexes 12a-g containing NHC ligands (Fig 1.3.5).35 
These complexes show potent and selective cytotoxicity against cancer cells and in 
vivo anti-tumor activities in mice bearing xenografts of HeLa (cervical) and 
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NCI-H460 (lung) cancer cells. Furthermore, they studied about the mechanism of 
action, and they found the specific engagement of Au(III) NHC complexes with 
various cellular targets, such as heat shock proteins (HSP60), vimentin, 
nucleophosmin (NPM) and Y-box binding protein 1 (YB-1). 
 
Fig 1.3.5 Au(III)- NHC complexes reported by Che and co-workers. 
 
Bochmann and co-workers reported a series of cyclometalated gold(III) 
complexes 13a-13c containing pyrazine-based (C^N^C)-type pincer ligand (Fig 
1.3.6).36 These complexes afford a new platform for the study of antiproliferative 
activities of gold(III) complexes. Of the whole series, complex 13a had the most 
effective activity against HL60 (leukemia), A549 (lung cancer) and MCF-7 (breast 
cancer), which gave IC50 values in submicromolar range, accompanied by low 
cytotoxicity against healthy human lung fibroblast cells. Complex 13a proved to be 
not affected by glutathione under physiological conditions, and it could stabilize the 
DNA G-quadruplex and i-motif structures, which was firstly reported in gold 
complexes. 
 
Fig 1.3.6 Pyrazine-based (C^N^C) Au(III) complexes reported by Bochmann and 
co-workers. 
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The gold(III) NHC complex (14, Fig 1.3.7) was prepared by Haque and 
co-workers.37 Complex 14 displayed remarkable antiproliferative activities against 
MCF-7 (breast carcinoma), PC-3 (prostate carcinoma) and U937 (histiocytic leukemia) 
cells in the nanomolar range with IC50 values of 0.31 nM, 0.34 nM and 190 nM, 
respectively. Moreover, human colorectal normal cells (CCD-18Co) were used to 
determine the cytotoxic selectivity of the compound towards cancer cells and its 
safety towards normal cells. Selectivity index (SI) results revealed that complex 14 
exhibited high selectivity towards all tested cancer cells with SI values of 57096, 
52095 and 93 for MCF-7, PC-3 and U937, respectively. 
 
Fig 1.3.7 Au(III) complexes reported by Haque and co-workers (14) and by Huynh 
and co-workers (15a-15e). 
 
Huynh and co-workers reported a series of Au(III) mono-, homobis- and 
heterobis-(NHC) complexes (15a-15e, Fig 1.3.7).38 The cytotoxic activities of these 
complexes against NCI-H1666 (non-small cell lung cancer) cells were tested using 
cisplatin as a reference drug (IC50 = 2.51 μM). In terms of benzimidazole moiety, the 
neutral monocarbene complex 15a (IC50 > 10 μM) was found to be less active than 
cisplatin, and displayed much lower activities as compared to the cationic homo- and 
heterobis-(carbene) complexes 15b and 15c with IC50 values of 0.536 μM and 0.210 
μM, respectively. Concerning the pyrazole moiety, complex 15d (IC50 > 10 μM) and 
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15e (IC50 = 1.46 μM) displayed lower cytotoxicity than analogue 15c towards 
NCI-H1666 cells.  
 
1.3.2.  Dinuclear gold(I)-NHC complexes as anticancer agents 
The group of Berners-Price was a pioneer in the research of gold(I) complexes 
containing NHC ligands as anticancer agents. They reported a series of dinuclear 
Au(I)-NHC complexes (16a-16g, Fig 1.3.8).39 These complexes were studied for their 
ability to induce mitochondrial membrane permeability (MMP) in isolated rat liver 
mitochondria. The rates and levels of uptake of these complexes into mitochondria 
were evaluated by measuring mitochondrial gold levels using inductively coupled 
plasma optical emission spectroscopy. The mechanism by which MMP is induced by 
these Au(I)-NHC complexes was not a purely function of the level of gold 
accumulation, but it may involve disruption of the function of a specific enzyme or 
interaction with a mitochondrial permeability transition pore (MPT) component. 
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Fig 1.3.8 Dinuclear gold(I)-NHC complexes reported by Berners-Price and 
co-workers (16a-16g). 
 
Another dinuclear NHC complex (17, Fig 1.3.9) was obtained through a 
transmetalation route by Goite, Castro and co-workers.40 Complex 17 was found to 
interact with DNA mainly through noncovalent interaction as π-π stacking and 
produced conformational changes in the structure of DNA. Sulphorhodamine-B (SRB) 
assay was used to distinguish between a cytostatic effect (reduction in cell 
proliferation) and a cytotoxic effect (decrease of the number of viable cells). Complex 
17 displayed a good cytostatic activity against MCF-7 (breast carcinoma), PC-3 
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(prostate carcinoma) and HT29 (colon carcinoma) cell lines (GI50 = 0.6, 1.3 and 2.3 
μM, respectively), while it showed a low cytotoxic effect on all cancer cell lines with 
a LC50 (50 % cytotoxicity) lower than 30 μM. 
Che and co-workers reported three dinuclear complexes (18a-18c, Fig 1.3.9) with 
mixed bridging diphosphine and bis(NHC) ligands. Complex 18a exhibited a 
favorable stability that enabled it to inhibit TrxR activity without being attacked by 
blood thiols. Complex 18a was found to be cytotoxic against breast carcinoma 
(MCF-7), nasopharyngeal carcinoma (SUNE-1), lung adenocarcinoma (NCI-H1975) 
and mouse melanoma (B16-F10) with IC50 values ranging from 1.3 to 3.2 μM, higher 
than those of cisplatin. Furthermore, this complex was found to inhibit tumor growth 
in mice bearing HeLa xenografts and highly aggressive mouse B16-F10 melanoma 
without observation of side effects under in vivo conditions.41 
 
Fig 1.3.9 Dinuclear Au(I)-NHC complexes reported by Castro and co-workers (17), 
by Che and co-workers (18a-18c), and by Sun and co-workers (19a-19b). 
 
Various new gold(I) pyrrolidinedithiocarbamato complexes (19a-19b, Fig 1.3.9) 
bearing NHC ligands were prepared by Sun and co-workers. A dinuclear gold(I) 
complex 19a with a bidentate carbene ligand displayed a potent cytotoxic (IC50 value 
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of 0.83 μM) and antimigratory activity in vitro towards cisplatin-resistant ovarian 
cancer cells A2780cis. Due to the rigid scaffold, the complex 19a enabled 
zinc(II)-based metal-organic framework (Zn-MOF) to be used as a carrier to improve 
its cellular uptake and release under physiological conditions. Notably, the 
biocompatible Zn-MOF didn’t exhibit cytotoxicity to the cancer cells, whereas the 
survival percentage of A2780cis cancer cells decreased significantly with increasing 
incubation time of 19a@Zn-MOF.42 
 
1.3.3.  Mononuclear gold(I) mono-NHC complexes as anticancer agents 
After the development of auranofin (Fig 1.3.10) as an antirheumatic drug and the 
discovery of its antiproliferative activity, gold(I) complexes start to play a vital role in 
metal-based anticancer drugs. Ott and co-workers previously reported a series of 
gold(I) NHC complexes (20a-20c, Fig 1.3.10) with 1,3-diethybenzimidazol-2-ylidene 
NHC ligands. These complexes of type NHC-Au-L (L= Cl, NHC, PPh3) were 
evaluated as potent TrxR inhibitors with remarkable antiproliferative activities in vitro 
against a wide range of tumor cells. Of the entire series, complex 20a with chloride 
substituent showed a strong and selective inhibition of TrxR, similar to auranofin. 
Moreover, this selective inhibition of TrxR over structural related enzymes like 
glutathione reductase (GR) and glutathione peroxidase (GPx) indicated that covalent 
interaction with selenium was relevant for the mechanism of drug action.43 
To study the mechanism of cell death induced by gold(I) NHC complexes, Wölfl 
and co-workers reported an organometallic complex of Au(I)(NHC)(phosphane) type 
(21, Fig 1.3.10). Strong cytotoxicity in vitro was found in various cancer cells, 
associated with irreversible loss of mitochondrial membrane potential as well as 
oxidative stress due to the inhibition of TrxR, leading to apoptotic cell death. 
Moreover, ELISA analysis of signal transduction pathway revealed the cleavage of 
poly-ADP-ribose polymerase (PARP), the decrease of anti-apoptotic Bcl-2 (B-cell 
lymphoma 2) and the activation of apoptotic signaling proteins like p38 
(mitogen-activated protein kinases) and JNK (c-Jun N-terminal kinases) during cell 
death. Further results showed that cell damage triggered by gold(I) complexes was 
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significantly different from other DNA damage agents due to the lack of p53 
phosphorylation.44 
 
Fig 1.3.10 Gold(I) mono-NHC complexes reported by Ott and co-workers (20, 22, 
23) and reported by Wölfl and co-workers (21). 
 
Since phosphine group is one of the most detailed studied ligand in gold complexes 
and exists in the lead complex auranofin, Ott and co-workers reported a series of 
organometallic complexes with NHC ligands containing different phosphanes as 
secondary ligands (22a-22d in Fig 1.3.10).45 All these complexes induced cytotoxicity 
in vitro against HT-29 (colon carcinoma) and MCF-7 (breast carcinoma) cells with 
IC50 values ranging from 0.41 μM to 8.85 μM. Moreover, these complexes can 
significantly inhibit the seleno-enzyme TrxR and zinc-finger enzyme PARP-1. In 
terms of the inhibition of TrxR, the activity depends on the size of the substituents of 
phosphane. Density functional theory (DFT) calculation showed that 
[Au(NHC)(PPh3)]I had the lowest binding energy for Au-PR3 bond, leading to the 
highest activity of PARP-1. 
To study about structure-activity relationship (SAR) of Au-NHC complexes, Ott 
and co-workers also reported a series of 20 Au-NHC complexes (general structure: 23, 
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Fig 1.3.10) with the aim of finding a correlation between TrxR inhibition, cytotoxicity 
and structures of the compounds. These complexes consisted of compounds with Au(I) 
and Au(III) atom containing coordinated halides, thiolates and diverse NHC ligands. 
From the data of TrxR inhibition, gold(I) NHC complexes were stronger TrxR 
inhibitors than gold(III) with IC50 values in the submicromolar or micromolar range, 
thiophenolate ligands afforded strong TrxR inhibition with IC50 values ranging from 
0.32 μM to 1.1 μM, and the insertion of amino acid into side chains of NHC nitrogens 
led to increased TrxR inhibition. Although a direct relationship between TrxR 
inhibition and cytotoxicity cannot be reached, the data indicated that TrxR played a 
vital role in the mechanism of action of gold complexes.46 
With the aim of enlarging SAR studies for the Au-NHC complexes, Gantin, Santini 
and co-workers designed 1,2,4-triazole based Group 11 NHC complexes (24, Fig 
1.3.11) and the antiproliferative activities of these complexes were evaluated in vitro 
towards various human cancer cell lines including cisplatin-sensitive and resistant 
cells. Among the entire series of complexes, the Cu(I)-NHC complex gave the most 
cytotoxic activity, which was a non-apoptotic cell death pathway, and Au(I) and Ag(I) 
NHC complexes were able to inhibit the activity of TrxR with IC50 values in the 
nanomolar range (10.1 nM and 7.2 nM, respectively), leading to oxidative stress 
followed by cell death via apoptosis.24 
 
Fig 1.3.11 Gold triazole-based NHC complexes reported by Gantin and co-workers 
(24) and reported by Růžička and co-workers (25a-25c). 
 
Three gold(I) complexes (25a-c, Fig 1.3.11) of type Au(NHC)X containing 
triazole-based NHC ligands and diverse halido ligands (X= Cl, Br, I) were reported by 
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Růžička and co-workers.47 The antiproliferative activities of these complexes were 
screened in vitro against various cancer cell lines, such as HepG-2 (liver cancer), 
HeLa S3 (cervical cancer), HL-60 and CCRF-CEM (leukemia) as compared to 
cisplatin and auranofin. It was shown that complexes 25a and 25b with chloride and 
bromide were more active than the complex 25c with iodide and cisplatin, and slightly 
less active than auranofin against HeLa S3 and HL-60 cell lines, but more effective 
than auranofin against HepG-2. In addition, the apoptotic properties of these 
complexes were confirmed using cell cycle analysis where they induced an obvious 
increase in sub-G1 population by around 50% compared to the non-treated control. 
All complexes also had some effects on cell cycle distribution by slightly increasing 
the percentage of G2/M phase, suggesting the mechanism of antiproliferative 
activities of the tested complexes may differ from that of auranofin. 
Mohr, Casini, Rigobello and co-workers reported a gold-NHC complex bearing 
fluorescent anthracenyl group (26, Fig 1.3.12).48 Complex 26 was evaluated for the 
cytotoxic activity in vitro against cancer and normal cells. It showed no selectivity 
between cancer cells (A2780s and A2780R) and normal cell (HEK-293T). Both on 
isolated enzyme and in cell extracts, this complex exhibited a pronounced TrxR 
inhibition compared with related enzyme GR. From the fluorescence microscopy 
experiments, the cellular distribution displayed a larger diffusion of these molecules in 
tumor cells when compared to normal cells. 
Similarly, Au(I)-NHC complex 27 (Fig 1.3.12) with a fluorescent coumarin group 
was evaluated for its cellular uptake and subcellular localization in the PC-3 human 
prostate cancer cell line by Gautier and co-workers. This complex was obtained by the 
combination of “auto-click” reaction with the transmetallation route. After incubation 
with complex 27, the fluorescence was found in the cytoplasm, not in the nucleus. 
Moreover, it could be specifically localized in mitochondria.49 
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Fig 1.3.12 Gold NHC complexes bearing chromophores reported by Casini and 
co-workers (26), Gautier and co-workers (27) and Gimeno and co-workers (28a-28f). 
 
Gimeno and co-workers reported a series of gold(I)-NHC complexes bearing a 
fluorescent acridine group (28a-28f, Fig 1.3.12).50 Their cytotoxicity against A549 
(human liver cancer) and Miapaca2 (pancreatic carcinoma) revealed 
thiolate-Au-NHCs had higher antiproliferative activities in vitro as compared to the 
corresponding chloride derivatives. In particular, complexes 28e and 28f with the 
tetra-O-acetyl-1-thio-β-D-glucopyranoside ligand displayed even better anticancer 
activities, especially in Miapaca2 cells reaching IC50 values of 2.8 μM and 3.4 μM, 
respectively. Furthermore, flow cytometry assay showed that apoptotic pathway was 
the main mechanism for cell death. From the fluorescent microscopy experiments, it 
was shown that these complexes were mainly located into lysosomes, and small 
amout of them have been accumulated in the nucleus. 
A series of gold(I) complexes bearing a glucopyranoside-incorporated NHC ligand 
were reported by D’Amora and co-workers (29a-29c, Fig 1.3.13).51 Different 
secondary ligands (chloride and phosphane) were coordinated to the gold atom, and 
these complexes were evaluated for their cytotoxicity in vitro against various cancer 
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cell lines, such as PC-3 (prostate cancer), A375 (malignant melanoma), U-2 OS 
(osteoblast) and MCF-7 (breast carcinoma) as compared to cisplatin. Among the 
entire series, complex 29a and 29b showed an EC50 (half maximal effective 
concentration) against PC-3 comparable with cisplatin, nevertheless, the complex 29c 
was inactive. 
Fig 1.3.13 Gold NHC complexes reported by Amora and co-workers (29a-29c) and 
reported by Richeter and co-workers (30a-30c). 
 
Richeter and co-workers reported several Au(I) complexes bearing 
porphyrins-incorporated NHC ligands (30a-30c, Fig 1.3.13). Photodynamic properties 
of these complexes to kill MCF-7 (human breast cancer) were investigated. The 
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results showed that these complexes 30a-30c were not effective in the dark whereas 
upon irradiation photocytotoxicity was observed, not only due to the photodynamic 
properties of porphyrin but also due to the peripheral Au(I) complex losing its thiolato 
ligand upon irradiation.52 
 
1.3.4.  Bis-NHC gold(I) complexes as anticancer agents 
The first discovery of mitochondria targeting property of bis-NHC gold(I) 
complexes was made by Berners-Price and co-workers. A series of Au(I) bis-NHC 
complexes functionalized with different alkyl substituents (31a-31d, Fig 1.3.14) was 
investigated about their cytotoxicity in vitro against two tumorigenic breast cell lines 
(MDA-MB-231, MDA-MB-468) and normal human mammary epithelial cells 
(HMEC). These complexes showed the selectivity between cancer cells and normal 
cells, and the degree of selectivity was related with the lipophilicity of these 
complexes. Furthermore, it was shown that complex 31a induced selective cell death 
through a mitochondrial apoptotic pathway. TrxR activity was inhibited by 50 % with 
5 μM of complex 31a, whereas no inhibition of glutaredoxin (GR) activity was found. 
Therefore, TrxR plays an important role in cytotoxicity and its inhibition may lead to 
the apoptosis in breast cancer cells.33 
 
Fig 1.3.14 Bis-NHC Au(I) complexes reported by Berner-Price and co-workers 
(31a-31d) and by Gust and co-workers (32a-32d). 
 
Gust and co-workers reported a series of cationic bis[1,3-diethyl-4,5- 
diarylimidazol-2-ylidene] gold(I) complexes (32a-32d, Fig 1.3.14).53 The 
antiproliferative activities in vitro against MCF-7 (breast carcinoma), MDA-MB-231 
(breast carcinoma) and HT-29 (colon carcinoma) cells were evaluated as compared to 
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cisplatin and fluorouracil (5-FU). Among all the complexes, 32b being the most 
cytotoxic compound, gave a pronounced IC50 value of 0.1 μM, which was 10-fold 
higher than that of cisplatin and 5-FU. However, the mode of action remained unclear. 
Thioredoxin reductase (TrxR), the estrogen receptor (ER) and the cyclooxygenase 
enzymes (COX), which may be considered as targets for the drug design, can be 
excluded. 
In the past few years, gold complexes bearing NHC ligands have drawn more and 
more attention. However, only gold mono(NHC) and homo-bis(NHC) complexes 
have been reported, whereas gold complexes with different kinds of NHC ligands 
were barely investigated. Triggered by the interest on heteroleptic complexes, Huynh 
and co-workers reported a series of cationic gold(I) complexes bearing 
pyrazole-derived NHC and 1,3-disubstitued benzimidazole-derived NHC ligands 
(33a-33h, Fig 1.3.15). The cytotoxicity of complexes 33a-33h was evaluated in vitro 
against NCI-H1666 (non-small cell lung cancer cell line) as compared with cisplatin. 
Among the entire series, complex 33a showed the best effective antiproliferative 
activity against NCI-H1666, with an IC50 value of 0.241 μM, and most of the 
complexes were more active than cisplatin.54 
Fig 1.3.15 Bis-NHC Au(I) complexes reported by Huynh and co-workers (33a-33h) 
and by Mao and co-workers (34a, 34b). 
 
Mao and co-workers reported two gold(I) complexes bearing NHCs derived from 
cyclophanes as potential anticancer agents (34a and 34b, Fig 1.3.15).55 They showed 
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better antiproliferative activities than cisplatin in vitro against human breast 
carcinoma (MDA-MB-231), human cervical carcinoma (HeLa), human lung 
adenocarcinoma cisplatin-sensitive A549 and cisplatin-resistant A549R cell lines. In 
addition, these two complexes were less cytotoxic than cisplatin against normal 
human liver cell line LO2. In terms of the study of mechanism of action, complex 34a 
and 34b induced apoptosis through mitochondria pathway since they could 
significantly reduce the mitochondrial membrane potential (MMP). Furthermore, they 
could stimulate the activation of caspase-3/7 and trigger apoptosis through 
caspase-dependent pathway. 
Since gold carbene complexes are considered to act on some protein targets but not 
on DNA, Gabbiani and co-worker designed two novel gold(I)-NHC complexes (35a 
and 35b, Fig 1.3.16) to study their reactivity with different kinds of proteins. Both 
complexes possessed pronounced cytotoxic activities in vitro against A2780 human 
ovarian carcinoma cells with IC50 values of 1.98 μM and 1.68 μM, respectively, and 
surprisingly showed even better cytotoxicity against the corresponding 
cisplatin-resistant A2780R cells with IC50 values of 0.68 μM and 0.75 μM, 
respectively. Binding with proteins was monitored through ESI-MS and UV-vis 
spectrophotometry: no adduct formation was found when reacted with cytochrome c 
and lysozyme, whereas copper chaperone Atox-1 bearing a characteristic CXXC motif 
displayed a potent affinity for gold complexes, which suggested that gold-NHC 
complexes were very selective in metalating proteins, and they could only form 
adducts with those proteins bearing specific structural motifs for metal recognition.56 
Fig 1.3.16 Au(I) NHC complexes reported by Gabbiani and co-workers (35a, 35b) 
and by Gornitzka, Hemmert and co-workers (36a-36d). 
 
Four novel gold(I) complexes bearing aliphatic amino-functionalized NHC ligands 
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(36a-36d, Fig 1.3.16) were synthesized, characterized and evaluated for their 
cytotoxicity in vitro on PC-3 prostate cancer cell line by Gornitzka, Hemmert and 
co-workers. The lipophilicity (log P) of these complexes was in good agreement with 
the antiproliferative activities. The most active complex 36d exhibited pronounced 
cytotoxicity against five different kinds of cell lines (PC-3 prostate cancer, MCF-7 
breast cancer, U87 brain cancer, A549 lung cancer and Hep3B liver cancer) with GI50 
values ranging from 400 nM to 1 μM, whereas it was insensitive to normal primary 
human umbilical vein endothelial cells (HUVECs) with an GI50 value over 5 μM, 
suggesting a selectivity between cancer cells and healthy cells.57 
In order to extend the structural diversity of coordinated NHC ligands, Ott and 
co-workers prepared gold(I) complex 37 (Fig 1.3.17) bearing an aminotriazole-based 
NHC ligand via silver(I) oxide route. The complex 37 displayed pronounced cytotoxic 
activities in vitro against HT-29 (colon carcinoma) and MDA-MB-231 (breast 
carcinoma) cells with IC50 values in the low micromolar range (2.1 μM and 1.0 μM, 
respectively), which is comparable with imidazole and benzimidazole-based 
[Au(NHC)2]
+ complexes. In addition, it showed moderate TrxR inhibition activity 
with an IC50 value of 1.2 μM. Cellular uptake studies demonstrated a fast 
accumulation in HT-29 cells, which could be related to cationic charge and lipophilic 
property of the complex.58 
 
Fig 1.3.17 Bis-NHC Au(I) complexes reported by Ott and co-workers (37) and by 
Saha, Dinda and co-workers (38). 
 
A novel Au(I)-NHC complexes (38, Fig 1.3.17) derived from 2-pyridin-2-yl- 
2H-imidazo[1,5-α]pyridine-4-ylium salt was synthesized by Saha, Dinda and 
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co-workers. The cytotoxic activities of complex 38 were carried out in vitro on a panel 
of cancer cells, such as HepG-2 (human hepatocellular carcinoma), HCT-116 (human 
colorectal carcinoma), MCF-7 (human breast adenocarcinoma) and A549 (human 
non-small lung carcinoma). In addition, IC50 values of 38 were 2-3 times lower than 
those of cisplatin. Furthermore, 38 could induce apoptotic change in cell morphology 
(namely, cell shrinkage and rounding, chromatin condensation, and DNA 
fragmentation), mediate cell cycle arrest at the G2/M phase, and mediate cell death 
through mitochondrial pathway in HepG-2 cells.59 
Three gold(I) complexes (39a-39c, Fig 1.3.18) of the type [Au(NHC)2]
+ bearing 
ferrocene-functionalized NHC ligands were prepared by Arambula et al.. From a 
series of cell proliferation assays, it was shown that their cytotoxic activities in vitro 
were proportional to the amount of ferrocene in the complexes (IC50 values of 39a < 
39b < 39c). Moreover, complex 39c (IC50 = 0.14 μM) displayed over 10 times higher 
antiproliferative activity than auranofin (IC50 = 1.67 μM) against A549 lung cancer 
cells. Complexes 39a-39c were capable of time-dependent TrxR inhibition similar to 
auranofin as a result of lipoate reduction and intracellular free zinc elevation. 
Furthermore, RNA microarray gene expression was used to explain the mechanism of 
action of gold complexes, and it revealed that 39c can induce oxidative stress in 
endoplasmic reticulum.60 
Fig 1.3.18 Bis-NHC Au(I) complexes reported by Arambula et al. (39a-39c) and by 
Casini and co-workers (40). 
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To study about the interaction of the biscarbene gold(I) complex and DNA 
sequence, [Au(9-methylcaffein-8-ylidene)2]BF4 (40, Fig 1.3.18) was investigated 
through different physio-chemical methods. Complex 40 was recently reported by 
Casini and co-workers to form stable adducts with human telomeric DNA (HT-DNA) 
folded into the G-quadruplexes.61 A few years later, Messori and co-workers reported 
the identification of conformational changes experienced by Tel23 
(5’-TAGGG(TTAGGG)3-3’) upon interaction with gold-bis(NHC) complex 40. A 
series of computational studies revealed the inherent non-covalent metallodrug/DNA 
interaction, and it was shown that Au(NHC)2/Tel23 adduct was capable of producing a 
strong and selective inhibition of telomerase activity in cancer cells, which could be a 
validated target for new anticancer drug development.62 
A series of gold-bis(NHC) complexes (41a-41d, Fig 1.3.19) were prepared by Ott 
and co-workers and their antiproliferative activities against cancer cells were 
evaluated. All these complexes were effective with IC50 values in the low micromolar 
and nanomolar range. Complexes 41c and 41d exhibited much higher activities in 
vitro than auranofin against four different kinds of cells (namely, HT-29 colon 
carcinoma, MCF-7 breast cancer, MDA-MB-231 breast cancer and RC-124 healthy 
human kidney cells) and reached IC50 values in the range of 0.05-0.18 μM. Protein 
binding and cellular uptake experiments indicated a strong correlation between 
cellular bioavailability and cytotoxic effects.63 
Fig 1.3.19 Bis-NHC Au(I) complexes reported by Ott and co-workers (41a-41d) and 
by Arambula and co-workers (42a and 42b). 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
31 
 
To achieve an approach of targeting antioxidant pathway, gold(I) complexes 
bearing 1,4-naphthoquinone-based NHC ligands (42a and 42b, Fig 1.3.19) were 
designed and synthesized by Arambula and co-workers and their cytotoxic effects 
were tested in vitro against a panel of human cancer cell lines. Complex 42a, 
containing two NHC-quinone groups, was found to show much higher 
antiproliferative activities than the corresponding mono(NHC)-Au complex. In 
addition, A549 cells treated with complex 42a, which was found to localize in 
mitochondria, led to an increase of ROS production. Furthermore, complex 42a was 
found to induce cell death via apoptotic pathway, and it was shown to be effective in 
zebrafish bearing A549 xenografts.64 
 
1.3.5.  Polynuclear NHC complexes as theranostic agents 
The first example concerning the luminescence studies of the intracellular 
distribution of biologically active NHC complexes was reported by Berners-Price and 
co-workers in 2006.65 Two dinuclear gold(I) complexes (43-cis and 43-trans, Fig 
1.3.20) bearing bidentate NHC ligands were designed to support Au-Au interactions 
of a predetermined length, which led to native luminescence of these complexes. 
Fig 1.3.20 Polynuclear NHC complexes reported by Berners-Price and co-workers 
(43-cis and 43-trans). 
 
The cellular uptake and distribution of complex 43-cis were evaluated in 
RAW264.7 cells (mouse macrophage cancer cell line) by fluorescence confocal 
microscopy. Comparison with bright-field images permitted exclusion of cell nuclei as 
targets. Furthermore, colocalization studies using LysoTracker red and MitoTracker 
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green manifested the localization of gold complexes in lysosomes rather than 
mitochondria (Fig 1.3.21).65 
 
Fig 1.3.21 (a) Bright-field image, (b) luminescence image showing 43-cis 
distribution and (c) luminescence image showing LysoTracker red distribution.65 
 
Incorporation of organic chromophores within the carbene structure has been a 
straightforward method in fluorescence confocal microscopy technologies, leading to 
the development of theranostic agents. In the previous paragraph, several NHC-metal 
complexes with organic chromophores have been mentioned about their anticancer 
activities, and additionally, they displayed luminescence that enabled them to study 
cellular distribution. Complex 34a and 34b (Fig 1.3.15) reported by Mao and 
co-workers contained fluorescent anthracene groups incorporated in the cyclic 
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bis(NHC) ligands.55 These complexes were excited at 405 nm and blue emission 
could be observed on the confocal microscopy. Colocalization assays with 
organelle-specific stains, such as MitoTracker green, manifested these complexes 
were localized in mitochondria and not in lysosomes (Fig 1.3.22). 
 
 
Fig 1.3.22 Determination of intercellular localization of compound by confocal 
microscopy (63 * oil-immersion objective lens). 34a and 34b were excited at 405 nm 
(blue). MitoTracker green was excited at 488 nm (green).55 
 
Other examples like complex 26 (Fig 1.3.12) bearing fluorescent anthracenyl 
group,48 complex 27 (Fig 1.3.12) with fluorescent coumarin group49 and complexes 
28a-28f (Fig 1.3.12) containing fluorescent acridine group50 could also act as 
theranostic agents for cellular distribution studies. 
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Fig 1.3.23 Au(I)-Ru(II) NHC complexes reported by Gornitzka, Hemmert and 
co-workers (44a-44c). 
 
Another way to make a bioactive molecule luminescence consists of the attachment 
of an organometallic dye. Gornitzka, Hemmert and co-workers reported three 
heterobimetallic gold(I)-ruthenium(II) complexes containing heteroditopic 
bipyridine-based NHC ligands (44a-44c, Fig 1.3.23).66 Then in vitro cytotoxic, 
antileishmanial and antimalarial activities of these complexes were evaluated, and all 
these complexes showed moderate effects due to the presence of Ru(bpy)3 moiety. 
The fluorescent confocal microscopy experiments indicated that 44b was localized in 
the cytoplasm. Experiments using MitoTracker green for mitochondria labeling and 
DAPI for nuclei labeling demonstrated that no colocalization could be found in 
mitochondria or in nucleus (Fig 1.3.24). 
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Fig 1.3.24 Fluorescence and transmission images of the cells treated with 44b (in 
red) and labeled with MitoTracker (in green, bottom) or DAPI (cyan, top).66 
 
1.3.6.  In vivo anticancer studies of Au(I)-NHC complexes 
Despite the general interest in the development of gold-based complexes and the 
high in vitro anticancer activity shown in several gold NHC complexes, there are only 
few studies to investigate their in vivo anticancer activity. 
Zou et al. evaluated the in vivo anticancer effect of the dinuclear gold(I) complex 
(18a, Fig 1.3.9) bearing a bridging bis(NHC) ligand and a diphosphine ligand. 
Complex 18a can significantly inhibit tumor growth in mice bearing HeLa xenograft 
and mice bearing highly aggressive mouse B16-F10 melanoma, whereas no mouse 
death or body weight loss were observed. Moreover, toxicity studies suggested that 
18a did not show systematic anaphylaxis on guinea pigs and localized irritation on 
rabbits.67 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
36 
 
Fig 1.3.25 Au(I)-NHC complexes for in vivo studies reported by Schobert and 
co-workers (45), Dinda, Saha and co-workers (46) and Tacke and co-workers (47). 
 
A series of gold(I) bis-carbene complexes (45a-45f, Fig 1.3.25) with NHC ligands 
derived from the plant metabolite combretastatin A-4 (CA-4) was designed and 
synthesized by Schobert and co-workers.68 The in vivo anticancer activity and 
tolerance of gold complexes 45d and 45f were investigated in a Balb/c mouse 
xenograft model of highly metastatic B16-F10 mouse melanoma cells. Two weeks 
after continuous implantation of 200,000 cells in mice, complexes 45d and 45f were 
repeatedly administered at 15 mg per kg body weight for two consecutive days. The 
results showed that this treatment was well tolerated by the mice, leading to a slight 
decrease in body weight, and noticeable tumor regression. 
Another gold bis(NHC) complex (46, Fig 1.3.25) was tested in vivo on mice 
bearing the B16-F10 mouse melanoma by Dinda, Saha and co-workers.69 Complex 46 
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was administered at the dosages of 5 and 10 mg/kg body weight per day from 15th day 
onward since the day of injection of B16-F10 cells in the mice till the 23rd day. 
Dose-dependent decrease in the tumor size was observed following treatment with 
complex 46, whereas body weight remained nearly constant. 
The two neural Au(I) complexes 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene 
gold(I) chloride 47a (Fig 1.3.25) and its 2',3',4',6'-tetra-O-acetyl-β-D-glucopyranosyl- 
1’-thiolate derivative 47b (Fig 1.3.25) were tested in vivo in a Caki-1 xenograft mouse 
model.70 Firstly, the maximum toterable dose (MTD) was determined with single 
injection to groups of two mice, giving values of 10 mg/kg for 47a and 7.5 mg/kg for 
47b. In tumor xenograft experiments, these complexes were given at MTD in six 
injections to two cohorts of six Caki-1 tumor-bearing NMRI: nu/nu mice. Complex 
47a at the dose of 10 mg/kg and complex 47b at the lower dose of 7.5 mg/kg induced 
both low toxicities in the form of abdominal swelling but no significant body weight 
loss was found in both groups. Both complexes displayed a significant and identical 
tumor volume growth reduction, and the optimal T/C values (tumor size in the treated 
group in relation of non-treated control) of 0.47 were observed on day 19 for 47a and 
on day 29 for 47b. 
 
1.4. Metal complexes for photodynamic therapy application 
1.4.1.  Mechanism of action of photodynamic therapy 
Photodynamic therapy (PDT), an emerging light-activated treatment for cancer, has 
been successfully used for skin cancer for over 100 years.71 PDT requires three 
essential non-toxic components, namely, light, a photosensitizer (PS) and molecular 
oxygen (Fig 1.4.1). Reactive oxygen species (ROS), such as singlet oxygen and free 
radicals, are generated by the energy transfer between the excited state of PS and the 
ground state of molecular oxygen, leading to cellular toxicity.72 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
38 
 
 
Fig 1.4.1 Mechanism of action of photodynamic therapy (PDT). 
 
Generally, absorption of light (photons) leads to a transform from a ground state 
(singlet state) of PS into an excited state (triplet state) via an excited singlet state. 
Then two kinds of relaxation reactions can occur (Fig 1.4.2). Firstly, the PS in triplet 
state can transfer its energy to molecular oxygen (3O2) leading to singlet oxygen (
1O2), 
which is the major cytotoxic agent involved in photodynamic therapy (type II process). 
Alternatively, the triplet state PS can react directly with a substrate, such as the cell 
membrane or a molecule, and transfer a hydrogen atom or electron to form radicals. 
These radicals interact with oxygen to produce oxidation products (1O2), which is a 
type I process.73 
 
Fig 1.4.2 Photosensitization process illustrated by a modified Jablonski diagram. 
 
1.4.2.  Ruthenium(II) complexes as photodynamic anticancer agents 
To date, Food and Drug Administration (FDA)-approved sensitizers for PDT were 
mainly porphyrinoid compounds. The first PS for treatment of different kinds of 
cancer all over the world including the United State (by FDA in 1995) was photofrin 
(Fig 1.4.3).74 However, its clinical trials were hampered by poor solubility of 
porphyrin derivatives, low quantum yield of singlet oxygen (1O2) production and lack 
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of selectivity between normal cells and cancer cells. In 2002, Foscan®  
(dihydroporphyrin or chlorine, Fig 1.4.3) was granted marketing authorization in 
several countries for the treatment of neck and head cancers.75 In urology, the french 
company Steba-Biotech has developed Tookad®, currently in phase III for the 
treatment of prostate cancer.76 Tookad® (Fig 1.4.3) is a palladium-containing 
lipophilic bacteriochlorophyll; his maximum absorption is at 760 nm which allows 
light to penetrate deeply into tissue (up to 2 cm instead of 3-5 mm for porphyrins), 
and its low distribution in tissue allows rapid clearance. These three PDT agents are 
based on tetrapyrrole or porphyrin derivatives. The phototoxicity induced by these 
PSs has an absolute dependence on oxygen, which excludes activity in hypoxic tissues 
and compromises clinical dosimetry in vivo. 
 Fig 1.4.3 Photosensitizers in clinical PDT. 
 
With regard to bladder cancer, Hexvix® (hexaminolevulinate, Fig 1.4.3), which 
induces fluorescence by cystoscopy in blue light, is a pro-drug indicated in addition to 
conventional cystoscopy in white light, to aid diagnosis and treatment in patients with 
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known or strongly suspected bladder carcinoma.77 It is a pro-drug with no 
photochemical activity that will enter the body and initiate a series of biochemical 
reaction in the cells after irradiation leading to the formation of PS drug, hypericin, a 
powerful PS. This is a polycyclic aromatic compound belonging to the class of 
quinone derivatives used for fluorescence diagnosis of bladder carcinoma.78 Hypericin 
has drawn a lot of attention in its possible use in the treatment of bladder cancer. It 
causes damage to the urothelial tumor, however, there are 2 to 5% of tumor cells that 
can survive after photodynamic treatment, which leads to the regrowth of tumors after 
a prolonged period of time. 
Various researchers in the field of coordination chemistry have recognized the 
importance of metals in medicine and have made significant progress towards the 
development of unique organometallic PSs.79 Most of the metal complexes proposed 
as PSs are ruthenium polypyridyl complexes, the Ru(II) complex TLD1433 (a Ru(II) 
Dyad derived from 2-(1-pyrenyl)-1H-imidazo[4,5-f][1,10]phenanthroline, Fig 1.4.4) 
being approved to enter phase Ib clinical trials for non-muscle invasive bladder cancer 
in Canada (Parenteral, NCT03053635).80 
 
Fig 1.4.4 Structure of TLD1433. 
 
Gasser and co-workers reported two Ru(II) polypyridyl complexes (48a and 48b, 
Fig 1.4.5) as PSs for PDT. Complex 48b displayed moderate phototoxicity against 
HeLa (human cervical cancer cells) in micromolar range with an IC50 value of 25.3 
μM, and more importantly, no dark toxicity was found for this compound. Complex 
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48a manifested phototoxicity in the nanomolar range with an IC50 value of 0.6 μM 
against HeLa cells, and phototoxic index (PI) was 80 relative to the dark experiments. 
From the confocal microscopy experiments, it was shown that complex 48a 
accumulated in the cytoplasm, particularly in mitochondria. The results confirmed by 
ICP-MS showed an accumulation of 67% of Ru taken up into mitochondria for 
complex 48a, and by comparison, the cellular uptake for complex 48b was more 
diffuse. Therefore, improving the cellular uptake of the complexes may help to 
increase the photodynamic activity and selectivity against cancer cells.81 
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 Fig 1.4.5 Ruthenium(II) complexes as PSs reported by Gasser and co-workers (48a 
and 48b) and by Chao and co-workers (49a-49d). 
Since the irradiation wavelength of the one-photon (OP) PSs for PDT was visible 
light, which had limited tissue penetration, further work was done to develop novel 
ruthenium two-photon (TP) PSs that were active in the red-to-NIR region. Chao and 
co-workers developed four ruthenium(II) polypyridyl complexes (49a-49d, Fig 1.4.5), 
which acted as mitochondria-targeting TP PDT agents. These complexes 49a-49d 
displayed remarkable singlet oxygen quantum yield (0.74-0.81) and two-photon 
absorption cross section (σ2) values were ranged from 124 to 198 GM (1 GM = 10-50 
cm4 s photon-1), which were much larger than that of tetraphenylporphyrin (H2TPP, σ 
= 2.2 GM). In addition, OP photocytotoxicity of these complexes towards HeLa 
monolayer cells was evaluated. Complexes 49a-49c exhibited similar phototoxic 
activity with IC50 values of 12.4-15.5 μM, whereas 49d displayed the lowest IC50 
value of 3.5 μM, having a PI value of over 28. Furthermore, two-photon 
photocytotoxicity against 3D multicellular spheroids (MCSs) was assessed. After laser 
irradiation, complex 49a-49d displayed a very effective inhibition of MCSs growth. 
Remarkably, complex 49d demonstrated the lowest IC50 value of 1.9 μM in TP PDT 
(λirr = 830 nm) for 3D MCSs, suggesting this cationic ruthenium(II) complex as a 
mitochondria-targeting TP PDT agent.82 
 
1.4.3.  Iridium(III) complexes as photodynamic anticancer agents 
Iridium(III) complexes as PSs were studied due to their easy synthesis, air and 
moisture stability. Furthermore, heteroleptic Ir(III) complexes with bipyridyl and 
cyclometalated ligands have displayed high photostability due to high metal-centered 
state and ease of modulation of HOMO and LUMO energy levels.79b 
Four cyclometalated iridium(III) complexes bearing β-carboline (a kind of 
biologically active alkaloid) ligands (50a-50d, Fig 1.4.6) was designed and 
synthesized by Mao and co-workers. Upon visible light (425 nm) irradiation, they 
displayed strong photocytotoxicity against cancer cells. Remarkably, complex 50b 
showed the most effective phototoxic activity with a PI value of over 833 against 
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A549 cells (human lung carcinoma) and high selectivity between cancer cells (A549) 
and normal cells (LO2). Further mechanism studies demonstrated that 50b-mediated 
PDT triggered caspase- and ROS-dependent apoptotic cell death through lysosomal 
damage and cathepsin B release. In addition, this compound could be used to monitor 
real-time lysosomal integrity during PDT.83 
Fig 1.4.6 Iridium(III) complexes as PSs reported by Mao and co-workers (50a-50d, 
51a-51d). 
 
Based on this work, Mao and co-workers reported a second generation of 
mixed-ligand phosphorescent iridium complexes (51a-51d, Fig 1.4.6).84 These 
complexes showed high luminescence quantum yields, long lifetimes and high 
aqueous photostability. Since complexes 51b and 51d with phenyl-pyridine (ppy) 
ligands were more lipophilic than 51a and 51c with bipyridine (bpy) ligands, they can 
be taken up into A549 (lung carcinoma) cells more effectively. The intracellular 
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phosphorescence intensity of 51b at pH roughly mimicking the lysosomal 
environment (5.0) was much stronger than that at pH in the physiological condition 
(7.4). This result manifested that the selective lysosomal targeting property of 51b 
originated from its pH-dependent emission. However, 51d showed similar 
phosphorescence intensity both in acidic and physiological condition, and it can 
specifically target mitochondria. Notably, complex 51b displayed the best PDT 
activity against various cell lines with a photocytotoxicity index (PI) ranging from 
12.7 to 54.1. From the study of mechanism, it was shown that 51b and 51d induced 
apoptotic cell death through caspase- and ROS-dependent pathways. The results 
revealed the potential of these iridium(III) complexes as novel photodynamic 
anticancer agents. 
Zhao and co-workers developed two PSs based on iridium(III) complexes (52a and 
52b, Fig 1.4.7), which specifically target the mitochondria and lysosomes. The singlet 
oxygen quantum yields (ΦΔ) of 52a and 52b were 0.17 and 0.21, respectively, which 
revealed their potentials as PDT agents. The phototoxic activities of these complexes 
under normoxia (normal oxygen condition) and hypoxia (low oxygen condition) were 
evaluated. The results indicated that mitochondria-targeting complex 52a had a better 
PDT activity than lysosome-targeted complex 52b, especially under hypoxia 
condition, which was an advantage for PDT applications in hypoxic solid tumors. One 
explanation was that the complex 52a displayed a more efficient inhibition of 
mitochondrial respiration leading to a higher mitochondria oxygen concentration.85 
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Fig 1.4.7 Iridium(III) complexes as PSs reported by Zhao and co-workers (52a and 
52b) and by Kwon and co-workers (53a-53d). 
 
To study the detailed mechanism of protein inactivation triggered by ROS, Kwon 
and co-workers reported four Ir(III) complexes (53a-53d, Fig 1.4.7).86 From MTT 
tests, it was shown that the complexes 53c and 53d had potentials to be PDT agents at 
low concentration upon low-energy light irradiation (1 J cm-2), due to their relatively 
high ROS generation ability. In addition, 53c could induce cell death upon TP 
irradiation (860 nm). Furthermore, two kinds of protein modifications (protein-protein 
cross-linking and protein oxidation) were verified by mass spectrometry (MS). In 
living cells, these modifications induced by these Ir(III) complexes were found at both 
endoplasmic reticulum and mitochondria, leading to an obvious effect for cancer cell 
death. 
To avoid the problem of aggregation-induced fluorescence quenching and reduced 
photocytotoxicity, the group of Chao designed a series of iridium(III) complexes 
(54a-54c, Fig 1.4.8) which had aggregation-induced emission (AIE) properties. As an 
AIE-active agent, the phosphorescence quantum yields (ΦPL) of complex 54a 
increased from 0.001 in DMSO to 0.044 in 90% water-DMSO. All these complexes 
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exhibited more efficient ROS generation in a 90% water-DMSO mixture. The cellular 
uptake and intracellular distribution experiments revealed that iridium complexes 
selectively accumulated in mitochondria. Furthermore, all the complexes showed low 
toxicity towards HeLa and LO2 cell lines, whereas after OP-PDT, the cytotoxicity 
increased drastically. Interestingly, all these complexes were less toxic towards 
noncancerous LO2 cell lines. Notably, complex 54a was found to be the most 
effective against HeLa cells with an IC50 value of 0.4 μM and a PI value of 75. 
Additionally, complex 54a, which exhibited the highest TP absorbing cross-section 
(214 GM in 90% DMSO-water), the highest ROS generation ability and the most 
impressive lethality towards 3D multicellular tumor spheroids (MCTS), was a 
promising candidate for TP-PDT.87 
 
Fig 1.4.8 Iridium(III) complexes as PSs reported by Chao and co-workers (54a-54c, 
55a-55d). 
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In the same group, they reported a series of novel cyclometalated iridium(III) 
complexes acting as co-drugs (55a-55d, Fig 1.4.8) with dichloroacetate (DCA) to 
obtain enhanced PDT anticancer activities. The 1O2 quantum yield values of these 
Ir(III) complexes were ranging from 0.53 to 0.74, comparable to that of H2TPP. The 
confocal imaging experiments displayed that all these complexes could accumulate in 
mitochondria to a high degree. Complexes 55a-55c including DCA moiety induced 
obvious decrease of mitochondrial membrane potential (MMP) as a result of efficient 
cellular uptake and successful release of DCA, while 55d and DCA caused slight 
changes. It was shown that obvious enhancement of anticancer activities was found 
for 55a-55c after OP irradiation, and they manifested lower toxicity against LO2 than 
other cancerous cells, whereas for DCA monotherapy and 55d without DCA moiety, 
no discrepancy occurred. Furthermore, after TP irradiation, complexes 55a-55c 
displayed significant inhibition of MCTSs growth. In particular, 55a was found to be 
the most potent towards both monolayer cells and hypoxia MCTSs, being a promising 
candidate for TP-PDT.88 
Weinstein, Bryant and coworkers reported two cationic iridium(III) complexes 
bearing bisbenzimidazole ligands (56a and 56b, Fig 1.4.9).89 The emission quantum 
yields of complexes 56a and 56b were 0.33 and 0.24, respectively, and complex 56a 
had a remarkable TP cross section of 112 GM at 760 nm. Clonogenic assay in HeLa 
cells was made to evaluate the cytotoxicity of these complexes. Both complexes 
displayed high photocytotoxicity, with LC50 (50 % lethal concentration) values of 0.3 
and 0.5 μM, respectively. Notably, complex 56a exhibited low dark cytotoxicity, with 
a phototoxic index (PI) value of over 333, suggesting its potential as a PDT agent. The 
mechanistic studies revealed that ROS production and apoptosis were the mode of 
action of cell death. Furthermore, TP excitation at 760 nm in 56a-treated HeLa cells 
showed high photocytotoxicity with light power of 25 mW (2720 J cm-2) whereas no 
cell death was found without the complex. 
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Fig 1.4.9 Iridium(III) complexes as PSs reported by Weinstein, Bryant and 
co-workers (56a and 56b) and by Tian et al. (57a-57e). 
 
Tian et al. developed a series of terpyridine-based cyclometalated Ir(III) complexes 
with TP-PDT anticancer activity (57a-57e, Fig 1.4.9).90 These five complexes showed 
varied luminescent lifetimes and quantum yields, demonstrating the tunable 
photophysical properties of iridium(III) complexes. The toxicity against HepG-2 
(liver carcinoma) cells under dark and UV light condition was evaluated, and the 
results revealed 57b displayed less dark toxicity whereas the obvious decrease of cell 
viability occurred under UV light irradiation. In addition, from the intracellular 
distribution experiments, it was shown that complex 57a was located in nuclear region, 
while the others accumulated in mitochondria. Furthermore, the potential of 57a and 
57b as candidates for TP-PDT agents was determined on mice with planted solid 
tumors (4T1 mammary carcinoma cells). Interestingly, when treated with complex 
57a, the tumor growth was significantly inhibited, comparable with the commercial 
PDT agent Chlorin e6 (Ce6). 
A series of biscyclometalated Ir(III) complexes bearing borondipyrromethene 
(BODIPY)-based ancillary ligands (58a-58c, Fig 1.4.10) was designed by Martinez, 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
49 
 
Ortiz and co-workers.91 Complexes 58a and 58b with BODIPY groups directly linked 
to acetylacetonate displayed higher molar absorption coefficient, stronger emission 
quantum yield and more singlet oxygen production (ΦΔ = 0.86 and 0.60, respectively) 
upon visible light irradiation than 58c (ΦΔ = 0.51, only upon UV light). Additionally, 
the dark and photocytotoxicity of complexes 58a and 58b were tested in HeLa tumor 
cells. The results revealed that when irradiated by green light (for 58a) and red light 
(for 58b), both complexes induced remarkable photocytotoxicity, whereas no dark 
toxicity was found for them. Notably, 58a exhibited much better photocytotoxicity 
than 58b, with an IC50 value of 50 nM. 
Fig 1.4.10 Iridium(III) complexes as PSs reported by Martinez, Ortiz and co-workers 
(58a-58c) and by Ruiz and coworkers (59a-59e). 
 
Ruiz and co-workers reported five novel biscyclometalated iridium(III) complexes 
of general formula [Ir(C^N)2(N^N)][PF6] (59a-59e, Fig 1.4.10) to study the effect of π 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
50 
 
system of the polypyridyl ligand on cytotoxicity against various cancer cells. The less 
lipophilic complexes 59a and 59b with lower cellular uptake displayed higher 
cytotoxicity than complexes 59c and 59d against A2780 (ovarian carcinoma), HeLa 
(cervical carcinoma) and MCF-7 (breast carcinoma) cell lines with IC50 values 
ranging from 0.5 μM to 1.8 μM. Moreover, 59a and 59b were more efficient than 
cisplatin and showed better selectivity between cancer cells and normal cells 
(MCF-10A noncancerous breast cells) with SI values of 3.7 and 6.4, respectively. 
Mechanistic studies revealed that these iridium complexes involved inhibition of 
protein translation targeting endoplasmic reticulum (ER) and induced cell death 
through apoptotic pathway. Furthermore, the phototoxic activities against HeLa cells 
of all these complexes were evaluated, and the results demonstrated that upon visible 
light (420 nm) irradiation, the toxicity was significantly enhanced with IC50 values 
ranging from 0.044 μM to 0.866 μM due to a remarkable increase of intracellular 
ROS production.92 
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2. NHC-gold complexes containing aliphatic 
amino-side arms 
2.1. Introduction 
  In this chapter, the synthesis and the characterization of a family of NHC-gold(I) 
complexes containing aliphatic amino-side arms and the related anticancer activities 
will be discussed. 
Our group reported the synthesis and the biological investigation of a series of 
gold(I) complexes (II-1a to II-1d, Fig 2.1) containing two 1-[2-(diethylamino)ethyl] 
imidazolydene ligands. These complexes have been tested for their cytotoxic activities 
against PC-3 cells. It was shown that the lipophilicity of these complexes was in good 
agreement with the observed biological activities.57 The most active complex II-1d 
displayed remarkable cytotoxicity against five cancer cell lines (PC-3 prostate cancer, 
MCF-7 breast cancer, U87 brain cancer, A549 lung cancer and Hep3B liver cancer) 
with GI50 values ranging from 400 nM to 1 μM, whereas for HUVECs (normal 
primary human umbilical vein endothelial cells), it exhibited low activity even at the 
highest concentration of 5 μM, which suggested a good selectivity of II-1d. 
 
Fig 2.1 Bis-NHC Au(I) complexes reported by our group (II-1a to II-1d). 
 
The cationic charge and the lipophilic properties of complex II-1d are typical 
characteristic for delocalized lipophilic cations (DLCs). It was previously reported 
that DLCs can pass through the lipid bilayer and selectively accumulate in 
mitochondria of carcinoma cells as the consequence of elevated mitochondrial 
membrane potential (ΔΨm) in tumor cells.33 A huge number of DLCs have shown 
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remarkable anticancer activities, and the selectivity between cancer cells and normal 
cells can be modulated by changing the log P values of DLCs. 
 
Fig 2.2 Scheme of the NHC gold(I) complexes used in this study. 
 
In the previous work, we fixed the nitrogen-containing side arm but differ in their 
non-functionalized groups, namely, methyl, butyl, benzyl and mesityl. Based on 
previous biological activities of gold complexes, we designed a new series of 
complexes using benzyl group on one side of the azolium ring and varied the amine 
on the other side (Fig 2.2) in order to extend the SAR study. 
 
2.2. Synthesis and characterization 
The carbene precursors (II-2a to II-2d, Fig 2.3) were readily obtained after a 
quaternization step of 1-benzylimidazole with 1-(2-chloroethyl) piperidine 
hydrochloride, 1-(2-bromoethyl)-1H-pyrrole, 4-(2-chloroethyl)morpholine 
hydrochloride and 3-chloro-N,N-dimethylpropylamine hydrochloride, respectively, in 
aceronitrile at 80 oC with moderate yields ranging from 33 to 76%. The most notable 
features in the 1H and 13C NMR spectra of the imidazolium salts are the resonances 
for imidazolium protons (H2) located at 8.76-9.51 ppm and the corresponding 
imidazolium carbons (C2) in the range of 136.89-137.72 ppm. The resonance of the 
hydrochloride proton is comprised between 11.24 and 11.47 ppm. The high resolution 
mass spectra of the proligands exhibit the classical peak correponding to 
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[M-Cl--HCl]+ for II-2a, II-2c and II-2d, and [M-Br-]+ for II-2b. 
 
Ligand R X Complex Yield (%) 
II-2a 
 
Cl II-3a 40 
II-2b  Br II-3b 50 
II-2c 
 
Cl II-3c 84 
II-2d 
 
Cl II-3d 84 
Fig 2.3 Synthesis of carbene precusors (II-2a to II-2d) and gold(I) complexes (II-3a 
to II-3d). 
 
We have chosen the convenient transmetalation route to prepare the four gold(I) 
complexes (II-3a to II-3d, Fig 2.3). Firstly, the silver precursor complexes were 
prepared by deprotonation of the imidazolium salts II-2a to II-2d, with an excess of 
the mild base Ag2O (1.05 equivalent) in dry methanol at room temperature. An ion 
exchange with one half equivalent of AgNO3 dissolved in acetonitrile was performed, 
in order to avoid the formation of insoluble compounds or ionic species of type 
[Ag(NHC)2][AgX2]. The carbene transfer reaction was thus carried out in situ, by 
adding one half equivalent of Au(SMe2)Cl, with respect to the ligand. Gold(I) 
complexes II-3a to II-3d were isolated as white or grey powders with yields ranging 
from 40 to 84%; all the synthesized complexes are highly stable towards air and 
moisture and soluble in CH3CN, MeOH and DMSO.  
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Fig 2.4 1H NMR spectra of II-2a (top) and II-3a (down). 
 
From the comparison between the spectra, the success of the reaction can be readily 
proved (Fig 2.4). The characteristic signal related to H2 proton of the imidazolium salt 
was absent in the 1H NMR spectrum of the complex accompanied by a significant 
shift of other peaks. These experimental evidences can be observed for all the other 
compounds. In all case, the integration fits with the number of protons of the analyzed 
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compounds. 
 
Fig 2.5 13C NMR spectrum of II-3a. 
 
The 13C spectra show the resonance for the carbene carbon atoms at 183.96, 184.45, 
183.95 and 183.84 ppm, for II-3a to II-3d, respectively (spectrum for II-3a, see Fig 
2.5). The elemental analysis of the gold(I) complexes correspond to the general 
[AuL2][NO3] formula for II-3a to II-3d and the HRMS exhibit the classical peak 
corresponding to the cationic fragment [M-NO3
-]+ for II-3a (m/z = 735.3448), II-3b 
(m/z = 699.2509), II-3c (m/z = 739.3036) and II-3d (m/z = 683.3130). 
 
2.3. Molecular structures 
Crystals of compounds II-3a and II-3c have been obtained by slow gas-phase 
diffusion of diethyl ether into a concentrated solution of the complexes in acetonitrile. 
Crystals of compounds II-3b and II-3d suitable for X-ray diffraction analysis were 
obtained by slow evaporation from a methanol solution of these complexes. 
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Fig 2.6 Molecular structure of II-3a in the solid state. The cationic part is depicted on 
the left side at a 30% level thermal ellipsoid plot. For clarity only one of two 
independent cations is shown and H-atoms, non-coordinating anions and a disorder of 
one piperidine group are omitted. The arrangement of the two independent cations is 
shown on the right side. Selected bond distances [Å] and angles [°]: Au1-C1 2.020(9), 
Au1-C18 1.995(9), C1-Au1-C18 176.5(4). 
 
The cations of II-3a formed a kind of dimers in the solid state (Fig 2.6) with a 
distance Au1-Au2 of 4.023 Å which is too long to be considered as an aurophilic 
interaction. This arrangement explains the fact that the four side-arms of the two NHC 
ligands are placed on the same side in report to the NHC-Au-NHC plane. The NHC 
planes in each cation show only slight torsions of 7° and 9°, respectively. The gold 
atoms are coordinated in a classical nearly linear manner for gold(I). The benzyl 
groups are in trans position related to the C-Au-C line. 
Au1
Au1
Au2
C1
C18
N2
N1
N3
N4
N5
N6
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Fig 2.7 Molecular structure of II-3b in the solid state. The cationic part is depicted on 
the left side at a 30% level thermal ellipsoid plot. For clarity H-atoms and 
non-coordinating anions are omitted. The arrangement of the cations in the solid state 
is shown on the right side. Selected bond distances [Å] and angles [°]: Au1-C1 
2.035(9), Au1-C17 2.034(9), C1-Au1-C17 178.1(4). 
 
The cations of II-3b formed also a kind of dimers in the solid state (Fig 2.7) with a 
distance Au1-Au1 of 5.764 Å which is also too long to be considered as an aurophilic 
interaction. In this arrangement the two side arms of one NHC ligand are on the same 
side of the connected NHC plane, but in this case the side arms of the other NHC of 
the cation are on the other side of the NHC-Au-NHC plane. In II-3b the NHC planes 
show a rotation of about 20° around the C-Au-C axis. The gold atoms are again 
coordinated in a classical nearly linear manner for gold(I). Fig 2.8 shows that the 
anions are located in canals between chains of cations.  
Au1
C1
C17
N2
N1
N3
N4 N5
N6
Au1
Au1
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Fig 2.8 Packing of II-3b in the solid state. 
 
 
Fig 2.9 Molecular structure of II-3c in the solid state. The cationic part is depicted on 
the left side at a 50% level thermal ellipsoid plot. For clarity only one of four 
independent cations is shown, H-atoms, non-coordinating anions and a disorder of one 
morpholine group are omitted. The arrangement of the cations in the solid state is 
shown on the right side. Selected bond distances [Å] and angles [°]: Au3-C65 
2.014(7), Au3-C81 2.015(7), C65-Au3-C81 174.8(3). 
 
Complex II-3c crystalized in the monoclinic space group P21 with four independent 
molecules in the asymmetric unit. The absolute structure parameter refined to x = 
0.245(7) and a disorder present in only one morpholine group has been treated. As in 
cations II-3a and II-3b, cations of II-3c formed a kind of dimers in the solid state 
Au3
C65
C81
N14
N13
N15
N16
N17
N18
Au1
Au2
O6
O5
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(Fig 2.9) with gold-gold distances out of range for aurophilic interactions (Au1-Au2 
4.136 Å and Au3-Au4 4.228 Å). All four independent cations show the same 
structural main features. As observed in II-3a, the four side-arms of the two NHC 
ligands of one cation are placed on the same side in report to the NHC-Au-NHC plane. 
The NHC planes in each cation show only slight torsions between 10° and 15°. The 
gold atoms are coordinated in a classical nearly linear manner for gold(I). The benzyl 
groups are in trans position related to the C-Au-C line. In II-3c the anions are more 
like located in wholes as in canals (Fig 2.10).  
 
Fig 2.10 Crystal packing of II-3c. 
 
 
Fig 2.11 Molecular structure of II-3d in the solid state. The cationic part is depicted 
on the left side at a 50% level thermal ellipsoid plot. For clarity H-atoms and 
non-coordinating anions are omitted. The crystal packing is shown on the right side. 
Selected bond distances [Å] and angles [°]: Au1-C1 2.012(2), C1-Au1-C1 180.0. 
Au1
C1
C1
N2N1
N3
N3
N2 N1
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In II-3d only half a molecule is present in asymmetric unit with the gold atom 
located on an inversion center (Fig 2.11). Cations are isolated from each other and the 
anions are placed in canals. The shortest gold-gold distances are 7.53 Å. The two 
NHC planes are perfectly coplanar. The side arms of one NHC ligand are placed on 
the same side of the plane of the corresponding NHC ring. The side arms of the 
second NHC ligand of one cation are situated on the other side of the NHC-Au-NHC 
plane. Looking on this plane the benzyl substituents are in trans position to each other. 
 
2.4. Antiproliferative activity 
The in vitro anticancer activities of these four Au(I)-NHC complexes II-3a to II-3d 
against four human cancer cell lines containing ovarian carcinoma (A2780 and its 
cisplatin-resistant variant A2780cis), hepatocellular carcinoma (HepG-2 and 
HepAD38) and the non-tumor Madin-Darby canine kidney epithelial (MDCK) cell 
line were examined by MTT assays93 (MTT: 3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazoliam bromide) and compared to the reference drug cisplatin. The 
cytotoxicity at 72 h against these five cell lines was depicted in terms of GI50 values 
and summarized in Table 2.1. This work has been done in collaboration with 
Raymond Wai-Yin Sun, Hong Kong. 
The cationic gold(I) bis(NHC) complexes II-3a and II-3b were found to display 
potent antiproliferative activities against cancer cell lines, with GI50 values ranging 
from 0.91 to 4.8 μM. The most active complex resulted to be II-3b with GI50 values 
of around 0.9 μM towards two kinds of ovarian cancer cell lines (A2780 and 
A2780cis). These results are indicative of a bioactivity of these complexes for cancer 
cells dependent on the nature of the groups on the NHC ligands. Importantly, this 
series of cationic gold(I) complexes (II-3a-II-3d) showed much higher cytotoxicity to 
ovarian carcinoma cell lines than to hepatocellular carcinoma ones. However, it 
should be mentioned that the commercial drug Sorafenib currently used to treat 
hepatocarcinoma exhibited a high IC50 value of 6.4 μM against HepG-2 cell line.94 
Remarkably, complexes II-3a and II-3b were found to be very effective towards 
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cisplatin-resistant ovarian cell line A2780cis, suggesting that these complexes are able 
to overcome the resistance to cisplatin with a resistant ratio of around 10.  
 
Table 2.1 Cytotoxic activity of gold(I) NHC complexes expressed as GI50 (μM) values 
towards selected cancer and normal cell lines as determined by MTT assay (72 h). 
 
complex A2780cis A2780 HepG-2 HepAD38 MDCK Log P 
II-3c 44±11 28±9 >50 >50 >50 -0.46±0.02 
II-3d 20±3 11±2 >50 >50 >50 -0.23±0.06 
II-3a 2.8±0.6 2.1±0.4 4.8±1.5 4.5±1.7 10±3 -0.01±0.01 
II-3b 0.97±0.11 0.91±0.23 3.1±1.1 1.1±0.2 5.9±1.5 0.29±.0.02 
cisplatin 34±2.40 3.2±0.61 4.31±1.10 12±1.3 27±3.8  
The GI50 values represent the concentrations of the complexes and compounds 
causing 50% inhibition of cellular growth. Data are expressed as mean ± standard 
error µM and are resulted from at least three independent experiments. 
 
In this series of cationic gold(I) bis(NHC) complexes, the two complexes II-3c and 
II-3d containing a morpholine moiety and an aliphatic amine, respectively, were 
found to be inactive against the cancer cell lines. All the complexes II-3a to II-3d 
showed a lower cytotoxic activity towards the healthy MDCK cells in comparison to 
cancer cells. The IC50 value of complex II-3b against a non-cancerous origin derived 
cell line MDCK was found to be 5.9 μM. In comparison to the A2780 cell line, II-3b 
exhibited a 6.5-fold selectivity towards cancerous cells than normal cells.  
In order to study SAR, lipophilicity of the gold complexes has been determined by 
using a shake-flask method.95 Stock solutions of these four compounds (50 μM) were 
prepared in the aqueous phase (previously saturated with n-octanol) and aliquots (1 
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mL) of each of these stock solutions were then added to an equal volume of the 
n-octanol phase (previously saturated with water). The resultant biphasic solutions 
were mixed for 1 h and then centrifuged (3000 × g, 5 min) to separate the phases. The 
concentrations of these complexes in the organic and aqueous phases were then 
determined using UV absorbance spectroscopy (260 nm). Log P was defined as the 
logarithm of the ratio of the concentrations of the studied complex in the organic and 
aqueous phases (Log P = Log [Au(org)]/[Au(aq)]). The obtained results are reported 
in Table 2.1.  
The Log P values (-0.01 ± 0.01 for II-3a, 0.29 ± 0.02 for II-3b, -0.46 ± 0.02 for 
II-3c and -0.23 ± 0.06 for II-3d) showed clearly a difference between II-3b 
containing a pyrrole group and the other complexes. In this series, the highest 
lipophilicity found for the complex II-3b correlates with the highest cytotoxic activity 
against cancer cells. These complexes ordered for cytotoxicity are II-3c < II-3d < 
II-3a < II-3b and exactly the same order was found for the lipophilicity. Moreover, 
this general trend can be related to an effect commonly known for DLCs.11a Due to the 
electric gradient between membrane’s inner and outer layers, DLCs can penetrate the 
hydrophobic barrier of cellular membranes and accumulate selectively in tumor cell 
mitochondria, due to a difference of around 60 mV between the mitochondrial 
membrane potential of cancerous and healthy cells. 
In conclusion, these data show that complex II-3b is active against a panel of 
cancer cell lines whereas reduced cytotoxicity is found towards healthy cells, which 
suggests that this complex is a good candidate as an anticancer agent with good 
prerequisites for in vivo tests. 
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3. NHC-gold complexes containing aromatic 
amino-side arms 
3.1. Introduction 
  In this chapter, the synthesis and the characterization of a family of NHC-gold(I) 
complexes containing amino groups linked to the NHC skeleton by an aromatic 
spacer and the related anticancer activities will be discussed. 
 
Fig 3.1 Sheme of the NHC gold(I) complexes used in this study. 
 
Recently, we have demonstrated that some mononuclear lipophilic cationic gold(I) 
bis(NHC) complexes containing aliphatic or aromatic functionalized arms displayed 
in vitro potent and selective anticancer activities on several human cancer cell lines.57, 
96 In chapter 2, we discussed about one class of our ligands characterized by a 
nitrogen containing group connected by aliphatic linkers to the NHC skeleton. By 
measuring the Log P values of the complexes II-3a to II-3d, we confirmed the direct 
relationship between cytotoxicity and lipophilicity. Herein, we present the synthesis 
and antiproliferative screening of an optimized series of complexes (Fig 3.1). Our 
pharmaco-modulation consisted in the replacement of the aliphatic linker by an 
aromatic linker in order to increase the lipophilicity. 
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3.2. Synthesis and characterization 
Firstly, we wanted to use the same synthetic route presented in chapter 2 to obtain 
the imidazolium salts. In the case of III-2a, we started from 1-benzylimidazole to 
react with 4-bromo-N,N-dimethylaniline under different conditions (Fig 3.2). In spite 
of the high temperature and the addition of catalysts, no formation of the imidazolium 
salt III-2a could be observed.  
Fig 3.2 Attempts to synthesize the proligand III-2a. 
 
Therefore, we changed the sequence of the synthetic route. Prior to the substitution 
reaction with the benzyl group, a copper-catalyzed N-arylation of imidazole with 
4-bromo-N,N-dimethylaniline in the presence of postassium carbonate and copper 
sulfate at 205 oC was carried out to achieve 4-(1H-imidazol-1-yl)-N,N- 
dimethylaniline. 
For the synthesis of the substituted imidazoles III-1c and III-1d, we started from 
imidazole to react with 1-(4-chlorophenyl)-1H-pyrrole and 4-(4-bromophenyl) 
morpholine, respectively, using the same procedure. Nevertheless, no reaction 
happened even after 3 days (Fig 3.3). So, we turned to use the stronger base potassium 
phosphate and copper(I) catalysts to obtain III-1c and III-1d (Fig 3.4). 
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Fig 3.3 Attempts to synthesize the substituted imidazoles III-1c and III-1d. 
 
In summary, the substituted imidazoles III-1a to III-1d were readily prepared by a 
copper-catalyzed N-arylation of imidazole with 4-bromo-N,N-dimethylaniline or 
4-bromo-N,N-diethylaniline in the presence of K2CO3 and CuSO4 at 205 °C for 10 h 
in the case of III-1a and III-1b respectively, and in the presence of K3PO4 and CuI at 
160 °C for 3 days in the case of III-1c and III-1d respectively (Fig 3.4). 
1-Arylimidazoles III-1a to III-1d were treated with benzyl chloride in dry acetonitrile 
at 80 °C for 10 h. Then the crude products were isolated by column chromatography 
on silica gel to obtain the four corresponding proligands III-2a to III-2d with yields 
ranging from 76 to 95%. They were classically characterized by 1H and 13C NMR 
spectroscopy, mass spectrometry and elemental analysis. The most notable features in 
the 1H and 13C NMR spectra of the imidazolium salts are the resonances for 
imidazolium protons (H2) located at 8.33-10.36 ppm, and the corresponding 
imidazolium carbons (C2) in the range of 135.22-136.09 ppm. 
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Fig 3.4 Synthesis of imidazolium salts III-2a to III-2d and gold(I) complexes III-3a 
to III-3d. 
 
The target gold(I) complexes III-3a to III-3d were synthetized according to the 
transmetalation pathway. Firstly, the silver precursor complexes were prepared by 
deprotonation of the imidazolium salts III-2a to III-2d, with an excess of the mild 
base Ag2O (1.05 equivalent) in dry methanol at room temperature. An ion exchange 
with AgNO3 dissolved in acetonitrile was performed, in order to avoid the formation 
of insoluble compounds or ionic species of type [Ag(NHC)2][AgBr2]. The carbene 
transfer reaction was thus carried out in situ, by adding one half equivalent of 
Au(SMe2)Cl, with respect to the ligand. Then the crude products were isolated after 
column chromatography on silica gel to achieve the gold complexes III-3a to III-3d 
as yellow powders with good yields ranging from 40% to 62%; all the synthesized 
complexes are highly stable towards air and moisture and even in solution. NMR 
spectroscopy unequivocally demonstrated the formation of the gold(I) complexes with 
the absence of the proton resonance of the acidic imidazolium and the 13C NMR 
spectra show the resonance for the carbene carbon atoms at 182.66 to 182.78 ppm, in 
good agreement with reported values for Au(I) bis(NHC) complexes.97 Protons 4 and 
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5 of the imidazole rings in the complexes were shifted upfield when compared to their 
corresponding proligands. The elemental analysis of the gold(I) complexes 
correspond to the general [AuL2][NO3] formula for III-3a to III-3d, attesting of their 
purity and the HRMS exhibit the classical peak corresponding to the cationic 
fragment [M-NO3
-]+ for III-3a to III-3d. 
 
3.3. Molecular structures 
Crystals of III-3a have been obtained by gas phase diffusion of diethylether in an 
acetonitrile solution of III-3a. 
 
Fig 3.5 Molecular structure of III-3a in the solid state. The cationic part is depicted as 
a 50% level thermal ellipsoid plot. H-atoms and non-coordinating anion are omitted 
for clarity. Selected bond distances [Å] and angles [°]: Au1-C1 2.012(7), Au1-C19 
2.013(8), C1-Au1-C19 177.4(4). 
 
The coordination sphere of the gold(I) cation (Fig 3.5) shows a classical linear 
geometry and the two NHC ring systems are slightly twisted with a torsion angle of 
around 8°. The two benzyl groups are in trans position in relation to the C-Au-C axe 
and to the NHC-Au-NHC plane. It is remarkable that the geometry around the 
nitrogen atom N3 is not planar as reflected in the total sum of the C-N-C angles, 
which is 350.45°. The crystal packing of III-3a presented in Figure 3.5 shows the 
arrangement of the NO3
- anions in channels in direction b. 
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Fig 3.6 Crystal packing of III-3a with view along b. 
 
Crystals of III-3b have been obtained by slow evaporation from methanol solutions 
of III-3b. 
 
Fig 3.7 Molecular structure of III-3b in the solid state. The cationic part is depicted as 
a 50% level thermal ellipsoid plot. For clarity only one of two independent cations is 
shown and H-atoms, non-coordinating anions and non-coordinating MeOH are 
omitted. Selected bond distances [Å] and angles [°]: Au1-C1 2.019(3), Au1-C21 
2.024(3), C1-Au1-C21 176.92(9). 
 
In the case of III-3b the asymmetric unit contains two cations, two anions and one 
molecule of MeOH. As visualized in Figure 3.7, in this complex, the benzyl groups 
are in trans position relative to the C-Au-C axe, but they are on the same side of the 
NHC-Au-NHC plane. Moreover, the two NHC planes of a cation are coplanar (Fig 
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3.8). 
 
Fig 3.8 Dimeric arrangement of III-3b with view along the C-Au-C axe on the left 
side and perpendicular to this on the right side. 
 
In the solid state, III-3b forms dimers with Au-Au distances of 3.45 Å (Au1-Au1) 
and 3.64 Å (Au2-Au2), respectively. One is in the range for aurophilic interaction 
(aurophilic interaction can occur when the distance between two gold atoms is less 
than 3.6 Å, around twice the van der Waals radius of gold atom),98 the other one not. 
Also in this case, the anions are located in channels following direction b. 
 
Fig 3.9 Crystal packing of III-3b with view along b. 
 
Crystals of III-3c have been obtained by slow evaporation from acetonitrile 
solutions of III-3c. 
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Fig 3.10 Molecular structure of III-3c in the solid state. The cationic part is depicted 
as a 30% level thermal ellipsoid plot. For clarity H-atoms, non-coordinating anions 
and disorders of one benzyl group are omitted. Selected bond distances [Å] and angles 
[°]: Au1-C1 2.024(16), Au1-C21 2.018(14), C1-Au1-C21 171.9(6), Au1-Au1 
3.309(2). 
 
In III-3c the groups show the same arrangement as in III-3b, which means that the 
benzyl groups are in trans relative to the C-Au-C axe and on the same side relative to 
the best plane formed by the NHC ring systems and the gold cation. In this case, a 
deformation of the linear geometry of the gold cation is reflected by the C-Au-C angle 
of 171.9°, this has also an effect on the co-planarity of the NHC rings, which are 
twisted by about 10°. This deformation can be explained by an aurophilic interaction 
(Fig 3.10) with an Au-Au distance of 3.309 Å.  
 
Fig 3.11 Dimeric arrangement of III-3c in the solid state. Left side shows the view 
perpendicular to the Au-Au bond and the on the right the view along the Au-Au bond 
is depicted. 
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The dimer shows a rotation of 36.2° of the two cations around the Au-Au bond 
showing a slightly crossed configuration of the two cations relatively to each other 
(Fig 3.11). Moreover, the anions are not located in channels or layers (Fig 3.12). 
 
Fig 3.12 Packing of III-3c with view along a. 
 
3.4. Antiproliferative activities 
We firstly evaluated the in vitro cytotoxicity of the cationic gold(I) bis(NHC) 
complexes III-3a to III-3d and proligands III-2c and III-2d on the representative 
PC-3 prostate and T24 bladder cancer cell lines using the colorimetric MTT assays. 
This work has been done in collaboration with Dr. Olivier Cuvillier (IPBS, France), 
who supervised me to make the biological measurements. PC-3 and T24 cells (5000 
cells/well) were seeded on a 24-well tissue culture plate and allowed to attach 
overnight. Then, cells were treated with complexes III-3a to III-3d and incubated for 
72 h. Complex-free solvent controls were also included (not shown) to verify the 
absence of unusual cellular behaviour. The values reported in Fig 3.13 and Fig 3.14 
are presented means ± standard error of the mean (SEM) of three independent 
experiments. 
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Fig 3.13 Cell viability of PC-3 prostate cancer cells treated for 72 h with increasing 
concentrations of gold complexes III-3a to III-3d, proligands III-2c and III-2d and 
auranofin. 
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Fig 3.14 Cell viability of T24 bladder cancer cells treated for 72 h with increasing 
concentrations of gold complexes III-3a to III-3d, proligands III-2c and III-2d and 
auranofin. 
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As shown in Fig 3.13 and Fig 3.14, the four complexes III-3a to III-3d induced a 
pronounced loss of PC-3 and T24 cancer cell viability with GI50 values lower than 
250 nM with the complex III-3b displaying the strongest activity (GI50 ≈ 30 nM). 
Interestingly, among all the tested complexes, complex III-3c was the only one 
exhibiting a clear dose-dependent effect. Very notably, the proligands III-2c and 
III-2d showed no cytotoxic activities against PC-3 and T24 cells. We used the 
anti-arthritic drug auranofin as a reference for gold complexes given its potential 
repurposing in cancer as a pro-oxidant therapy with ongoing clinical trials in leukemia 
and lung cancer alone or in a combined modality. Remarkably, auranofin displayed a 
weaker efficacy towards prostate and bladder cells (GI50 ≈ 1 μM) as compared to all 
the tested complexes III-3a to III-3d (Fig 3.13 and Fig 3.14). 
The MC3T3 osteoblast precursor cell line is derived from mouse calveria, and it 
was used as non-cancerous cell model. Whereas less selectivity between cancer and 
non-cancerous cells was found for complexes III-3a, III-3b and III-3d, MC3T3 cells 
showed a pronounced insensitivity to complex III-3c up to the concentration of 0.5 
µM (GI50 value > 0.9 μM, Fig 3.15). 
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Fig 3.15 Cell viability of MC3T3 osteoblastic cancer cells treated for 72 h with 
increasing concentrations of gold complexes III-3a to III-3d and auranofin. 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
74 
 
In order to study about the SAR, we have determined the lipophilicity of the gold 
complexes III-3a to III-3d using a shake-flask method.8b The obtained results were 
reported in Table 3.1.  
 
Table 3.1 Lipophilicity for complexes III-3a to III-3d expressed as Log P. 
Complex Log P 
III-3a 1.256±0.047 
III-3b 0.926±0.030 
III-3c 1.033±0.060 
III-3d 0.501±0.024 
 
In our group, we have previously reported that lipophilic mononuclear cationic 
gold(I) bis(NHC) complexes containing amino groups on NHC scaffold were highly 
cytotoxic and selective. For example, a cationic gold(I) bis(NHC) complex involving 
a 1-[2-(diethylamino)ethyl] group on one side and a mesitylene group on the other 
side of the NHC ligands, with a Log P value of 1.13, showed GI50 values of 400 nM 
against PC-3 prostate cancer cells and > 5 μM on normal primary human umbilical 
vein endothelial cells (HUVECs).57 The corresponding benzyl containing complex 
had a Log P of 0.3 and showed a GI50 value of 1.44 μM on PC-3 prostate cancer cells. 
By replacing the aliphatic linker of this complex by an aromatic one (complex III-3b), 
the Log P value increased to 0.9 and the GI50 value on PC-3 prostate cancer cells 
decreased to 30 nM. In the case of complex III-3c, the log P is about 1 and the GI50 
value on HepG-2 cells is 640 nM, whereas the corresponding aliphatic connected 
pyrrole system display a log P value of 0.3 and an GI50 value on HepG-2 cells of 3.1 
μM.96 In summary, the Log P values of the tested complexes reflect the high 
lipophilicity of these complexes in good agreement with the obtained antiproliferative 
activities, whereas too high lipophilicity may also lead to the loss of selectivity.  
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Fig 3.16 Cell viability of PC-3, T24, HepG-2, A549, U-2 OS, MCF-7, MC3T3 and 
NIH3T3 treated for 72 h with increasing concentrations of gold complex III-3c. 
 
Accordingly, complex III-3c was selected as the most effective and selective 
compound for further in vitro screening on a representative panel of cancer cells, such 
as MCF-7 (human breast adenocarcinoma), HepG-2 (human liver cancer), A549 
(human lung carcinoma) and U-2 OS (human osteosarcoma) in addition to PC-3 and 
T24 cancer cell models. Two non-cancerous cell lines (MC3T3 mouse osteoblasts and 
NIH3T3 murine fibroblasts) were used as controls. All these cell lines were seeded at 
5000 cells/well in 24-well tissue culture plates, and allowed to attach overnight and 
then exposed to the graded concentrations of complex III-3c (0.1 μM to 5 μM) for 72 
h. The values reported in Fig 3.16 represent as the mean of three independent 
experiments.  
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Fig 3.17 Dose- response curves for the in vitro tested activity of complex III-3c 
towards PC-3, T24, HepG-2, A549, U-2OS, MCF-7, MC3T3 and NIH3T3 cell lines. 
 
All the viability values, obtained by MTT assay, were used to create log 
concentration versus percentage of cell viability curves (Fig 3.17). The GI50 values 
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were calculated from dose-response curves obtained by nonlinear regression analysis 
for each cell line (Table 3.2). 
 
Table 3.2 GI50 values of complex III-3c after 72h. 
GI50 values of complex III-3c after 72h 
Origin Cell line GI50 
Prostate cancer PC-3 0.25 μM 
Bladder cancer T24 0.24 μM 
Liver cancer HepG-2 0.64 μM 
Lung cancer A549 0.23 μM 
Osteosarcoma U-2 OS 0.24 μM 
Breast cancer MCF-7 0.12 μM 
Osteoblast MC3T3 0.90 μM 
Fibroblast NIH3T3 1.30 μM 
 
The GI50 values of complex III-3c were in the range of 0.12 μM to 0.25 μM for all 
tested cancer cell lines except for HepG-2 with a GI50 value of 0.64 μM. It should be 
pointed out that hepatocarcinoma is notoriously refractory to chemotherapy and even 
sorafenib, a commercial drug to treat hepotocarcinoma, displays a high GI50 value of 
6.4 μM on HepG-2 cell line.94 In contrast, the cytotoxicity of complex III-3c towards 
MC3T3 osteoblasts and NIH3T3 fibroblasts was low with GI50 values of 900 nM and 
1.3 μM, respectively. Compared with auranofin (GI50 value of 1.05 μM for PC-3 and 
1.80 μM for NIH3T3), complex III-3c displayed better selectivity between cancer 
cells and healthy cells with SI values of ranging from 2.1 to 10.8. In conclusion, these 
MTT results suggested that complex III-3c was highly active against various cancer 
cell lines and was selective with limited effects towards non-cancerous cells.  
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Fig 3.18 Cell viability of PC-3 (left) and T24 (right) cells treated with increasing 
concentrations of gold complex III-3c for the indicated times. 
 
Furthermore, the kinetic effects of gold complex III-3c on PC-3 and T24 cancer 
cell lines have been evaluated. As shown in Fig 3.18, the cell viability after treated 
with different concentrations of III-3c decreases with time, which means the 
cytotoxic activities of III-3c against PC-3 and T24 are enhanced with time. Taking 
PC-3 as an example, the GI50 value of 3c after 24 h was 810 nM, 550 nM for 48 h, and 
decreased to 250 nM at 72 h (Fig 3.18). This result displayed clearly the high growth 
inhibitory ability of III-3c against tested cancer cells. Interestingly, a linear increasing 
of the GI50 value over a period of 72 h could be observed. It is important to verify this 
tendency in order to exclude the possibility of a recovery of cell viability after the 
complex impact. 
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Fig 3.19 GI50 values of complex III-3c against PC-3 after 24 h, 48 h and 72 h. 
 
Another method to study the cytotoxic effect of gold complexes concerns 
clonogenic assay. Clonogenic assay or colony formation assay determines the ability 
of a cell to form a large colony (> 50 cells).99 It was the method of choice to 
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determine the effectiveness of radiotherapy or cytotoxic agents. As shown in Fig 3.20, 
no visible colony formation was observed at concentration of over 0.25 μM for PC-3 
cells and over 0.5 μM for T24 cell. This assay manifested the ability of complex 
III-3c to inhibit significantly the number of PC-3 and T24 colonies even at low 
concentration when compared to the controls. It gave more accurate information about 
the ability of a single cell to proliferate than MTT tests since it essentially tests every 
cell in the population for its ability to undergo “unlimited” division.99 
 
 
Figure 3.20 Colony formation in PC-3 (top) and T24 (bottom) cells treated with 
increasing concentrations of complex III-3c and stained with crystal violet after 8 
days (for PC-3) and 6 days (for T24) of cultivation. 
 
3.5. Optimization of gold(I) bis(NHC) complexes 
After increasing the lipophilicity of cationic gold(I) complexes, better anticancer 
activities were achieved. However, this series of gold complexes containing aromatic 
side-arms are mainly toxic towards non-cancerous cells, such as MC3T3 and NIH3T3. 
The lack of selectivity between healthy and cancer cells triggers us to do some 
pharmaco-modulation to optimize the system for gold(I) complexes.  
It has been previously reported by our group that gold(I) NHC complexes 
containing quinoline and thioanisole functionalized groups displayed better 
cytotoxicity than the complexes bearing a benzyl moiety against a panel of cancer cell 
lines with GI50 values ranging from 0.11 μM to 0.67 μM.96 Therefore, we replaced 
benzyl groups by quinoline and thioanisole groups on one side of the azolium cycle, 
and used pyrole and piperidine containing side arms on the other side. We designed 
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and synthesized a novel series of four proligands (III-5a to III-5c, Fig 3.21) and their 
corresponding gold(I) complexes (III-6a to III-6d, Fig 3.21). 
 
Fig 3.21 Synthesis of imidazolium salts (III-5a to III-5d) and gold(I) complexes 
(III-6a to III-6d). 
 
The substituted imidazoles III-4a and III-4b were readily prepared with a good 
yield of 80% by a copper-catalyzed N-arylation reaction with 4-bromothioanisole and 
2-chloroquinoline, respectively, in the presence of K2CO3 and CuSO4 at 205 
oC for 10 
h. 1-(4-Methylthiophenyl)-1H-imidazole (III-4a) and 2-(1H-imidazol-1-yl)quinoline 
(III-4b) were reacted with 1-(2-bromoethyl)-1H-pyrrole in dry acetonitrile at 80 oC 
for 10 h. Then the crude products were purified by column chromatograpy on silica 
gel to obtain the proligands III-5a and III-5c with yields of 40 % and 32 %, 
respectively. Similarly, the proligands III-5b and III-5d were achieved by reacting 
III-4a and III-4b with 1-(2-chloroethyl)piperidine hydrochloride with yields spanning 
from 20 % to 26 %. They were classically characterized by 1H and 13C NMR 
spectroscopy, mass spectrometry and elemental analysis. The most notable features in 
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the 1H and 13C NMR spectra of the imidazole salts are the resonance for imidazolium 
protons (H2) located at 9.41 to 10.05 ppm, and the corresponding imidazolium 
carbons (C2) in the range of 135.81 to 137.33 ppm. 
The target gold(I) bis(NHC) complexes III-6a to III-6d were synthesized 
according to the transmetalation method. Firstly, the silver precursor complexes were 
prepared by deprotonation of the imidazolium salts III-5a to III-5d, with one 
equivalent of the mild base Ag2O in dry methanol at room temperature. An ion 
exchange with AgNO3 dissolved in dry acetonitrile was performed, in order to avoid 
the formation of insoluble compounds or ionic species of type [Ag(NHC)2][AgX2]. 
The carbene transfer reaction was thus carried out in situ, by adding one half 
equivalent of Au(SMe2)Cl, with respect to the proligands. Then the crude products 
were purified by column chromatography on silica gel to obtain gold(I) bis(NHC) 
complexes III-6a to III-6d as pale-yellow powders with moderate to good yields 
ranging from 30% to 78%, and all the complexes were highly stable towards air, 
moisture and even in solution. NMR spectroscopy clearly demonstrated the formation 
of the gold(I) complexes with the disappearance of the proton resonance of the acidic 
imidazolium and the 13C spectra displayed the resonance for the carbene carbon at 
182.43 to 183.13 ppm. The elemental analysis of the gold(I) complexes correspond to 
the general [AuL2][NO3] formula for III-6a to III-6d, manifesting of their purity and 
the HRMS exhibit the classical peak corresponding to the cationic fragment 
[M-NO3
-]+ for III-6a to III-6d. 
 
Molecular structures 
Crystals of III-6c have been obtained by slow evaporation from an acetonitrile 
solution of III-6c. 
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Fig 3.22 Molecule structure of III-6c in the solid state. On the left side the cationic 
part is depicted as a 50% level thermal ellipsoid plot. On the right side the dimeric 
arrangement is shown. For clarity H-atoms, non-coordinating anion, acetonitrile and 
disordered water molecules are omitted. Selected bond distances [Å] and angles [°]: 
Au1-C1 2.023(2), Au1-C19 2.023(2), C1-Au1-C19 177.20(7), Au1-Au1 3.424. 
 
 The geometrical environment of Au1 in III-6c (see Fig 3.22) is in perfect 
agreement with other NHC-Au-NHC cations. The atoms forming the NHC-Au-NHC 
skeleton are coplanar and the pyrrole side arms are situated on the same side of this 
plane. The short Au-Au distances are in good agreement with aurophilic interactions. 
As shown in Fig 3.23 the acetonitrile and water molecules are located in channels in 
the crystal packing, while the anions are more in-between the cations. 
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Fig 3.23 Packing of III-6c in the solid state with view along a. 
 
Crystals of III-6d have been obtained by slow evaporation from a methanol 
solution of III-6d. 
 
Fig 3.24 Molecule structure of III-6d in the solid state. The cationic part is depicted 
as a 50% level thermal ellipsoid plot. For clarity H-atoms, non-coordinating anion and 
a disordered methanol molecule are omitted. Selected bond distances [Å] and angles 
[°]: Au1-C1 2.022(5), Au1-C20 2.018(5), C1-Au1-C20 179.1(2), Au1-Au1 3.715. 
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Fig 3.25 Packing of III-6d in the solid state with view along b. 
 
 The geometrical environment of Au1 in III-6d (see Fig 3.24) is very similar to 
other cations of this type. The atoms forming the NHC-Au-NHC skeleton are nearly 
coplanar with aslight torsan angel of 4° of the two NHC planes around the C-Au-C 
axis. The piperidine side arms are on the same side of the central NHC-Au-NHC 
plane due to a dimeric arrangement of the cations with long Au-Au distances of of 3.7 
Å. As shown in Fig 3.25 the disordered methanol meolecules are located in channels 
in the crystal packing and the the anions in other channels, separated by the cations 
from the methanol. 
 
In order to investigate the antiproliferative activities of this novel series of gold(I) 
cationic bis(NHC) complexes III-6a to III-6d, they were screened in vitro against 
PC-3 human prostate cancer cells and non-cancerous NIH3T3 murine fibroblast cells. 
This work has been done in collaboration with Dr. Olivier Cuvillier (IPBS, France), 
who supervised me to make the biological measurements. Results of the preliminary 
cytotoxic activities are presented in Table 3.3. 
The GI50 values reported express the mean of three independent experiments 
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analyzed 72 h after treatment. Auranofin, a commercial drug for anti-arthritis, was 
used as a reference. Gold complexes III-6a to III-6c were more cytotoxic against 
PC-3 than auranofin with GI50 values ranging from 0.53 to 0.71 μM. Interestingly, all 
the complexes III-6a to III-6c induced less cytotoxicity than auranofin against 
non-cancerous NIH3T3 cells, which exhibited a higher selectivity between cancer 
cells and normal cells than auronofin. 
 
Table 3.3 GI50 values of gold (I) complexes III-6a to III-6d and auronofin against 
PC-3 and NIH3T3 after 72h. 
Complex PC-3 (μM) NIH3T3 (μM) Log P 
III-6d 0.55 1.97 0.168±0.011 
III-6c 0.70 3.00 0.479±0.014 
III-6a 0.71 2.70 0.549±0.009 
III-6b 0.53 1.85 0.843±0.060 
Auranofin 1.05 1.80  
 
In order to study the SAR of these gold(I) complexes, lipophilicity of this series of 
gold complexes has been measured. The obtained results are reported in Table 3.3. All 
the complexes displayed pronounced cytotoxicity with GI50 values ranging from 0.53 
μM to 0.71 μM. However, no linear correlation between cytotoxic activity and 
lipophilicity could be observed. Compared with the family of gold(I) complexes 
containing aromatic amino side-arm (III-3a to III-3d), this series of compounds 
III-6a to III-6b showed less lipophilicity and less cytotoxicity towards healthy cell 
lines (NIH3T3) although they displayed lower anticancer activities than III-3a to 
III-3d against the tested cancer cell lines (PC-3). In addition, all these complexes 
exhibited higher antiproliferative activities towards cancer cells than the complexes 
bearing aliphatic amino side-arm (II-3a to II-3d). 
In summary, lipophilicity plays an important role in cytotoxic activity. Nevertheless, 
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higher lipophilicity may lead to a better anticancer activity, but it can also trigger 
higher cytotoxicity against healthy cells, resulting in less selectivity. Therefore, the 
further optimization by pharmaco-modulation will be done to develop some gold 
complexes with high anticancer activity and low toxicity towards healthy cells. 
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4. Mechanistic studies of gold(I) complexes 
(III-3c and IV-1) 
In this chapter, we will discuss about the mechanism of action of Au(I)-NHC 
complexes, such as cellular uptake, inhibition of isolated TrxR and cellular reducing 
agents, and reactive oxygen species (ROS) generation. 
In chapter 3, the gold complex (III-3c, Fig 4.1) was found to be the most effective 
and selective one among all the tested compounds. In addition, the cationic bis(NHC) 
complex (IV-1, Fig 4.1),96 which was previously synthesized by Dr. Catherine 
Hemmert in our group, showed also high cytotoxic potency and selectivity. Therefore, 
they were chosen for mechanistic studies. 
 
Fig 4.1 Structures of NHC gold(I) complexes III-3c and IV-1 used in this study. 
 
4.1. Cellular uptake 
Since both cationic Au-NHC complexes III-3c and IV-1 belong to the class of 
DLCs, they are expected to easily penetrate the cell membrane and efficiently 
accumulate in mitochondria of cancer cells due to the 60 mV difference of 
mitochondrial membrane potential between cancer cells and normal cells. 
Relationship between high cytotoxicity and intracellular accumulation is reported in 
previous literature.100 
Therefore, we evaluate the cellular uptake of complex III-3c in PC-3 cells by a 
method based on gold quantification by inductive coupled plasma atomic emission 
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spectroscopy (ICP-AES). The measurements were performed under serum-free cell 
culture medium in order to avoid protein binding. For this purpose, cells were 
incubated with a 2 μM solution of complex III-3c for up to 4 h at 37 oC and 5 % CO2, 
and the gold and protein contents of the cells were determined by ICP-AES and 
Bradford method, respectively. As shown in Fig 4.2, complex III-3c induced a 
time-dependent gold uptake in PC-3 cells. Additionally, an acute increase of cellular 
gold content occurred upon treatment with complex III-3c culminating a 0.087 μg/mg 
protein after 4 h of treatment, which corresponds to 0.46 nmol of gold per mg of 
protein. This result suggests the rapid cellular accumulation of the intact gold 
bis(NHC) and a good cellular bioavailability, which is in good agreement with the 
antiproliferative activity of this complex. 
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Figure 4.2 Gold uptake by PC-3 cells exposed to 2 μM of III-3c (left) and by HepG-2 
cells exposed to 2 μM of IV-1 (right). 
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For the gold complex IV-1, the same method was used. HepG-2 cells were 
incubated with a 2 μM solution of complex IV-1 for 1, 2 and 4 h at 37 oC and 5% CO2, 
and the gold and protein levels of the cells were determined by ICP-AES and the 
Bradford method, respectively. Complex IV-1 showed a cellular gold level of 0.63 
μg/mg protein after 1 h of exposure, which then increased over the total incubation 
period of 4 h to 3.01 μg/mg protein. This result manifested a fast cellular uptake of 
complex IV-1, in accordance with cytotoxic activity of the complex. 
The in vitro cytotoxicity of complex IV-1 towards HepG-2 cells has been tested, 
giving a GI50 value of 0.46 μM. In addition, it has been discussed in chapter 3 that 
complex III-3c induces an anticancer activity on HepG-2 cells with a GI50 value of 
0.64 μM. From the Fig 4.2, it is shown that complex IV-1 induces more cellular 
uptake than complex III-3c. Therefore, there is a certain correlation between cellular 
uptake and in vitro cytotoxic activity. Higher cellular uptake may lead to better 
cytotoxicity. 
 
4.2. Inhibition of mammalian TrxR 
The ubiquitous selenoenzyme TrxR is considered as one of the common targets for 
gold complexes, as gold displays a high infinity to selenol groups.26, 101 TrxR is a 
NADPH-dependent flavoprotein responsible for cell homeostasis regulation and 
inhibition of TrxR could lead to apoptosis through a mitochondrial pathway.8d, 102 
However, if gold displays a high affinity towards thiol and selenol groups, the 
inhibition potency of TrxR is influenced by the N-substituted groups of the NHC 
ligands and cannot be always correlated to the in vitro cytotoxicity. For example, Ott 
and co-workers reported a series of 20 structural diverse Au-NHC complexes (general 
structure: IV-2, Fig 4.3) with the aim of identifying the relationship between TrxR 
inhibition, antiproliferative activity and structural features of compounds.46 Most of 
the tested complexes displayed cytotoxic activity towards HT-29 colon 
adenocarcinoma cells with GI50 values in the low micromolar range. The most active 
complex was IV-2a with a GI50 value of 2.8 μM. However, the IC50 value of this 
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complex towards isolated TrxR was just 5.08 μM. Therefore, a direct correlation 
between the cytotoxicity of complexes and the inhibition of TrxR could not be 
reached. 
 
Figure 4.3 Structures of gold(I) NHC complexes (IV-2) reported by Ott and 
co-workers. 
 
The potential of complex III-3c to inhibit the target enzyme TrxR was studied in 
vitro on purified rat liver TrxR. Moreover, inhibition of reducing agents present in cell 
extracts has been tested in vitro. Both tests used a previously reported assay based on 
the NADPH dependent reduction of the sulfide bond of the substrate 5,5’- 
dithiobis-2-nitrobenzoic acid (DTNB) by the isolate enzyme.103 Complex III-3c was 
able to inhibit isolated TrxR in the low micromolar range with an IC50 value of 2.2 
μM (Fig 4.4). In order to evaluate the inhibition of cellular reducing agents, PC-3 cells 
were exposed to complex III-3c in graded concentrations for 1 h and after treatment, 
the cells were monitored colorimetrically for their ability to reduce DTNB. The IC50 
value for cellular reducing agents was 7.0 μM, which is in the same level as the 
isolated TrxR one (Fig 4.3). 
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Figure 4.4 IC50 values of complex III-3c towards isolated TrxR (left) and reducing 
agents in PC-3 cells (right). 
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In addition, the inhibition of isolated rat liver TrxR and reducing agents present in 
cell extracts for complex IV-1 was tested in vitro. Complex IV-1 was able to inhibit 
isolated TrxR in the low micromolar range with an IC50 value of 2.1 μM (Fig 4.5). In 
order to evaluate the inhibition of cellular reducing agents, HepG-2 cells were 
exposed to complex IV-1 in graded concentrations for 1 h and after treatment, the cell 
extracts were monitored colorimetrically for their ability to reduce DTNB. The IC50 
value for cellular reducing agents was 2.0 μM, which is very close to the isolated 
TrxR one (Fig 4.5). 
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Figure 4.5 IC50 values of complex IV-1 towards isolated TrxR (left) and reducing 
agents in HepG-2 cells (right). 
 
Recently, a novel series of cationic gold(I) bis(NHC) complexes (IV-3a to IV-3d, 
Fig 4.6) designed by Ott and co-workers displayed high cytotoxicity against cancer 
cells, whereas they just showed moderate to low inhibitory activities towards isolated 
mammalian TrxR enzyme with IC50 values ranging from 16.3 to 127.8 μM.63 It has 
been previously reported that neutral mono(NHC) gold(I) complexes were more 
effective TrxR inhibitors than their cationic bis(NHC) analogues, which can be 
illustrated in the case of 1,3-diethlbenzimidazol-2-ylidene NHC ligand.43 The Au(I) 
bis(NHC) complex IV-4b (IC50 = 4.89 μM) was found to be less active compared with 
the mono(NHC) complex IV-4a (IC50 = 0.36 μM) towards isolated TrxR. Generally, 
the neutral complexes are less stable in solution and particularly in physiological 
medium because of the lability of the halide, which generates a vacant site on the gold 
and allow a fast coordination with selenocysteine residue of the TrxR. Overall, as 
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discussed in the introduction section, the TrxR appears to be a common relevant target 
among others shared for this kind of gold complexes. 
 
Figure 4.6 Structures of gold(I) NHC complexes (IV-3 and IV-4) reported by Ott and 
co-workers. 
 
4.3. Effects on intracellular ROS levels 
Generation of reactive oxygen species (ROS) is a key characteristic of apoptotic 
cell death. ROS are mostly the products of the physiological mitochondrial cell 
metabolism and are involved in cellular redox homeostasis. Their formation may 
perturb the cellular antioxidant defense system. Au(I)-NHC complexes have been 
reported to generate ROS, which may be due to the inhibition of the TrxR, one of the 
antioxidant enzymes present in the mammalian cell together with catalase, glutathione 
peroxidase and superoxide dismutase that carry out the removal of ROS from the 
cells.43, 104 
In order to examine whether ROS played a role in cytotoxicity induced by complex 
IV-1, we used N-acetylcysteine (NAC), a ROS scavenger, to study its effect on cell 
viability. For this purpose, HepG-2 cells were pretreated with NAC at different 
concentrations (2 mM, 5 mM and 10 mM) for 1 h before the gold complex (1 μM) 
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was added. After treatment, the results showed that NAC substantially 
dose-dependently reduced the ROS accumulation and cytotoxicity of complex IV-1 in 
HepG-2 cells (Fig 4.7). These data suggested cytotoxicity induced by IV-1 was 
ROS-dependent, which is in line with other previously reported gold complexes. 
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Figure 4.7 Effects of NAC at different concentrations on IV-1–induced cytotoxicity. 
Data are presented as means ± SEM of three independent experiments. *p<0.05, 
**p<0.005, ***p<0.001, compared with the cell viability of complex IV-1 alone. 
 
Similarly, PC-3, T24 and HepG-2 cells were pretreated with NAC or gluotathione 
reduced (GSH) at different concentrations (2 mM, 5 mM and 10 mM) for 1 h prior to 
the addition of the gold complex III-3c (1 μM). As shown in Fig 4.8, in case of 
HepG-2 cells, without treatment of NAC and GSH, the cell viability was around 30%. 
After treated with 10 mM of NAC and GSH, the cell viability increased sharply to 
approximately 70%, which suggests that both NAC and GSH substantially reduced 
cytotoxic activity of complex III-3c in HepG-2 cells. In addition, this tendency was 
dose-dependent since the cell viability treated with 2 mM and 5 mM of NAC and 
GSH was around 45% and 60%, respectively. The same results can be also observed 
in PC-3 and T24 cells. Therefore, both NAC and GSH can dose-dependently reduced 
ROS production and cytotoxicity of complexes III-3c in various cancer cells, 
suggesting that cell death triggered by comlex III-3c was ROS-dependent. 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
94 
 
PC-3
0 2 5 10
0
20
40
60
80
100
NAC
GSH
* **
**
* **
**
Concentration of NAC and GSH (mM)
c
e
ll
 v
ia
b
il
it
y
(%
 o
f 
c
o
n
tr
o
l)
T24
0 2 5 10
0
20
40
60
80
100 NAC
GSH
*
**
**
* **
**
Concentration of NAC and GSH (mM)
c
e
ll
 v
ia
b
il
it
y
(%
 o
f 
c
o
n
tr
o
l)
 
HepG-2
0 2 5 10
0
20
40
60
80
100 NAC
GSH
**
***
**
*
** **
Concentration of NAC and GSH (mM)
c
e
ll
 v
ia
b
il
it
y
(%
 o
f 
c
o
n
tr
o
l)
 
Figure 4.8 The impact of N-Acetyl-L-Cystein (NAC) and reduced gluothione (GSH) 
on the cytotoxicity of complex III-3c (1 μM). PC-3, T24 and HepG-2 cells were 
treated with complex III-3c (1 μM) for 24 h in the absence or presence of different 
concentrations of NAC and GSH. Cell viability was measured by MTT assay. Data 
are presented as means ± SEM of three independent experiments. *p<0.05, **p<0.005, 
***p<0.001, compared with the cell viability of complex III-3c alone. 
 
Moreover, the effect of complex III-3c on the ROS levels in PC-3 cells was 
determined by the nitroblue tetrazolium chloride (NBT) and 3,3’-diaminobenzidine 
(DAB) assays. DAB is oxidized by H2O2 in the presence of peroxidases and produces 
reddish brown precipitate. NBT reacts with O2
-. to form a dark blue insoluble 
formazan compound.105 For DAB assays, PC-3 cells were seeded in 24-well plates. 
After 24 h of incubation at 37 oC and 5% CO2, the cell culture medium was replaced 
by fresh medium containing gold complex III-3c (1 μM), and the plates were 
incubated for different period of time (0 h, 3 h, 6 h and 24 h). 500 μL of 
3,3’-diaminobenzidine solution (DAB, 2.5 mM) in potassium phosphate buffer were 
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added to the plates after removal of medium. After 4 h of incubation, ROS generation 
was quantified by spectrophotometry with a microplate reader at 405 nm absorbance. 
For NBT assays, the PC-3 cells were plated in 24-well plates and the tested complex 
III-3c was added at concentration of 1 μM after 24 h of incubation at 37 oC and 5% 
CO2. Then a 0.1% solution of NBT (250 μL per well) in PBS was added to the cells 
after removal of the medium at different time point (0 h, 3 h, 6 h and 24 h). After 
another 4 h of incubation, the supernatant NBT solution was discarded and the 
reduced formazan was dissolved equentially in 360 μL of 2 M KOH followed by 400 
μL of DMSO and read at 620 nm using KOH/DMSO as a blank. 
As shown in Fig 4.9, after 3 h of incubation in PC-3 cells, complex III-3c at 
concentration of 1 μM induced around 30 % increase of O2-. levels and 15 % elevation 
of H2O2 production compared with untreated control cells. However, with the increase 
of time, the ROS production decreased to the same level as the controls perhaps due 
to cell death. 
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Figure 4.9 ROS levels in PC-3 cells as determined by NBT assays (left) and DAB 
assays (right). 
 
Furthermore, the effect of gold complex III-3c on intracellular ROS levels was 
detected by fluorometric assays with 2’,7’–dichlorofluorescein diacetate (DCFDA), a 
fluorogenic dye that measures hydroxyl, peroxyl and other ROS production within the 
cells. After diffusion into the cells, DCFDA is deacetylated by cellular esterases to a 
non-fluorescent compound, which is later oxidized by ROS into 2’,7’-dichloro 
fluorescin (DCF). DCF is a highly fluorescent compound which can be detected by 
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fluorescence spectroscopy with maximum excitation and emission wavelengths of 485 
nm and 535 nm, respectively.106 As shown in Fig 4.10, PC-3, T24 and HepG-2 cells 
treated with auranofin (5 μM) and gold complex III-3c (1 μM and 5 μM) significantly 
triggered the generation of ROS in cells within 6 h. In the case of HepG-2 cells, 
compared with the control, for cells treated with 1 μM and 5 μM of complex III-3c, 
the mean fluorescence intensity increased by 50 %, which indicated that gold complex 
III-3c can significantly induce elevation of intracellular ROS levels. 
Collectively, all these results suggest that ROS play an important role in cell death 
induced by the two tested complexes III-3c and IV-1. 
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Figure 4.10 Induction of ROS by gold complexes (auranofin and complex III-3c) on 
PC-3, T24 and HepG-2 cells after different times of treatment. *p<0.05, **p<0.005, 
***p<0.001, compared with ROS generation at 0 h. 
 
In summary, the mechanistic studies of complexes III-3c and IV-1 showed by 
monitoring the cellular uptake that these two cationic gold(I) bis(NHC) complexes are 
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biologically available. In addition, they were inhibitors of TrxR enzyme, a common 
target for various gold(I) complexes, and the cell death induced by them was 
ROS-dependent. 
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5. Gold complexes as antileishmanial agents 
5.1. Introduction 
Among tropical diseases, leishmaniasis remains one of the most neglected 
concerning available controls and affects more and more countries. In 2007 this 
parasitic disease was endemic in 88 countries, in 2012 in 98 countries (mainly in 
tropical and sub-tropical regions, but also in southern Europe, especially around the 
Mediterranean area), and the number of cases grows continuously and is still certainly 
underestimated because reporting of this disease is mandatory in only 33 of the 98 
countries involved.107 The major factors for Leishmania propagation are mass 
migration of non-immune populations, deteriorating of socio-economic conditions and 
increase of immune-deficient people, leading to a resurgence of leishmaniasis 
worldwide. Actually, this disease affects approximately 12 million people with 
approximately 1.3 million new cases every year and is the second most lethal parasitic 
infection all over the world with about 50,000 deaths per year.108 The Leishmania 
parasite is transmitted in its promastigote form to the mammalian host by the bite of 
infected sandflies (Phlebotominae) during their blood meal. Then promastigotes target 
cells of the immune system, macrophages and dendritic cells, where they differentiate 
into amastigotes forms, living inside the digestive vacuole of these host cells, 
responsible for leishmaniasis. The life cycle of Leishmania is descripted in more 
detail in Fig 5.1. 
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Figure 5.1 Scheme of the life cycle of Leishmania.109 
 
For many years, treatment of humans has relied on pentavalent antimonials using 
compounds like sodium stibogluconate and meglumine antimoniate (Fig 5.2), but 
these antimonials were found to be toxic with life-threatening adverse effects, such as 
cardiac arrhythmia and acute pancreatitis. Later, antimonials were successfully 
replaced by antibiotics, amphotericin B (Fig 5.2) and its formulations, paromomycin 
(Fig 5.2) and the only orally administered drug miltefosine (Fig 5.2).110 Sitamaquine 
and fexinidazole (Fig 5.2) are the only new drugs in phase II clinical trial.111 
Nevertheless, none of these drugs are ideal for treatment due to their high toxicity, 
resistance issues, prohibitive prices, long treatment regimen and mode of 
administration.110 Until now, there is no available vaccine for humans, however, dogs 
can be preventively treated by the CaniLeish® (Europe), Leishmune® or Leish-Tec® 
(Brazil) vaccines.112 Therefore, the need for the discovery and development of more 
efficient drugs with reduced side effects in their treatment against Leishmania is in 
high demand for health researchers. 
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 Figure 5.2 Commercial drugs currently used against leishmaniasis. 
 
Recently, besides anticancer activities, we also tested gold(I) NHC complexes for 
other biomedical applications, in particular the parasite disease leishmaniasis.113 A 
series of cationic or neutral gold complexes containing quinoline functionalized NHC 
ligands (V-1a to V-1e, Fig 5.3) were designed and prepared by Dr. Catherine 
Hemmert in our group, and tested for their antileishmanial activities in collaboration 
with Pr. Alexis Valentin (IRD-Pharma-DEV, Toulouse).113a Proligands and their 
corresponding gold complexes were evaluated in vitro towards Leishmania infantum. 
All these complexes showed potent anti-leishmanial activities against L. infantum 
promastigotes (IC50 values ranging from 0.39 to 1.86 μM), whereas proligands were 
inactive. The three most active complexes (V-1a, V-1b and V-1d, Fig 5.3) were also 
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tested towards L. infantum intracellular amastigotes, the relevant form in human cycle, 
giving low IC50 values of 0.40, 0.96 and 0.24 μM, respectively. 
Furthermore, cytotoxicity was assessed on the murine J774A.1 macrophages to 
determine the selectivity of action. The highest selectivity index close to 10 has been 
observed for the neutral complex V-1b. This complex displays an antipromastigotes 
activity 38 times and 3 times higher than the one of amphotericin B and pentamidine, 
respectively, but 5.8 times lower than the one of miltefosine, and an antiamatisgotes 
activity 4.3 times lower than the one of miltefosine also. Overall, SAR can be brought 
out for this family of gold complexes. Firstly, the results evidenced the key role of the 
gold cation in antileishmanial activities against L. infantum promastigotes and 
intracellular amastigotes. Secondly, the charge of the complex constitutes an 
important factor for the selectivity: the neutral gold complex V-1b can be considered 
as the hit molecule in this study.  
 
Fig 5.3 NHC-Au(I) complexes as antileishmanial agents (V-1a to V-1e) reported in 
our group. 
 
Within this framework, the next step of our work was the pharcomodulation of our 
lead complex V-1b by fine tuning either the non-fuctionalized group (alkyl or aryl) 
or/and the functionalized entities, in order to improve both activity and selectivity 
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towards intracellular amatisgote forms of Leishmania. Therefore, we investigated the 
antileishmanial potency of nine mononuclear neutral gold(I) complexes containing 
NHC ligands (V-2a to V-2i, Fig 5.4), including five new complexes.113b  
Fig 5.4 Neutral Au(I)-NHC complexes as antileishmanial agents (V-2a to V-2i) 
reported from our group. 
 
5.2. Synthesis and Characterization 
I participated in this study with the synthesis of complexes V-2e and V-2f. The 
synthesis and characterization of proligands II-2b and II-2c have been mentioned in 
Chapter 2, Section 2.2. 
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Ligand R X Complex Yield (%) 
II-2c 
 
Cl V-2e 90 
II-2b  Br V-2f 50 
Fig 5.5 Synthesis of gold(I) complexes V-2e and V-2f. 
 
The neutral gold(I) complexes V-2e and V-2f were synthesized via the 
transmetalation route (Fig 5.5). Firstly, the silver precursor complexes were prepared 
by deprotonation of the imidazolium salts II-2c and II-2b, with one equivalent of the 
mild base Ag2O in acetonitrile at room temperature. The carbene transfer reaction was 
then carried out in situ, by adding a little excess (1.2 equivalent) of Au(SMe2)Cl, with 
respect to the ligands. Gold(I) complexes V-2e and V-2f were isolated as grey 
powders with good yields. NMR spectroscopy unequivocally demonstrated the 
formation of the gold(I) complexes; the 13C NMR spectra show the resonance for the 
carbene carbon in the range of 170.5 to 170.7 ppm, in good agreement with reported 
values for NHC-Au-X (X = halide).97 The elemental analysis of the gold(I) complexes 
correspond to the general formula AuLCl and the HRMS exhibit the classical peaks 
corresponding to the cationic fragments [M-Cl-]+ for compounds V-2e and V-2f. 
 
5.3. Molecular structure 
Crystals of V-2e suitable for X-ray diffraction analysis were obtained by slow 
evaporation from an acetonitrile solution of this compound (Fig 5.6). 
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Fig 5.6 Crystal structure of V-2e depicted at 50% level. Hydrogen atoms have been 
omitted for clarity. Selected bond lengths [Å] and angles [°]: Au-C1 1.992(7), Au-Cl 
2.284(2), C1-Au-Cl 179.4(2). 
 
Crystals of V-2f suitable for X-ray diffraction analysis were obtained by slow 
evaporation from an acetonitrile solution of this compound (Fig 5.7). 
 
Figure 5.7 Crystal structure of V-2f depicted at 50% level. Hydrogen atoms have been 
omitted for clarity. Selected bond lengths [Å] and angles [°]: Au-C1 1.982(4), Au-Cl 
2.309(1), C1-Au-Cl 177.6(2). 
 
In these two complexes gold-carbon distances between 1.98 Å and 2.00 Å and 
gold-chlorine distances between 2.28 Å and 2.31 Å are in good agreement with other 
NHC-Au-Cl complexes. The C-Au-Cl angles show a nearly perfect linear 
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coordination (176° to 180°) which represents the classical geometry for gold in the 
oxidation state +1. The shortest gold-gold distances of 5.7 Å (V-2e) and 4.05 Å (V-2f) 
are too long for aurophilic interactions, so these two complexes present isolated units 
without strong intermolecular interactions. 
 
5.4. Antileishmanial activity 
The antileishmanial activity of complexes V-2a to V-2i were screened in vitro on 
both the promastigote and the axenic amastigote stages of L. infantum by determining 
their inhibitory concentration 50% (IC50), in collaboration with Pr. Alexis Valentin and 
Dr. Sandra Bougeade Delmas (IRD-Pharma-DEV, Toulouse). These complexes were 
also evaluated in vitro for their cytotoxicity, measured by cytotoxic concentration 50% 
(CC50) on J774A.1 macrophages, giving access to selectivity index (SI = CC50/IC50). 
The results were summarized in Table 5.1. Except complex V-2e, all gold(I) 
complexes were active against promastigote and axenic amatisgote forms of L. 
infantum, with IC50 values ranging from 2.52 to 11.16 μM and from 0.19 to 2.17 μM, 
respectively. In terms of antipromastigote activity, the NHC-Au(I)-Cl complexes were 
rather toxic for the most part, with SI values between 0.24 to 1.78, except the complex 
V-2d with a SI value of 3.09. Complexes V-2a to V-2d and V-2f to V-2h were more 
efficient than miltefosine (IC50 = 20.26 μM) and show the same level of selectivity as 
that of pentamidine (SI = 0.40) and miltefosine (SI = 2.30). Moreover, the 
gold(I)-NHC complexes were more active against the axenic amastigote form of L. 
infantum when compared to their antipromastigote activity and five of them were 
selective against axenic parasites with SI values ranging from 9.14 to 40.29. 
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Table 5.1 In vitro antileishmanial activity and cytotoxicity of complexes V-2a to V-2i. 
Compound L. infantum 
promastigotes 
IC50 (µM)a 
L. infantum 
axenic 
amastigotes 
IC50 (µM)a 
J774A.1 
CC50 (µM)a 
Selectivity 
index Pro 
CC50/IC50 (Pro) 
Selectivity 
index Ama 
CC50/IC50 
(Ama) 
Selectivity 
index 
Pro/Ama 
IC50 (Pro)/IC50 
(Ama) 
V-2a 11.16±0.15 1.17±0.21 11.20±2.07 1.00 9.60 9.54 
V-2b 4.68±0.61 0.68±0.02 3.69±0.73 0.79 5.40 6.88 
V-2c 8.27±0.15 0.73±0.09 6.72±0.17 0.81 9.20 11.33 
V-2d 2.52±0.51 0.19±0.04 7.79±1.14 3.09 40.29 13.26 
V-2e 57.03±0.46 11.07±1.04 32.39±1.22 0.57 2.93 5.15 
V-2f 10.32±1.29 2.17±0.14 9.30±076 0.90 4.29 4.76 
V-2g 6.05±0.17 0.71±0.05 10.76±2.23 1.78 15.23 8.52 
V-2h 2.78±0.28 0.40±0.13 0.66±0.08 0.24 1.64 6.95 
V-2i 6.76±0.72 0.88±0.30 8.04±1.14 1.19 9.14 7.68 
AmphotericinBb 0.04±0.01 0.05±0.01 1.31±0.09 34.47 24.11 0.80 
Pentamidineb 1.64±0.03 1.50±0.21 0.65±0.17 0.40 0.43 1.09 
Miltefosineb 20.46±0.72 0.66±0.03 47.13±1.79 2.30 71.78 31.00 
Doxorubicinc   0.047±0.001    
a Mean of three independent experiments. 
b Amphotericin B, Miltefosine and Pentamidine were used as antileishmanial compounds of reference. 
c Doxorubicin was used as positive control of cytotoxicity. 
 
These complexes can be separated into two families. One family of complexes 
(V-2a to V-2c, V-2g) used in this study contained a quinoline moiety on one side of 
the azolium ring and several aliphatic or aromatic groups on the other side, namely 
methyl (V-2g), benzyl (V-2a), mesityl (V-2b) and thioanisole (V-2c). Concerning this 
series, it should be noted that all these complexes showed strong activities against 
amatisgotes with IC50 values between 0.68 and 1.17 μM. This means that the 
antiamastigote activity was not affected by the nature of the second subtituent on the 
NHC. However, it is the second substituent that affects the toxicity against J774A.1 
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macrophages. The most lipophilic complex of this series, the mesityl substituted V-2b, 
gave the lowest CC50 value of 3.69 μM and the lowest selectivity index of 5.4 and the 
less lipophilic one, the methyl substituted V-2g, shows a high CC50 value of 10.76 μM 
giving a selectivity index of 15.23, which represents the second best value of all the 
complexes tested in this study. Complexes V-2a and V-2c showed also very good 
selectivity indexes of 9.60 and 9.20, respectively. As observed for the complex V-2g, 
the bipyridylmethyl substituted complex V-2h displayed a low SI value of 1.64, due to 
its high toxicity against J774A.1 macrophages (CC50 value of 0.66 μM). 
Another family of complexes (V-2a, V-2d to V-2f and V-2i) concerned benzyl 
substituted ligands with complex V-2a being the common point with the quinoline 
series. From the table 5.1, we can see that both the morpholine containing complex 
V-2e and pyrrole bearing complex V-2f showed moderate activities against 
amatisgotes with IC50 values of 11.07 and 2.17 μM and low SI values of 2.93 and 4.29, 
respectively. Moreover, the thioanisole substituted complex V-2i displayed very 
similar activity (IC50 = 0.88 μM) and selectivity (SI = 9.14) as obtained for the 
quinoline/benzyl complex V-2a and the thioanisole/quinoline complex V-2c. 
Interestingly, complex V-2d showed the lowest IC50 value (0.19 μM) and the highest 
SI value (40.29) of all the tested complexes and was the lead-complex of this 
pharmaco-modulation work. 
Another important aspect in the development for antileishmanial drug is capacity to 
differentiate between promastigote and amastigote stages. It should be noted that the 
reference drugs Amphotericin B and Pentamidine have SI (Pro/Ama) values around 1, 
and Miltefosine shows a high SI value of 31, due to its low antipromastigote activity. 
All the tested complexes display high SI (Pro/Ama) values ranging from 4.76 to 13.66, 
with the best value for the most active complex V-2d. 
In conclusion, a new family of five neutral gold(I) complexes based on 
functionalized NHCs has been synthesized and fully characterized. Together with four 
previously described ones, they were screened in vitro against both promatigote and 
axenic amastigote forms of L. infantum. Moreover, their cytotoxicity was evaluated on 
the murine J774A.1 macrophages in order to determine their selectivity of action. 
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From this study, 7 of 9 gold(I) NHC complexes displayed good antiamastigote 
activities with IC50 values ranging from 0.19 to 1.17 μM. In particular, the most active 
one, bearing simple mesityl and benzyl substituents, represents a promising 
metallodrug showing selectivity of action against the pathological relevant form of 
Leishmania. 
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6. Iridium(III) NHC complexes as theranostic 
agents with potential for photodynamic 
therapy (PDT) 
6.1. Introduction 
  In this chapter, the synthesis and characterization of eight cyclometalated 
iridium(III) complexes containing NHC ligands, their photophysical properties and 
related photodynamic anticancer activities will be discussed. 
  In the literature, only a limited number of iridium(III) bis(NHC) complexes for an 
application as photosensitizers (PSs) have been reported. Mao and co-workers 
reported three cyclometalated iridium(III) complexes containing two phenylpyridine 
ligands and one bis-NHC ligand (VI-1a to VI-1c, Fig 6.1) as theranostic and 
photodynamic anticancer agents.114 All these complexes displayed better cytotoxicity 
than cisplatin and their precursor [IrCl(ppy)2]2 against various cancer cells with IC50 
values ranging from 1.0 to 10.4 μM, and they were less toxic against normal LO2 
cells than against cancer cells with IC50 values ranging from 8.0 to 17.3 μM. In 
addition, by measuring the lipophilicity of these complexes, the direct relationship 
between log P and antiproliferative activity was obtained. Complexes VI-1a to VI-1c 
could be taken up into HeLa cells very efficiently, and particularly accumulate in 
mitochondria. Mechanistic studies demonstrated that complexes VI-1a to VI-1c 
induced cell death in HeLa cells through apoptotic pathway involving ROS generation, 
release of cytochrome c and activation of caspase. Furthermore, the photocytotoxicity 
of all the complexes were tested against HeLa, A549 and cisplatin-resistant A549R 
cells upon 365 nm light irradiation. Of note, the cytotoxicity of complexes VI-1a to 
VI-1c against various cancer cells was enhanced significantly upon irradiation with PI 
values ranging from 9 to 3488, which suggests that these iridium(III) complexes have 
potential to be utilized as photodynamic therapeutic agents. 
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Fig 6.1 Iridium(III)-bisNHC complexes as PSs reported by Mao and co-workers 
(VI-1a to VI-1c and VI-2a to VI-2d). 
 
Following these interesting results, the same group reported four cyclometalated 
iridium(III) complexes with bisNHC ligands (VI-2a to V-2d, Fig 6.1) as 
mitochondria-targeting photodynamic anticancer agents.115 In this series, they did not 
change the bisNHC ligands, whereas they did some pharmaco-modulation by using 
two different kinds of C^N ligands like phenylquinoline and pyridylbenzothiophene. 
These complexes VI-2a to VI-2d displayed higher cytotoxicity than cisplatin against 
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A549 and A549R with IC50 values spanning from 1.2 to 5.6 μM. The antiproliferative 
activities of these complexes were correlated with the lipophilicity and their cellular 
uptake abilities. Complex VI-2a entered A549 cells, and it was localized in 
mitochondria. Mechanistic studies showed that these complexes can induce a series of 
events associated with cell death containing mitochondrial depolarization, ROS 
production, activation of caspase and apoptosis. Due to their high singlet oxygen 
quantum yields ranging from 0.32 to 0.62, the phototoxic activities of these 
complexes upon 450 nm LED light irradiation were tested. The IC50 values of VI-2a 
to V-2d decreased very significantly after irradiation, and the PI values of VI-2a were 
over 500 towards A549 and A549R cells, VI-2a being a potential visible light PDT 
agent. 
 
6.2. Synthesis and characterization 
The objective of the project was the preparation of luminescent cyclometalated 
iridium(III) NHC complexes as theranostic agents with PDT activity. The Fig 6.2 
shows schematically three families of iridium complexes that we have designed. The 
difference between the three families of complexes resides in the NHC ligands. The 
first two families contain a bis-carbene ligand in which the two NHCs are bridged by 
a methylene (C1) and an ethylene (C2), giving rise to cationic complexes. The other 
one (C0) contains only one mono-carbene ligand and one chloride, leading to a neural 
complex. Moreover, compared to the work of Mao, we introduced different NHC 
ligands bearing aliphatic or aromatic, nitrogen or sulfur functionalized groups, with 
the aim of modulating the steric hindrance and the lipophilicty of the resulting 
complexes. 
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Fig 6.2 Three families of iridium NHC complexes. R and R’ will be defined later. 
 
The bis(imidazolium) salts VI-3a to VI-3g were synthesized by two methods (Fig 
6.3). Method 1: firstly, 1,1’-methylene bis(1H-imidazole) was obtained using 
modified protocols of Tejeda.116 Then it was reacted with 2.2 equivalents of alkyl 
halides, such as 2-bromopropane (a), 1-bromo-2-methylpropane (b), benzyl chloride 
(c) and 1-(2-chloroethyl) piperidine hydrochloride (d) to obtain the carbene precursors 
with yields ranging from 34% to 71%. In the case of 4-bromothioanisole, we failed to 
obtain the carbene precursor using the same conditions. Method 2: the substituted 
imidazoles were achieved by reacting imidazole with various alkyl and aryl halides 
like 4-bromothioanisole (e), benzyl chloride (f) and 1-bromo-2-methylpropane (g). 
Following that, they were reacted with an excess of dibromomethane or 
dibromoethane to obtain the desired proligands with yields ranging from 44% to 90%. 
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Fig 6.3 Two synthetic approaches to obtain proligands VI-3a to VI-3g. 
 
The proligands VI-3a to VI-3g have been characterized by 1H, 13C NMR 
spectroscopy, elementary analysis and mass spectrometry (MS). The most notable 
feature in the 1H and 13C NMR spectra of imidazolium salts are the resonances for 
imidazolium protons (H2) located between 9.06-10.31 ppm and the corresponding 
imidazolium carbons (C2) in the range of 136.97-139.38 ppm. The mass spectra (MS) 
of the proligands exhibit the classical peaks corresponding to [M-X-]+ cations. 
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Fig 6.4 Synthesis of iridium(III) NHC complexes VI-4a to VI-4h. 
 
The iridium precursor [IrCl(ppy)2]2
117
 and the carbene precursor VI-3h
113a were 
prepared according to literature procedures. The iridium(III) NHC complexes VI-4a 
to VI-4h (Fig 6.4) were prepared by reacting [IrCl(ppy)2]2 with carbene precursors 
VI-3a to VI-3h in the presence of Ag2O or K2CO3 in dry acetonitrile at 80 
oC for 10 h. 
In the case of complex VI-4g, the use of Ag2O led to some by-products, so we turned 
to use K2CO3 to form the carbene. After cooling to room temperature, an excess of 
NH4PF6 was added to change the anion. Iridium complexes VI-4a to VI-4h were 
purified by column chromatography and obtained as yellow powders with moderate 
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yields ranging from 11% to 60%. All the synthesized iridium complexes are soluble in 
CH3CN, MeOH and DMSO and highly stable in the physiological environment. Some 
ligands (VI-3f, VI-3h) and corresponding complexes (VI-4f, VI-4h) were prepared 
by Clément Sanz (M2R, Université Toulouse 3 Paul Sabatier, 2017), Valentin Boiteau 
and Yoan Colas (trainees of ENSIACET, 2017), which were supervised by me. 
 
 
 
Fig 6.5 1H NMR spectra of VI-3a (top) and VI-4a (bottom). 
 
NMR spectroscopy unequivocally manifested the formation of the iridium(III) 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
116 
 
complexes with the absence of the proton resonance of the acidic imidazolium (H2, 
see Fig 6.5); the 13C NMR spectra showed the resonance for the carbene carbon atoms 
in the range of 162.74-164.87 ppm for complexes VI-4a to VI-4g, in good agreement 
with reported values for iridium(III) bisNHC complexes114 and 180.36 ppm for the 
complex VI-4h, in line with the reported values for iridium monoNHC complexes.118 
Since the structure of complex VI-4h is not symmetric, each carbon atom has 
different attribution (Fig 6.6). The elementary analysis of the iridium complexes 
correspond to the general [Ir(ppy)2L][PF6] formula for VI-4a to VI-4g and 
Ir(ppy)2(L)Cl formula for VI-4h. The HRMS displayed the classical peaks 
corresponding to the cationic fragment [M-PF6
-]+ for VI-4a to VI-4g and the cationic 
fragment [M-Cl-]+ for VI-4h. For the configuration of iridium complexes, we obtained 
two different isomers, such as Λ (lambda) and Δ (delta), which can not be 
distinguished by NMR spectroscopy. 
 
 
Fig 6.6 13C NMR spectra of VI-4a (top) and VI-4h (bottom). 
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However, we failed to get some bis(imidazolium) salts (VI-5a to VI-5c, Fig 6.7) 
and iridium complexes (VI-7a and VI-7b, Fig 6.7). For the proligands VI-5a and 
VI-5c, almost no reaction occurred even under toluene reflux condition. In the case of 
VI-5b, 1H NMR spectra showed some by-products, such as mono and bis-substituted 
imidazolium salts. In addition, we managed to obtain the bis(imidazolium) salts VI-6a 
and VI-6b through the previously described method (Fig 6.3). Nevertheless, we failed 
to get the two corresponding iridium complexes VI-7a and VI-7b, probably due to the 
steric hindrance of the two bulky substituents (mesityl and quinoline) directly 
connected with the NHCs.  
Fig 6.7 Attempts to synthesize the bis(imidazolium) salts (VI-5a to VI-5c) and the 
iridium complexes (VI-7a and VI-7b). 
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6.3. Molecule structures 
Crystals of VI-4a to VI-4c and VI-4f to VI-4g have been obtained by gas phase 
diffusion of diethylether in a dichloromethane solution of these complexes. 
   
Fig 6.8 Molecule structure of VI-4a in the solid state. Hydrogen atoms and 
non-coordinating anions are omitted for clarity. Selected distances [Å] and angles [°]: 
Ir-C1 2.120(4), Ir-C8 2.102(4), Ir-C14 2.057(4), Ir-C25 2.049(4), Ir-N5 2.069(3), 
Ir-N6 2.056(3), C25-Ir1-N6 79.85(11), C25-Ir1-C14 86.27(12), N6-Ir1-C14 91.88(12), 
C25-Ir1-N5 90.95(12), N6-Ir1-N5 167.82(10), C14-Ir1-N5 79.47(12), C25-Ir1-C8 
97.75(12), N6-Ir1-C8 94.16(12), C14-Ir1-C8 173.25(13), N5-Ir1-C8 94.99(12), 
C25-Ir1-C1 177.74(13), N6-Ir1-C1 98.53(11), C14-Ir1-C1 92.22(12), N5-Ir1-C1 
90.43(11), C8-Ir1-C1 83.91(12). 
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N4
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Fig 6.9 Molecule structure of VI-4b in the solid state. Hydrogen atoms, disorder of 
the side arms and non-coordinating anions are omitted for clarity. Selected distances 
[Å] and angles [°]:Ir1-C1 2.107(3), Ir1-C9 2.130(3), Ir1-C16 2.049(3), Ir1-C27 
2.052(3), Ir1-N5 2.051(2), Ir1-N6 2.058(2), C16-Ir1-N5 80.00(11), C16-Ir1-C27 
84.74(11), N5-Ir1-C27 94.39(12), C16-Ir1-N6 91.27(11), N5-Ir1-N6 169.93(10), 
C27-Ir1-N6 79.69(12), C16-Ir1-C1 98.77(12), N5-Ir1-C1 92.36(11), C27-Ir1-C1 
172.84(12), N6-Ir1-C1 93.95(11), C16-Ir1-C9 175.17(12), N5-Ir1-C9 96.41(10), 
C27-Ir1-C9 92.34(12), N6-Ir1-C9 91.99(10), C1-Ir1-C9 84.56(12). 
 
 
Fig 6.10 Molecule structure of VI-4c in the solid state. Hydrogen atoms, 
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non-coordinating anions and disordered dichloromethane are omitted for clarity. 
Selected distances [Å] and angles [°]:Ir1-C1 2.113(8), Ir1-C12 2.086(10), Ir1-C22 
2.055(8), Ir1-C33 2.066(9), Ir1-N5 2.055(8), Ir1-N6 2.056(7), C22-Ir1-N5 80.2(3), 
C22-Ir1-N6 92.4(3), N5-Ir1-N6 171.5(3), C22-Ir1-C33 81.1(3), N5-Ir1-C33 95.4(4), 
N6-Ir1-C33 79.3(3), C22-Ir1-C12 100.4(3), N5-Ir1-C12 89.1(3), N6-Ir1-C12 96.4(3), 
C33-Ir1-C12 175.5(4), C22-Ir1-C1 172.8(3), N5-Ir1-C1 95.0(3), N6-Ir1-C1 91.9(3), 
C33-Ir1-C1 94.0(3), C12-Ir1-C1 84.9(3). 
 
 
Fig 6.11 Molecule structure of VI-4f in the solid state. Only one of two cations 
presented in the asummetric unit is shown. Hydrogen atoms, anions, disordered ether 
molecules are omitted and ppy ligands are simplified for clarity. Selected distances [Å] 
and angles [°]: Ir-C1 2.087(10), Ir-C13 2.161(9), Ir-C23 2.049(8), Ir-C34 2.043(9), 
Ir-N5 2.041(7), Ir-N62.027(7), N6-Ir1-N5 172.7(3), N6-Ir1-C34 80.4(3), N5-Ir1-C34 
92.7(3), N6-Ir1-C23 96.9(3), N5-Ir1-C23 79.1(3), C34-Ir1-C23 77.3(3), N6-Ir1-C1 
95.9(3), N5-Ir1-C1 90.1(3), C34-Ir1-C1 165.0(3), C23-Ir1-C1 88.8(3), N6-Ir1-C13 
88.7(3), N5-Ir1-C13 94.9(3), C34-Ir1-C13 99.0(3), C23-Ir1-C13 172.7(3), C1-Ir1-C13 
95.4(3). 
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Fig 6.12 Molecule structure of VI-4g in the solid state. Hydrogen atoms, anions and a 
disorder of one side arm are omitted and ppy ligands are simplified for clarity. 
Selected distances [Å] and angles [°]: Ir-C1 2,145(2), Ir-C10 2,134(2), Ir-C17 
2,069(2), Ir-C28 2,043(2), Ir-N5 2,065(2), Ir-N6 2.044(2), C28-Ir1-N6 79.75(9), 
C28-Ir1-N5 92.85(9), N6-Ir1-N5 172.41(8), C28-Ir1-C17 80.25(9), N6-Ir1-C17 
98.14(9), N5-Ir1-C17 78.80(10), C28-Ir1-C10 100.25(9), N6-Ir1-C10 90.65(9), 
N5-Ir1-C10 92.33(9), C17-Ir1-C10 171.12(10), C28-Ir1-C1 163.02(9), N6-Ir1-C1 
98.16(9), N5-Ir1-C1 88.43(9), C17-Ir1-C1 83.40(9), C10-Ir1-C1 96.61(9). 
 
All here presented iridium structures show some common features: the iridium 
atom is coordinated by a bis-NHC ligand and two phenylpyridine ligands and the four 
carbon atoms and the two nitrogen atoms linked to iridium form a distorted octahedral 
geometry. It is notable that the carbene carbon atoms are in trans positions to the 
deprotonated carbon atoms of the ppy ligands and the two nitrogen atoms are in all 
cases also in trans positions related to the central iridium. The Ir-C(carbene) distances 
are in the range of 2.09 and 2.16 Å. The Ir-C distances (2.04 to 2.07 Å) and the Ir-N 
distances (2.03 to 2.07) of the ppy ligands are nearly the same in all cases. The ppy 
ligands show in all complexes very similar N-Ir-C bite angles between 78.8 and 80.4°. 
The only remarkable differences could only be observed for the bisNHC systems. The 
C-Ir-C angles in the C1 ligands is between 83.9 and 84.6°, while it is much more open 
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for the C2 ligands with angles between 95.4 and 96.6°, a significant difference of 
about 10° between the C1 and the C2 systems. 
 
6.4. Photophysical studies 
All complexes have been photophysically investigated at standard pressure and 
room temperature in solution. Fig 6.13 illustrated the photophysical characterization 
of the complex VI-4a in CH2Cl2 solution at 298 K. 
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Fig 6.13 Normalized absorption (red) and emission (blue) spectra of complex VI-4a 
in CH2Cl2 solution. 
 
The strong absorption bands below 300 nm correspond to spin-allowed 1π→π* 
electronic ligand-centered LC transitions. The structureless bands at 300-360 nm were 
attributed to phenyl-to-pyridine ligand-to-ligand charge transfer (LLCT) and 
Ir-to-phenylpyridine metal-to-ligand charge transfer (MLCT). The lowest-lying bands 
in the visible region over 360 nm can be assigned to both singlet and triplet MLCT 
transitions.119 No significant difference in the absorption spectra of complexes VI-4a 
to VI-4h can be found in CH2Cl2 solution. 
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Fig 6.14 Normalized emission spectra of iridium complexes VI-4a to VI-4h in 
CH2Cl2 solution. 
 
The room temperature luminescence spectra of complexes VI-4a to VI-4h in 
CH2Cl2 are shown in Fig 6.14. After excitation at 360 nm, all the complexes except 
VI-4h showed similar blue-green emission with a maximum wavelength around 500 
nm. The neutral iridium complex VI-4h displayed two emission maxima at 425 nm 
and 535 nm. All the complexes showed vibronically structured phosphorescence 
spectra in CH2Cl2 solution at room temperature, which indicated that the emissive 
excited state had both LC π→π* and MLCT characters.119b 
 
Table 6.1 Photophysical data of iridium complexes VI-4a to VI-4h. 
Complex Medium ε (M–1cm–1) ΦPL(%) τ1/ns 
VI-4a CH2Cl2 17552 1.2 190.7 
VI-4b CH2Cl2 8937 1.6 166.4 
VI-4c CH2Cl2 6159 1.6 179.7 
VI-4d CH2Cl2 8174 1.6 187.0 
VI-4e CH2Cl2 12474 1.1 167.4 
VI-4f CH2Cl2 6799 0.2 
___ 
VI-4g CH2Cl2 7381 0.2 
___ 
VI-4h CH2Cl2 10544 0.2 
___ 
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  The photophysical data are summaried in Table 6.1. The molar attenuation 
coefficient also known as the molar extinction coefficient (Ɛ) is a measurement of 
how strongly a compound attenuates light at a certain wavelength. From the table 6.1, 
it was shown that the molar attenuation coefficients of complexes VI-4a to VI-4h at 
360 nm were ranging from 6159 to 17552 M–1cm–1.  
In addition, the relative emission quantum yields (ΦPL) of these complexes at room 
temperature were measured by using quinine sulfate in 1 N H2SO4 as a reference 
standard (ΦPL = 0.55).120 For the C1 system (VI-4a to VI-4e), the quantum yields 
were in the range of ΦPL = 1.1 – 1.6 % in CH2Cl2 solution; and for C2 and C0 system 
(VI-4f to VI-4h), just 0.2 % (Table 6.1). 
The emission lifetime refers to the average time that the compound stays in its 
excited state before emitting a photon. Table 6.1 showed that the excited-state 
lifetimes of complexes VI-4a to VI-4e are in the range of 166.4-190.7 ns. 
 
6.5. In vitro cytotoxicity 
The in vitro cytotoxicity of the tested complexes VI-4a to VI-4h was evaluated 
against two cancer cells PC-3 (human prostate), T24 (human bladder) and the 
non-cancerous NIH3T3 (murine fibroblasts) using colorimetric MTT tests after 48 h 
of treatment (Table 6.2). The iridium precursor [IrCl(ppy)2]2 and auranofin were used 
as references. These results are summarized in Table 6.2. All the complexes except 
VI-4d containing piperidine substituents displayed higher cytotoxicity than auranofin 
against the two tested cancer cell lines (PC-3 and T24) with GI50 values ranging from 
0.25 to 0.95 μM. To study the SAR, the lipophilicity of complexes VI-4a to VI-4h 
was determined by a shake-flask method (Table 6.2).100 Unfortunately, no significant 
relationship between lipophilicity and anticancer activity was found for our 
iridium(III) complexes. However, the lowest cytotoxicity of complex VI-4d could be 
attributed to its lowest log P value. The two most cytotoxic complexes VI-4f and 
VI-4h with GI50 values ranging from 0.25 to 0.29 μM against PC-3 and T24 are 
among the most lipophilic complexes. 
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Table 6.2 Cytotoxic activity of iridium(III) NHC complexes expressed as GI50 (μM) 
values towards selected cancer and normal cell lines as determined by MTT assay (48 h). 
Complex PC-3 T24  NIH3T3 Log P 
VI-4a 0.48 0.31 3.3 -0.063±0.032 
VI-4b 0.51 0.38 3.5 0.842±0.222 
VI-4c 0.41 0.43 7.1 0.581±0.047 
VI-4d 3.8 3.2 > 20 -0.407±0.012 
VI-4e 0.71 0.95 8.5 0.035±0.080 
VI-4f 0.25 0.29 2.5 0.847±0.116 
VI-4g 0.91 0.91 4.1 0.519±0.061 
VI-4h 0.27 0.25 2.7 0.861±0.009 
[IrCl(ppy)2]2 > 20 14.8 >20  
Auranofin 1.2 1.0 1.3  
GI50 values correspond to the concentration of complexes causing 50 % inhibition of 
cell growth. Data were obtained from three independent experiments. 
 
All the iridium(III) complexes were evaluated in vitro for their cytotoxicity towards 
healthy NIH3T3 cells, giving access to the selectivity index (SI, ratio of GI50 values 
towards NIH3T3 to that towards PC-3). From the results (Table 6.2), complexes 
VI-4a to VI-4h showed some selectivities for cancer cells since they were found to be 
less active against non-cancerous NIH3T3 cells than cancer cells (T24 and PC-3). 
Notably, compared with auranofin (SI value around 1), iridium complexes VI-4a to 
VI-4h exhibited better selectivity with SI values ranging from 4.5 to 17.3. The iridium 
precursor was less cytotoxic than all these complexes against all the tested cell lines. 
Therefore, comparison the anticancer activity of iridium complexes VI-4a to VI-4h 
with that of the precursor showed clearly the importance of the presence of NHC 
ligands. 
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6.6. In vitro photodynamic activities 
Iridium complexes with long-lived excited states can be used as effective singlet 
oxygen (1O2) sensitizers.
121 1O2 is considered to be the main cytotoxic agent in 
photodynamic therapy (PDT).122 Subsequently, the photocytotoxicity of complexes 
VI-4a to VI-4h was tested against PC-3 and T24 cancer cells. Cells were treated with 
increasing concentrations of the complexes (from 0.01 μM to 20 μM) for 4 h in the 
dark. After that, the medium was removed and replaced by fresh culture medium prior 
to 10 min irradiation at 365 nm light (4 W). Cell viability was determined by MTT 
assay 44 h after the end of irradiation. The phototoxic index (PI) was calculated as the 
ratio of GI50 values in the dark to those upon light irradiation. The results showed that 
GI50 values of complexes VI-4a to VI-4e (C1 system) upon light irradiation were 
decreased by 1.8- to 5.2-fold as compared with the values obtained in the dark except 
complex VI-4d (Table 6.3). However, no significant difference in cytotoxicity was 
found for cancer cells treated with complex VI-4f to VI-4h (C2 and C0 systems), 
iridium precursor and auranofin in the presence and absence of light. Notably, among 
all the complexes, VI-4a displayed the most potent photodynamic anticancer activity 
with phototoxic index of 5.2 and 2.6 for PC-3 and T24, respectively. These 
preliminary results suggested that these complexes may be used as potent 
photodynamic anticancer agents. 
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Table 6.3 GI50 values (μM) and phototoxic indexes of the tested complexes (VI-4a to 
VI-4h) towards different cell lines. 
Complex PC-3 T24 
 Dark Light PI Dark Light PI 
VI-4a 0.48 0.092 5.2 0.31 0.12 2.6 
VI-4b 0.51 0.15 3.4 0.38 0.16 2.4 
VI-4c 0.41 0.19 2.2 0.43 0.24 1.8 
VI-4d 3.8 3.2 1.2 3.2 1.1 3.1 
VI-4e 0.71 0.24 3.0 0.95 0.25 3.8 
VI-4f 0.25 0.36 n.a. 0.29 0.75 n.a. 
VI-4g 0.91 1.3 n.a. 0.91 2.3 n.a. 
VI-4h 0.27 0.27 n.a. 0.25 0.37 n.a. 
[IrCl(ppy)2]2 >20 >20 n.a. 14.8 >20 n.a. 
Auranofin 1.2 1.2 n.a. 1.1 1.2 n.a. 
GI50 values correspond to the concentration of complexes causing 50 % inhibition of 
cell growth. Data were obtained from three independent experiments.  
Phototoxic index (PI) is the ratio of GI50 values in the dark to those upon light 
irradiation. Cells were treated with the complexes for 4 h and then irradiated at 365 
nm light (4 W) for 10 min. 
 
In addition, the effects of different incubation times on the photocytotoxicity of 
iridium complexes was evaluated. PC-3 and T24 cells were treated with iridium 
complexes VI-4a and VI-4e for 12 h, and then irradiated at 365 nm light for 10 min. 
Cell viability was determined by MTT assays 36 h after the end of irradiation. From 
Fig 6.16 and Fig 6.17, it was shown that GI50 values of complex VI-4a towards PC-3 
and T24 cells upon light irradiation were 0.092 μM and 0.17 μM, respectively, which 
is in the same level as previous measurements obtained for 4 h of incubation. The 
same phenomenon was found for complex VI-4e (GI50 ≈ 0.20 μM and 0.29 μM 
towards PC-3 and T24 cells, respectively), suggesting that the different incubation 
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times had no effects on the photocytotoxicity of our iridium complexes. 
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Fig 6.15 Dose- response curves for the in vitro photocytotoxicity of iridium 
complexes (VI-4a and VI-4e) towards PC-3 cells. 
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Fig 6.16 Dose- response curves for the in vitro photocytotoxicity of iridium 
complexes (VI-4a and VI-4e) towards T24 cells. 
 
Furthermore, in vitro toxicity of iridium complex VI-4a against A549 and HepG-2 
cells upon 365 nm irradiation was measured. For this purpose, cells were treated with 
increasing concentrations of the complexes (from 0.01 μM to 1 μM) for 4 h in the 
dark. After that, the medium was removed and replaced by fresh culture medium prior 
to 10 min irradiation at 365 nm light (4 W). Cell viability was determined by MTT 
assay 44 h after the end of irradiation. In the case of A549 cells, the GI50 value in the 
dark was 0.65 μM, and after light irradiation, the toxicity was increased by four times 
with a GI50 value of 0.16 μM. Nevertheless, the toxicity in the dark and 
photocytotoxicity towards HepG-2 cells were decreased significantly with GI50 values 
in the micromolar range. 
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Fig 6.17 Dose- response curves for the in vitro photocytotoxicity of iridium complex 
VI-4a towards A549 cells in the dark (left) and upon irradiation (right). 
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Fig 6.18 Dose- response curves for the in vitro photocytotoxicity of iridium complex 
VI-4a towards HepG-2 cells in the dark (left) and upon irradiation (right). 
 
6.7. Cellular localization 
Due to the photophysical properties of these iridium complexes, the intracellular 
distribution can be readily monitored by fluorescent microscopy. This work has been 
done in collaboration with Dr. Serge Mazères (IPBS, Toulouse). 
The most active complex VI-4a has been selected for the cellular localization. The 
photophysical studies showed that complex VI-4a had a maximum excitation 
wavelength at 360 nm. Microscopy imaging experiments were performed with PC-3 
cells which were cultured in 6-well plates and on glass slides (180,000 cells per well) 
for 18 h before treated with complex VI-4a at different concentrations (0.25 μM, 0.5 
μM and 1 μM). After 24 hours, a MitoTracker deep red probe was incubated on live 
cells at a final concentration of 200 nM during 15 min at 37 oC in a 5 % CO2 
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humidified incubator and then observed in two channels 440-544 nm for complex 
VI-4a (two-photon excitation at 720 nm) and 644-700 nm for MitoTracker (excitation 
at 633 nm) at the same time. 
 
Fig 6.19 Determination of intercellular localization of complex VI-4a by confocal 
microscopy. PC-3 cells were incubated with complex VI-4a (0.5 μM) for 24 h, and 
then co-incubated with MitoTracker Deep Red (200 nM) for 10 min at 37 oC. The 
iridium complex VI-4a was excited at 720 nm (two photon) and the emission was 
collected at 440-544 nm. MTR was excited at 633 nm and the emission was collected 
at 644-700 nm. Full image for zoom 4 (up) was 53.14 μm * 53.14 μm; and 106.27 μm 
* 106.27 μm for zoom 2 (down). 
 
The fluorescence of the complex VI-4a was evaluated using a Zeiss LSM 710 
NLO-Meta Confocal microscope. Treatment of PC-3 cells with 0.5 μM of complex 
VI-4a led to development of an intense fluorescence in the cytoplasm (Fig 6.19, B). 
The specific subcellular location was investigated by staining the organelles with the 
specific fluorescent probe (Fig 6.19, C). As depicted in Fig 6.19, D, complex VI-4a 
mainly localize into mitochondria which are stained with MitoTracker. Pearson’s 
correlation coefficient for complex VI-4a and MitoTracker is 88 %. These results 
manifested that the cytotoxic properties of iridium complexes may originate from 
mitochondria mediated cell death. 
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  In conclusion, three families of cyclometalated iridium(III) complexes bearing 
different NHC ligands have been prepared and characterized. The first two families 
contain a bis-carbene ligand in which the two NHCs are bridged by a methylene (C1) 
and an ethylene (C2), giving rise to cationic complexes VI-4a to VI-4g. The other one 
(C0) contains only one mono-carbene ligand and one chloride, leading to a neutral 
complex VI-4h. All the iridium complexes, except VI-4d with piperidine substituents, 
displayed higher antiproliferative activity than auranofin against various cancer cells. 
Moreover, they exhibited better selectivity between cancer cells (PC-3 and T24) and 
normal cells (NIH3T3) than auranofin. Therefore, the charge on the iridium 
complexes has no effect on their antiproliferative activity and selevtivity. Notably, 
complex VI-4a can be rapidly and efficiently taken up into PC-3 cells and specifically 
localize into mitochondria. Interestingly, complexes VI-4a to VI-4e (C1 system) can 
act as efficient photosensitizers. The cytotoxicity of VI-4a to VI-4e against PC-3 and 
T24 was increased substantially upon irradiation at 365 nm. Therefore, our 
preliminary studies demonstrated that these iridium(III) complexes had high potential 
to be mitochondria-targeted theranostic and photodynamic anticancer agents. 
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7. Conclusions and perspectives 
In this work, three series of new N-heterocyclic carbene (NHC) gold(I) complexes 
containing functionalized nitrogen groups bridged to the NHC by aliphatic or 
aromatic linkers and one series of original cationic and neutral cyclometalated 
iridium(III) complexes bearing bisNHC ligands or a monoNHC have been 
synthesized, fully characterized and studied for their anticancer activities. 
The first family consists of four cationic AuI(NHC)2 complexes (II-3a to II-3d) 
containing nitrogen groups connected to the NHC by aliphatic side arms. These 
complexes were investigated for their in vitro antiproliferative activity towards four 
human cancer cell lines, including ovarian carcinoma (A2780 and its 
cisplatin-resistant variant A2780cis), hepatocellular carcinoma (HepG-2 and 
HepAD38) and the non-cancerous Madin-Darby canine kidney epithelial (MDCK) 
using MTT assays. Two complexes displayed potent anticancer activity and exhibited 
higher cytotoxicity against ovarian carcinoma than hepatocellular carcinoma. Notably, 
they were found to be very effective towards A2780cis, when compared to the 
reference drug cisplatin. Importantly, these complexes showed low cytotoxicity 
towards the healthy MDCK cells, demonstrating selectivity for cancer cells. 
Regarding structure-activity relationship (SAR), the higher lipophilicity found for the 
complex II-3b correlates with the higher cytotoxic activity and selectivity against 
cancer cells, which is a common feature for delocalized lipophilic cations (DLCs).11a 
In order to increase the lipophilicity of our complexes, we performed 
pharmaco-modulation to synthesize a second family of four cationic AuI(NHC)2 
complexes (III-3a to III-3d) containing nitrogen groups linked to the NHC by an 
aromatic spacer. The in vitro cytotoxicity of these lipophilic complexes and their 
proligands III-2c and III-2d were evaluated on the representative PC-3 prostate and 
T24 bladder cancer cell lines and non-cancerous MC3T3 osteoblasts by colorimetric 
MTT assays. Whereas the carbene precusors were inactive, all the complexes 
exhibited high cytotoxicity with GI50 values in the nanomolar range, but 
unfortunatedly, less selectivity for cancer cells was found for three of them (III-3a, 
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III-3b and III-3d). These results highlight that high lipophilicity of these complexes 
is in good agreement with the obtained cytotoxic activity, nevertheless too high 
lipophilicity can also lead to poor selectivity. Accordingly, complex III-3c was 
selected for further in vitro screening on six cancer cell lines (prostate PC-3, bladder 
T24, lung A549, bone U-2 OS, liver HepG-2 and breast MCF-7) and two 
non-cancerous cell lines (MC3T3 osteoblasts and NIH3T3 fibroblasts). The obtained 
GI50 values of these complexes were in the nanomolar range, suggesting that this 
complex was highly cytotoxic towards various cancer cells with restricted effects on 
healthy cells. Clonogenic assays manifested the impressive cytotoxicity of this 
complex by inhibiting significantly the number of PC-3 and T24 colonies at low 
concentration. 
Taking into account the anticancer activity and selectivity of the two first series, we 
designed and synthesized an optimized third series of four AuI(NHC)2 complexes 
(III-6a to III-6d) with an intermediate lipophilicity between the first two. These 
complexes were tested in vitro for their antiproliferative effects on human prostate 
cancer cell line PC-3 and non-cancerous NIH3T3 fibroblasts. These four complexes 
displayed high and specific cytotoxic activity towards cancer cells. 
Mechanistic studies on complexes III-3c were conducted. Bioavailability has been 
evidenced by a fast cellular uptake. Moreover, this complex inhibited effectively TrxR, 
a common target for gold(I) complexes, and its cytotoxicity towards PC-3, T24 and 
HepG-2 cells was found to be ROS-dependent. 
Overall, the biological results showed that some of our lipophilic cationic gold(I) 
complexes can be considered as good candidates with good prerequisites for in vivo 
tests, in order to provide some conclusive evidence and to pursue the development of 
gold-based anticancer agents. 
Besides anticancer activities, we also tested neutral AuI(NHC)Cl complexes V-2a to 
V-2i for other biomedical applications in parasite disease leishmaniasis. These 
complexes were screened in vitro against both promastigote and axenic amastigote 
forms of L. infantum. Moreover, their cytotoxicity was evaluated on the murine 
J774A.1 macrophages in order to determine their selectivity of action. 7 of 9 gold(I) 
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complexes displayed good antiamastigote activities with IC50 values ranging from 
0.19 to 1.17 μM. In particular, the most active complex V-2d, bearing simple mesityl 
and benzyl substituents, represents a promising metallodrug showing selectivity of 
action against the pathological relevant form of Leishmania. 
Another axe of research was focused on the synthesis and characterization of new 
IrIII(ppy)2(NHC) complexes as theranostic agents with potential for photodynamic 
therapy (PDT). These complexes can be separated to three families: 1) five cationic 
IrIII(ppy)2 complexes containing bis(NHC) ligands where the two NHC skeletons are 
bridged by a CH2 group (VI-4a to VI-4e), 2) two cationic Ir
III(ppy)2 complexes 
containing bis(NHC) ligands where the two NHC skeletons are linked by a CH2CH2 
group (VI-4f and VI-4g) and 3) one neutral IrIII(ppy)2 complexes containing one NHC 
ligand and one chloride (V-4h). After excitation at 360 nm, the cationic complexes 
showed similar blue-green emission with a maximum wavelength of around 500 nm, 
while the neutral complex displayed two emission maxima at 425 nm and 535 nm. 
The in vitro cytotoxicity of these complexes was evaluated on the representative 
human PC-3 prostate and T24 bladder cancer cell lines and non-cancerous NIH3T3 
fibroblasts by colorimetric MTT assays. The iridium precursor [IrCl(ppy)2]2 was less 
active than all these complexes against the two tested cancer cells, demonstrating the 
critical role of NHC ligands. The complexes with Log P values beween -0.06 and 0.86 
(VI-4a to VI-4c and VI-4e to VI-4h) gave very good GI50 values ranging from 0.25 to 
0.95 μM for the two cancer cell lines, while one complex VI-4d with a Log P value of 
-0.4 possessed GI50 values of 3.8 and 3.2 μM, respectively. The selectivity of the 
seven active complexes evaluated by the ratio of GI50 values of NIH3T3 to those of 
the two cancer cell lines varies between 4.5 and 17.3, suggesting moderate to good 
selectivity. 
To gain further mechanistic insights, we have performed confocal microscopy 
experiments by treating PC-3 cells with the most active C1-linked complex VI-4a. 
The results showed that this complex can be quickly and effectively taken up into 
PC-3 cells and specifically localize into mitochondria. Moreover, these complexes can 
act as efficient photosensitizers. For this purpose, some preliminary in vitro 
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experiments in the dark and upon UV light irradiation have been made. The 
cytotoxicity of these complexes was increased substantially upon 365 nm light 
irradiation, which suggested their potential as a mitochondria-targeting theranostic 
anticancer agents. 
 
In the near future, it would be interesting to improve iridium complexes to become 
activable upon two-photon (TP) irradiation in the near IR for deeper penetration of 
tissues. For this purpose, conjugation of chromophores to the iridium complexes can 
help to extend π-conjugated systems to achieve NIR emission. Subsequently, the 
addition of a vector to the PS that target receptors expressed on specific cancer cells 
will lead to the better selectivity towards cancer cells with limited side effects to 
normal cells. The vector could be a variety of biomolecules such as antibodies, 
proteins and peptide etc. 
Concerning our cationic AuI(NHC)2 complexes, some of them displayed very 
interesting anticancer activities and high selectivity. It would be very interesting to 
modify these complexes by vector-incorporation to become more selective.  
Another possibility is the combination of gold and iridium complexes by designing 
heterobimetallic complexes. Such theranostic complexes with rich photophysical 
properties of the iridium unit will help to understand some mechanistic aspects, and 
the activation with the specific wavelength will enable these organometallic 
complexes to execute dual modes of action, TrxR deactivation by the gold and direct 
ROS production by the iridium. 
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Experimental section 
General information 
Unless stated, all reactions were performed under air. All reagents were used as 
received from commercial suppliers. Reactions involving silver compounds were 
performed with the exclusion of light. 1H (300 or 400 MHz) and 13C NMR spectra (75 
or 100 MHz) were recorded at 298 K on Bruker AV300 or Bruker AV400 
spectrometers in CDCl3, CD3CN, CD3OD and DMSO-d6 as solvants. All chemical 
shifts for 1H and 13C are relative to TMS using 1H (residual) or 13C chemical shifts of 
the solvent as a secondary standard. The temperature was set at 298 K. All the 1H and 
13C signals were assigned on the basis of chemical shifts, spin-spin coupling constants, 
splitting patterns and signal intensities, and by using 1H-1H COSY45, 1H-13C HSQC, 
1H-13C HMBC, 13C and 1H experiments. Gradient-enhanced 1H COSY45 experiments 
were realized including 2 scans per increment. 1H-13C correlation spectra using a 
gradient-enhanced HSQC sequence (delay was optimised for 1JCH of 145 Hz) were 
obtained with 2 scans per increment. Gradient-enhanced HMBC experiments were 
performed allowing 62.5 ms for long-range coupling evolution (8 scans were 
accumulated). Typically, 1024 t2 data points were collected for 256 t1 increments. 
Elemental analyses were carried out by the “Service de Micro-analyse du Laboratoire 
de Chimie de Coordination (Toulouse)”. Mass spectrometry analysis were performed 
on a Nermag R1010 (FAB+/meta-nitrobenzylalcohol (MNBA)) spectrometer by the 
“Plateau technique de GC-LC/MS du Laboratoire de Chimie de Coordination 
(Toulouse)”. High Resolution Mass Spectrometry (HRMS) analysis were performed 
with a Xévo G2 QTOF Waters spectrometer using electrospray ionization (ESI) by the 
“Service de Spectrométrie de Masse de Chimie UPS-CNRS (Toulouse)”.  
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1. NHC-Au(I) complexes containing aliphatic 
amino-side arms 
Fig 1.1 General numbering for NMR attribution. 
 
1.1. Preparation of imidazolium salts 
1.1.1. 1-Benzyl-3-[2-(piperidine-4-yl)ethyl]-1H-imidazol-3-ium chloride 
hydrochloride (II-2a) 
 
  In a pressure flask, 1-(2-chloroethyl)piperidine hydrochloride (290 mg, 1.58 mmol) 
and benzylimidazole (300 mg, 1.9 mmol) were dissolved in 10 mL of dry MeCN. The 
mixture was stirred at 80 °C for 48 h. After cooling to room temperature, the 
precipitate formed was filtered, washed with Et2O and dried under vacuum to give a 
white solid (370 mg, 60% yield). Anal. Calcd. For C17H25Cl2N3: C, 59.65; H, 7.36; N, 
12.28. Found: C, 59.44; H, 7.58; N, 12.18. 1H NMR (300 MHz, DMSO-d6): δ 11.47 (s, 
1H, HCl), 9.50 (s, 1H, H2), 7.92 (s, 1H, H5), 7.82 (s, 1H, H4), 7.49-7.39 (m, 5H, 
benzyl), 5.44 (s, 2H, H6), 4.73 (t, 2H, J= 6 Hz, H7), 3.62-3.40 (m, 4H, H10), 
2.97-2.87 (m, 2H, H8), 1.92-1.67 (m, 6H, H11, H12). 13C NMR (75 MHz, DMSO-d6): 
δ 137.7 (1C, C2), 135.0 (1C, benzyl), 129.4 (2C, benzyl), 129.2 (1C, benzyl), 128.9 
(2C, benzyl), 123.3 (1C, C5), 123.2 (1C, C4), 54.6 (1C, C6), 52.8 (2C, C10), 52.5 (1C, 
C7), 43.5 (1C, C8), 22.4 (2C, C11), 21.7 (1C, C12). HRMS (ES+): calcd. for C17H24N3 
270.1970; found 270.1975. 
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1.1.2. 1-Benzyl-3-[2-(1H-pyrrol-1-yl)ethyl]-1H-imidazol-3-ium bromide (II-2b) 
  
  In a pressure flask, 1-(2-bromoethyl)-1H-pyrrole (220 mg, 1.26 mmol) and 
benzylimidazole (200 mg, 1.26 mmol) were stirred in 10 mL of dry MeCN at 80 °C 
for 72 h. After cooling to room temperature, the solvent was evaporated to give a 
brown paste. The paste was dissolved in CH2Cl2 and precipitated with Et2O. The 
precipitate was filtered, washed with Et2O and dried under vacuum to give a brown 
solid (320 mg, 76% yield). Anal. Calcd. For C16H18BrN3: C, 57.84; H, 5.46; N, 12.65. 
Found: C, 57.70; H, 5.33; N, 12.58. 1H NMR (400 MHz, DMSO-d6): δ 8.87 (s, 1H, 
H2), 7.76 (s, 1H, H5), 7.56 (s, 1H, H4), 7.43-7.27 (m, 5H, Bn), 6.61 (t, 2H, J= 2.0 Hz, 
H10), 5.97 (t, 2H, J= 2.0 Hz, H11), 5.38 (s, 2H, H6), 4.55 (t, 2H, J= 5.2 Hz, H7), 4.36 
(t, 2H, J= 5.2 Hz, H8). 13C NMR (100 MHz, DMSO-d6): δ 136.9 (1C, C2), 135.1 (1C, 
Bn), 129.4 (2C, Bn), 129.1 (1C, Bn), 128.6 (2C, Bn), 123.3 (1C, C5), 123.0 (1C, C4), 
121.0 (2C, C10), 108.8 (2C, C11), 52.2 (1C, C6), 50.6 (1C, C7), 48.4 (1C, C8). 
HRMS (ES+): calcd. for C16H18N3 252.1501; found 252.1496. 
 
1.1.3. 1-Benzyl-3-(2-morpholinoethyl)-1H-imidazol-3-ium chloride 
hydrochloride (II-2c) 
  
  In a pressure flask, 4-(2-chloroethyl)morpholine hydrochlodide (585 mg, 3.14 
mmol) was suspended in 10 mL of dry MeCN. The mixture was heated at 80 °C and 
stirred until the solid was completely dissolved. Then benzylimidazole (745 mg, 4.71 
mmol) was slowly added to the solution. The mixture was stirred for 72 h at 80 °C. 
After cooling to room temperature, the precipitate formed was filtered, washed by 
CH2Cl2 and dried under vacuum to give a pale-yellow solid (700 mg, 76% yield). 
Anal. Calcd. For C16H23Cl2N3O: C, 55.82; H, 6.73; N, 12.21. Found: C, 55.64; H, 
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6.87; N, 12.06. 1H NMR (400 MHz, CD3OD): δ 9.25 (s, 1H, H2), 7.81 (s, 1H, H5), 
7.71 (s, 1H, H4), 7.53-7.45 (m, 5H, benzyl), 5.46 (s, 2H, H6), 4.79 (t, 2H, J= 6.8 Hz, 
H7), 4.01 (s, 4H, H11), 3.76 (t, 2H, J= 6.8 Hz, H8), 3.50 (s, 4H, H10). 13C NMR (100 
MHz, CD3OD): δ 137.1 (1C, C2), 133.3 (1C, benzyl), 129.1 (2C, benzyl), 129.0 (1C, 
benzyl), 128.7 (2C, benzyl), 123.0 (1C, C5), 122.7 (1C, C4), 63.3 (2C, C11), 55.0 (1C, 
C6), 53.1 (1C, C7), 52.2 (2C, C10), 42.9 (1C, C8). HRMS (ES+): calcd. for 
C16H22N3O 272.1763; found 272.1771 
 
1.1.4. 1-[2-Dimethyl)propyl]-benzylimidazolium chloride hydrochloride (II-2d) 
  
  In a pressure flask, 3-chloro-N,N-dimethylpropylamine hydrochloride (300 mg, 
1.90 mmol) was suspended in 10 mL of dry MeCN. After the solid was completely 
dissolved, benzylimidazole (450 mg, 2.85 mmol) was slowly added to the solution. 
The reaction mixture was stirred for 72 h at 80 °C. After cooling to room temperature, 
the solvent was removed under vacuum to give a pale-yellow paste. The paste was 
dissolved in MeCN and precipitated with Et2O. The precipitate was filtered, washed 
with Et2O and dried under vacuum to give a pale-yellow solid (200 mg, 33% yield). 
Anal. Calcd. For C15H23N3Cl2: C, 56.97; H, 7.33; N, 13.29. Found: C, 57.09; H, 7.38; 
N, 13.31.1H NMR (400 MHz, DMSO-d6): δ 11.24 (s, 1H, HCl), 9.51 (s, 1H, H2), 7.90 
(s, 1H, H5), 7.86 (s, 1H, H4), 7.46-7.40 (m, 5H, benzyl), 5.46 (s, 2H, H6), 4.35 (t, 2H, 
J= 7.2 Hz, H7), 3.06 (t, 2H, J= 7.2 Hz, H9), 2.73 (s, 6H, H11), 2.32-2.25 (m, 2H, H8). 
13C NMR (100 MHz, DMSO-d6): δ 137.0 (1C, C2), 135.2 (1C, benzyl), 129.5 (2C, 
benzyl), 129.2 (1C, benzyl), 128.8 (2C, benzyl), 123.3 (1C, C5), 123.1 (1C, C4), 53.4 
(1C, C6), 52.4 (1C, C7), 46.7 (1C, C9), 42.4 (2C, C11), 24.7 (1C, C8). HRMS (ES+): 
calcd. for C15H22N3 244.1814; found 244.1823. 
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1.2.  Preparation of gold(I) bis(NHC) complexes 
1.2.1. Complex II-3a 
 
  In a Schlenk tube 1-benzyl-3-(2-(piperidin-1-yl)ethyl)-1H-imidazol-3-ium chloride 
hydrochloride (100 mg, 0.29 mmol) was suspended in 10 mL of dry MeOH and Ag2O 
(69 mg, 0.29 mmol) was added. The mixture was stirred at room temperature for 3 h 
under nitrogen in the dark. A solution of AgNO3 (25 mg, 0.15 mmol) in 2 mL of 
MeCN was added and the mixture was stirred for 1 h. Finally, Au(SMe2)Cl (43 mg, 
0.15 mmol) was added and after stirring for 1 h, the mixture was filtered through a 
pad of celite. The solvent was evaporated under reduced pressure to give a white solid 
(40 mg, 40% yield). Anal. Calcd. For C34H46AuN7O3: C, 51.19; H, 5.81; N, 12.29. 
Found: C, 51.29; H, 5.63; N, 12.31.1H NMR (400 MHz, CD3CN): δ 7.35-7.23 (m, 
14H, benzyl, H4, H5), 5.36 (s, 4H, H6), 4.23 (t, 4H, J= 6 Hz, H7), 2.67 (t, 4H, J= 6 
Hz, H8), 2.36 (t, 8H, J= 4.8 Hz, H10), 1.47-1.39 (m, 12H, H11, H12).13C NMR (100 
MHz, CD3CN): δ 184.0 (2C, C2), 136.9 (2C, C2), 128.9 (4C, benzyl), 128.2 (2C, 
benzyl), 127.1 (4C, benzyl), 122.6 (2C, C5), 121.8 (2C, C4), 58.8 (2C, C6), 54.4 (4C, 
C10), 54.0 (2C, C7), 48.7 (2C, C8), 25.9 (4C, C11), 24.0 (2C, C12). HRMS (ES+): 
calcd. for C34H46AuN6 735.3449; found 735.3448. 
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1.2.2. Complex II-3b 
 
  In a Schlenk tube 3-(2-(1H-pyrrol-1-yl)ethyl)-1-benzyl-1H-imidazol-3-ium 
bromide (100 mg, 0.3 mmol) was suspended in 10 mL of dry MeOH and Ag2O (67.3 
mg, 0.3 mmol) was added. The mixture was stirred at room temperature for 3 h under 
nitrogen in the dark. A solution of AgNO3 (25 mg, 0.15 mmol) in 2 mL of MeCN was 
added and the resulting mixture was stirred at room temperature overnight. Then the 
mixture was filtered through a pad of celite. After that, Au(SMe2)Cl (44 mg, 0.15 
mmol) was added and after stirring for 1 h, the mixture was filtered through a pad of 
celite. The solvent was evaporated under reduced pressure to give a grey solid (50 mg, 
50 % yield). Anal. Calcd. For C32H34AuN7O3: C, 50.46; H, 4.50; N, 12.87. Found: C, 
50.22; H, 4.60; N, 12.80. 1H NMR (300 MHz, CD3CN): δ 7.37-7.04 (m, 14H, benzyl, 
H4, H5), 6.39 (t, 4H, J= 2.1 Hz, H10), 5.97 (t, 4H, J= 2.1 Hz, H11), 5.24 (s, 4H, H6), 
4.42 (t, 4H, J= 6 Hz, H7), 4.24 (t, 4H, J= 6 Hz, H8). 13C NMR (75 MHz, CD3CN): δ 
184.5 (2C, C2), 136.6 (2C, benzyl), 128.8 (4C, benzyl), 128.2 (2C, benzyl), 127.2 (4C, 
benzyl), 122.4 (2C, C5), 121.8 (2C, C4), 120.7 (4C, C10), 108.5 (4C, C11), 53.9 (2C, 
C6), 52.3 (2C, C7), 49.4 (2C, C8). HRMS (ES+): calcd. for C32H34AuN6 699.2510; 
found 699.2509. 
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1.2.3. Complex II-3c 
  
In a Schlenk tube 1-benzyl-3-(2-morpholinoethyl)-1H-imidazol-3-ium chloride 
hydrochloride (100 mg, 0.29 mmol) was suspended in 10 mL of dry MeOH and Ag2O 
(67.3 mg, 0.29 mmol) was added. The mixture was stirred at room temperature for 3 h 
under nitrogen in the dark. A solution of AgNO3 (25 mg, 0.15 mmol) in 2 mL of 
MeCN was added and the mixture was stirred for 1 h. Finally, Au(SMe2)Cl (43 mg, 
0.15 mmol) was added and after stirring for 1 h, the mixture was filtered through a 
pad of celite. The solvent was evaporated under reduced pressure to give a grey solid 
(97 mg, 84% yield). Anal. Calcd. For C32H42AuN7O5: C, 47.94; H, 5.28; N, 12.23. 
Found: C, 48.08; H, 5.35; N, 12.29. 1H NMR (300 MHz, CD3CN): δ 7.37-7.22 (m, 
14H, benzyl, H4, H5), 5.36 (s, 4H, H6), 4.23 (t, 4H, J= 6 Hz, H7), 3.52 (t, 8H, J= 4.8 
Hz, H10), 2.72 (t, 4H, J= 6 Hz, H8), 2.39 (t, 8H, J= 4.8 Hz, H9). 13C NMR (75 MHz, 
CD3CN): δ 184.0 (2C, C2), 136.9 (2C, benzyl), 128.9 (4C, benzyl), 128.2 (2C, 
benzyl), 127.1 (4C, benzyl), 122.6 (2C, C5), 121.9 (2C, C4), 66.5 (4C, C11), 58.4 (2C, 
C6), 54.1 (2C, C7), 53.4 (4C, C10), 48.2 (2C, C8). HRMS (ES+): calcd. for 
C32H42AuN6O2 739.3035; found 739.3036. 
 
1.2.4. Complex II-3d 
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In a Schlenk tube 1-benzyl-3-(3-(dimethylamino)propyl)-1H-imidazol-3-ium 
chloride hydrochloride (146 mg, 0.46 mmol) was suspended in 10 mL of dry MeOH 
and Ag2O (106 mg, 0.46 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (39 mg, 0.23 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 1 h. Finally, 
Au(SMe2)Cl (67 mg, 0.23 mmol) was added and after stirring for 1 h, the mixture was 
filtered through a pad of celite. The solvent was evaporated under reduced pressure to 
give a grey solid (143 mg, 84% yield). Anal. Calcd. For C30H42AuN7O3: C, 48.32; H, 
5.68; N, 13.15. Found: C, 48.25; H, 5.71; N, 13.28. 1H NMR (400 MHz, CD3OD): δ 
7.45-7.24 (m, 14H, benzyl, H4, H5), 5.41 (s, 4H, H6), 4.27 (t, 4H, J= 6.8 Hz, H7), 
2.30 (t, 4H, J= 6.8 Hz, H9), 2.21 (s, 12H, H10), 2.08-2.01 (m, 4H, H8). 13C NMR 
(100 MHz, CD3OD): δ 183.8 (2C, C2), 136.7 (2C, benzyl), 128.7 (4C, benzyl), 128.0 
(2C, benzyl), 126.9 (4C, benzyl), 122.2 (2C, C5), 122.0 (2C, C4), 55.6 (2C, C6), 54.0 
(2C, C7), 48.8 (2C, C9), 44.0 (4C, C11), 28.7 (2C, C8). HRMS (ES+): calcd. for 
C30H42AuN6 683.3136 found 683.3130. 
 
2. NHC-Au(I) complexes containing aromatic 
amino-side arms 
 
Fig 2.1 General numbering for NMR attribution. 
 
2.1.  Preparation of imidazolium salts 
2.1.1. 3-Benzyl-1-[4-(dimethylamino)phenyl]-1H-imidazol-3-ium chloride 
(III-2a) 
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  Imidazole (3.0 g, 44 mmol), 4-bromo-N,N-dimethylaniline (4.4 g, 22 mmol), 
K2CO3 (3.04 g, 22 mmol) and a catalytic amount of CuSO4 were stirred in a closed 
pressure flask at 205 °C for 10 h. After cooling to room temperature, the crude 
product was extracted by dichloromethane, filtered and evaporated to dryness. The 
resulting residue was purified by column chromatography on silica gel with a mixture 
of CH2Cl2 and MeOH (30:1) as eluent to give 4-(1H-imidazol-1-yl)-N,N- 
dimethylaniline (III-1a) as a yellow solid (3.7 g, 90% yield). 1H NMR (400 MHz, 
CDCl3): δ 7.79 (s, 1H, H2), 7.28-7.23 (m, 4H, H4/H5/H8), 6.78 (d, 2H, J = 8.8 Hz, 
H9), 3.02 (s, 6H, H11). A mixture of III-1a (400 mg, 2.13 mmol) and benzyl chloride 
(296 mg, 2.34 mmol) in MeCN was stirred in a closed pressure flask at 80 °C for 10 h. 
After cooling down to room temperature, the solution was evaporated to dryness. The 
residue was purified by column chromatography on silica gel with a mixture of 
CH2Cl2 and MeOH (10:1) as eluent to give III-2a as a highly hydroscopic yellow 
solid (512 mg, 76 % yield). Anal. Calcd. For C18H20ClN3: C, 68.89; H, 6.42; N, 13.39. 
Found: C, 68.67; H, 6.38; N, 13.48. 1H NMR (400 MHz, DMSO-d6): δ 10.02 (s, 1H, 
H2), 8.22 (s, 1H, H5), 8.02 (s, 1H, H4), 7.59 (d, 2H, J = 9.2 Hz, H8), 7.57-7.54 (m, 
2H, benzyl), 7.46-7.40 (m, 3H, benzyl), 6.86 (d, 2H, J = 9.2 Hz, H9), 5.52 (s, 2H, H6), 
2.97 (s, 6H, H11). 13C NMR (100 MHz, DMSO- d6): δ 151.3 (1C, C10), 135.2 (1C, 
C2), 135.1 (1C, benzyl), 129.4 (2C, benzyl), 129.2 (1C, benzyl), 129.0 (2C, benzyl), 
124.0 (1C, C7), 123.3 (1C, C5), 123.1 (2C, C8), 122.1 (1C, C4), 112.7 (2C, C9), 52.1 
(2C, C11), 49.0 (1C, C6). HRMS (ES+): calcd. for C18H20N3 278.1657; found 
278.1658. 
 
2.1.2. 3-Benzyl-1-[4-(diethylamino)phenyl]-1H-imidazol-3-ium chloride (III-2b) 
  
  Imidazole (1 g, 14.7 mmol), 4-bromo-N,N-diethylaniline (1.67 g, 7.34 mmol), 
K2CO3 (2.01 g, 7.34 mmol) and a catalytic amount of CuSO4 were stirred in a closed 
pressure flask at 205 °C for 10 h. After cooling to room temperature, the crude 
product was extracted by CH2Cl2, filtered and evaporated to dryness. The resulting 
residue was purified by column chromatography on silica gel with a mixture of 
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CH2Cl2 and MeOH (30:1) as eluent to give N,N-diethyl-4-(1H-imidazol-1-yl)aniline 
(III-1b) as a brown solid (1.43 g, 90% yield). 1H NMR (400 MHz, CDCl3): δ 7.73 (s, 
1H, H2), 7.21 (d, 2H, J = 9.2 Hz, H8), 7.18-7.17 (m, 2H, H4/H5), 6.72 (d, 2H, J = 9.2 
Hz, H9), 3.40 (q, 4H, J = 7.2 Hz, H11), 1.21 (t, 6H, J = 7.2 Hz, H12). A mixture of 
III-1b (300 mg, 1.39 mmol) and benzyl chloride (194 mg, 1.53 mmol) in MeCN was 
stirred in a closed pressure flask at 80 °C for 10 h. After cooling down to room 
temperature, the solution was evaporated to dryness. The residue was purified by 
column chromatography on silica gel with a mixture of CH2Cl2 and MeOH (10:1) as 
eluent to give III-2b a highly hydroscopic yellow solid (443 mg, 93% yield). Anal. 
Calcd. For C20H24ClN3: C, 70.26; H, 7.08; N, 12.29. Found: C, 70.47; H, 7.28; N, 
12.48. 1H NMR (400 MHz, DMSO-d6): δ 9.98 (s, 1H, H2), 8.19 (s, 1H, H5), 8.00 (s, 
1H, H4), 7.55-7.51 (m, 4H, benzyl/H8), 7.47-7.40 (m, 3H, benzyl), 6.81 (d, 2H, J = 
9.2 Hz, H9), 5.50 (s, 2H, H6), 3.40 (q, 4H, J = 7.2 Hz, H11), 1.11 (t, 6H, J= 7.2 Hz, 
H12). 13C NMR (100 MHz, DMSO-d6): δ 148.5 (1C, C10), 135.2 (1C, C2), 135.1 
(1C,benzyl), 129.4 (2C, benzyl), 129.2 (1C, benzyl), 128.9 (2C, benzyl), 123.6 (2C, 
C8), 123.3 (1C, C7), 123.1 (1C, C5), 122.2 (1C, C4), 112.0 (2C, C9), 52.6 (1C, C6), 
44.3 (2C, C11), 12.7 (2C, C12). HRMS (ES+): calcd. for C20H24N3 306.1970; found 
306.1967. 
 
2.1.3. Benzyl-1-(1H-pyrrol-1-yl)-1H-imidazol-3-ium chloride (III-2c) 
  
  Imidazole (268.5 mg, 3.94 mmol), 1-(4-chlorophenyl)-1H-pyrrole (500 mg, 2.81 
mmol), K3PO4 (1.19 g, 5.62 mmol) and CuI (107 mg, 0.56 mmol) in DMF were 
placed in a closed pressure flask, then stirred at 160 °C for 3 days. After cooling to 
room temperature, distilled water was added to the reaction and the crude was 
extracted with EtOAc. The organic layer was washed with brine and dried over 
Na2SO4. After filtration and evaporation of the solvent under reduced pressure, the 
residue was purified by column chromatography on silica gel with a mixture of 
CH2Cl2 and MeOH (30:1) as eluent to give 1-(1H-pyrrol-1-yl)-1H-imidazole (III-1c) 
as a yellow solid (300 mg, 51% yield). 1H NMR (400 MHz, DMSO-d6): δ 8.33 (s, 1H, 
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H2), 7.82 (s, 1H, H5), 7.76-7.71 (m, 4H, H8/H9), 7.45 (t, 2H, J = 2.4 Hz, H11), 7.16 
(s, 1H, H4), 6.30 (t, 2H, J = 2.4 Hz, H12). A mixture of III-1c (200 mg, 0.96 mmol) 
and benzyl chloride (133 mg, 1.05 mmol) in MeCN was stirred in a closed pressure 
flask at 80 °C for 10 h. After cooling down to room temperature, the solution was 
evaporated to dryness. The residue was purified by column chromatography on silica 
gel with a mixture of CH2Cl2 and MeOH (10:1) as eluent to give III-2c as a yellow 
solid (306 mg, 95% yield). Anal. Calcd. For C20H18ClN3: C, 71.53; H, 5.40; N, 12.51. 
Found: C, 71.57; H, 5.38; N, 12.48. 1H NMR (400 MHz, DMSO-d6): δ 10.36 (s, 1H, 
H2), 8.41 (s, 1H, H5), 8.10 (s, 1H, H4), 7.94-7.89 (m, 4H, H8/H9), 7.59-7.43 (m, 7H, 
benzyl/H11), 6.33 (s, 2H, H12), 5.56 (s, 2H, H6). 13C NMR (100 MHz, DMSO- d6): δ 
140.9 (1C, C10), 136.1 (1C, C2), 135.0 (1C, benzyl), 131.9 (1C, C7), 129.4 (2C, 
benzyl), 129.3 (1C, benzyl), 129.0 (2C, benzyl), 123.7 (2C, C8), 123.6 (1C, C5), 
122.1 (1C, C4), 120.4 (2C, C9), 119.6 (2C, C11), 112.7 (2C, C12), 52.8 (1C, C6). 
HRMS (ES+): calcd. for C20H18N3 300.1501; found 300.1500. 
 
2.1.4. 3-Benzyl-1-[4-(morpholin-4-yl)phenyl]-1H-imidazol-3-ium chloride 
(III-2d) 
 
  To a mixture of 4-phenylmorpholine (816 mg, 5 mmol) and DMSO (429 mg, 5.5 
mmol) in EtOAc (20 mL) was added hydrobromic acid (48 %, 1.85 g, 5.5 mmol) at 
60 °C under air. The mixture was stirred at 60 °C, then potassium carbonate (1 g) was 
added to the solution and the mixture was stirred for another 0.5 h. After cooling 
down to room temperature and evaporation of the solvent under vacuum, the residue 
was purified by column chromatography on silica gel with a mixture of hexane and 
EtOAc (10:1) as eluent to give 4-(4-bromophenyl)morpholine as a white solid (1.03 g, 
85% yield). 1H NMR (400 MHz, CDCl3): δ 7.37 (d, 2H, J = 8.8 Hz), 6.78 (d, 2H, J = 
8.8 Hz), 3.86 (t, 4H, J = 4.8 Hz), 3.12 (t, 4H, J = 4.8 Hz). Imidazole (275.6 mg, 4.05 
mmol), 4-(4-bromophenyl)morpholine (700 mg, 2.89 mmol), K3PO4 (1.2 g, 5.65 
mmol) and CuI (110 mg, 0.56 mmol) in DMF were placed to a closed pressure flask, 
then stirred at 160 °C for 3 days. After cooling to room temperature, distilled water 
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was added to the reaction and the crude was extracted with EtOAc. The organic layer 
was washed with brine and dried over Na2SO4. After filtration and evaporation of the 
solvent under reduced pressure, the residue was purified by column chromatography 
on silica gel with a mixture of CH2Cl2 and MeOH (30:1) as eluent to give 
4-[4-(1H-imidazol-1-yl)phenyl]morpholine (III-1d) as a yellow solid (200 mg, 30% 
yield). 1H NMR (400 MHz, DMSO-d6): δ 8.13 (s, 1H, H2), 7.66 (s, 1H, H5), 
7.76-7.71 (d, 2H, J = 8.8 Hz, H8), 7.45 (m, 3H, H4/H9), 3.75 (t, 4H, J = 4.8 Hz, H12), 
3.14 (t, 4H, J = 4.8 Hz, H11). HRMS (ES+): calcd. for C13H16N3O 230.1293; found 
230.1293. A mixture of III-1d (150 mg, 0.65 mmol) and benzyl chloride (121.5 mg, 
0.96 mmol) in MeCN was stirred in a closed pressure flask at 80 °C for 10 h. After 
cooling down to room temperature, the solution was evaporated to dryness. The 
residue was purified by column chromatography on silica gel with a mixture of 
CH2Cl2 and MeOH (10:1) as eluent to give III-2d as a highly hydroscopic yellow 
solid (200 mg, 91 % yield). Anal. Calcd. For C20H22ClN3O: C, 67.50; H, 6.23; N, 
11.81. Found: C, 67.57; H, 6.38; N, 11.58. 1H NMR (400 MHz, DMSO-d6): δ 10.15 (s, 
1H, H2), 8.27 (s, 1H, H5), 8.04 (s, 1H, H4), 7.65 (d, 2H, J = 8.8 Hz, H8), 7.55 (m, 2H, 
benzyl), 7.47-7.40 (m, 3H, benzyl), 7.15 (d, 2H, J = 8.8 Hz, H9), 5.52 (s, 2H, H6), 
3.76 (t, 4H, J = 4.8 Hz, H12), 3.22 (t, 4H, J = 4.8 Hz, H11). 13C NMR (100 MHz, 
DMSO-d6): δ 152.1 (1C, C10), 135.4 (1C, C2), 135.2 (1C, benzyl), 129.4 (2C, benzyl), 
129.2 (1C, benzyl), 129.0 (2C, benzyl), 126.4 (1C, C7), 123.4 (1C, C5), 123.1 (2C, 
H8), 122.1 (1C, C4), 115.6 (2C, H9), 66.4 (2C, C12), 52.6 (1C, C6), 48.2 (2C, C11). 
HRMS (ES+): calcd. for C20H22N3O 320.1763; found 320.1761. 
 
 
Fig 2.2 General numbering for NMR attribution. 
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2.1.5. 3-(2-(1H-Pyrrol-1-yl)ethyl)-1-(4-(methylthio)phenyl)-1H-imidazol-3-ium 
bromide (III-5a) 
 
  Imidazole (3.24 g, 47.6 mmol), 4-bromothioanisole (4.83 g, 23.8 mmol), K2CO3 
(3.29 g, 23.8 mmol) and a catalytic amount of CuSO4 were stirred in a closed pressure 
flask at 205 °C for 10 h. After cooling to room temperature, the crude product was 
extracted by CH2Cl2, filtered and evaporated to dryness. The resulting residue was 
washed three times with Et2O (20 mL) to give 1-(4-methylthiophenyl)-1H- imidazole 
(III-4a) as a grey solid (3.6 g, 80% yield). 1H NMR (400 MHz, CDCl3): δ 7.84 (t, 1H, 
J= 1.2 Hz, H2), 7.38-7.32 (m, 4H, HSMePh), 7.27 (t, 1H, J= 1.2 Hz, H5), 7.22 (t, 1H, J= 
1.2 Hz, H4), 2.54 (s, 3H, HSMePh). In a pressure flask, a mixture of III-4a (200 mg, 
1.05 mmol) and 1-(2-bromoethyl)-1H-pyrrole (183 mg, 1.05 mmol) was dissolved in 
10 mL of dry MeCN. The mixture was stirred at 80 °C for 72 h. After cooling to room 
temperature, the solvent was removed by vacuum to give a brown paste. The paste 
was dissolved in CH2Cl2 and precipitated with Et2O. The precipitate was filtered, 
washed with Et2O and dried under vacuum to give III-5a as a brown solid (154 mg, 
40% yield). Anal. Calcd. For C16H18BrN3S: C, 52.75; H, 4.98; N, 11.53. Found: C, 
52.82; H, 4.86; N, 11.66. 1H NMR (400 MHz, DMSO-d6): δ 9.41(s, 1H, H2), 8.25 (s, 
1H, H5), 7.66 (s, 1H, H4), 7.62 (d, 2H, J= 8.4 Hz, HSMePh), 7.51 (d, 2H, J= 8.4 Hz, 
HSMePh), 6.72 (s, 1H, H9), 6.01 (s, 1H, H10), 4.61 (t, 2H, J= 6 Hz, H6), 4.36 (t, 2H, J= 
6 Hz, H7), 2.55 (s, 3H, HSMePh). 
13C NMR (100 MHz, DMSO-d6): δ 141.5 (1C, 
CSMePh), 135.8 (1C, C2), 131.8 (1C, CSMePh), 127.2 (2C, CSMePh), 123.7 (1C, C5), 
122.7 (2C, CSMePh), 121.5 (1C, C4), 121.2 (2C, C9), 108.9 (2C, C10), 50.9 (1C, C6), 
48.4 (1C, C7), 15.0 (1C, CSMePh). HRMS (ES
+): calcd. for C16H18N3S 284.1221; found 
284.1219. 
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2.1.6. 1-(4-(Methylthio)phenyl)-3-(2-(piperidin-1-yl)ethyl)-1H-imidazol-3-ium 
chloride hydrochloride (III-5b) 
  
  In a pressure flask, a mixture of III-4a (400 mg, 2.1mmol) and 
1-(2-chloroethyl)piperidine hydrochloride (387 mg, 2.1 mmol) was dissolved in 10 
mL of dry acetonitrile. The mixture was stirred at 80 °C for 72 h. After cooling to 
room temperature, the precipitate formed was filtered, washed with CH2Cl2 and dried 
under vacuum to obtain III-5b as a white solid (205 mg, 26% yield). Anal. Calcd. For 
C17H25Cl2N3S: C, 54.54; H, 6.73; N, 11.22. Found: C, 54.23; H, 6.44; N, 11.08. 
1H 
NMR (400 MHz, DMSO-d6): δ 11.37 (s, 1H, HCl), 10.04 (s, 1H, H2), 8.29 (t, 1H, J= 
2 Hz, H5), 8.09 (t, 1H, J= 2 Hz, H4), 7.75 (d, 2H, J= 8.4 Hz, HSMePh), 7.53 (d, 2H, J= 
8.4 Hz, HSMePh), 4.77 (t, 2H, J= 6.4 Hz, H6), 3.70-3.52 (m, 4H, H9), 2.94 (m, 2H, H7), 
2.56 (s, 3H, HSMePh), 1.94-1.68 (m, 6H, H10/H11). 
13C NMR (100 MHz, DMSO-d6): δ 
141.3 (1C, CSMePh), 137.0 (1C, C2), 132.1 (1C, CSMePh), 127.2 (2C, CSMePh), 123.6 (1C, 
C5), 123.0 (2C, CSMePh), 121.7 (1C, C4), 54.7 (1C, C6), 52.7 (2C, C9), 43.7 (1C, C7), 
22.3 (2C, C10), 21.7 (1C, C11), 15.0 (1C, CSMePh). HRMS (ES
+): calcd. for C17H24N3S 
302.1691; found 302.1683. 
 
2.1.7. 3-(2-(1H-Pyrrol-1-yl)ethyl)-1-(quinolin-2-yl)-1H-imidazol-3-ium bromide 
(III-5c) 
  
  Imidazole (2.451 g, 36 mmol), 2-chloroquinoline (3 g, 18 mmol), K2CO3 (2.488 g, 
18 mmol) and a catalytic amount of CuSO4 were stirred in a closed pressure flask at 
205 °C for 10 h. After cooling to room temperature, the crude product was extracted 
by CH2Cl2, filtered and evaporated to dryness. The resulting residue was washed three 
times with Et2O (20 mL) to give 2-(1H-imidazol-1-yl) quinoline (III-4b) as a brown 
solid (2.8 g, 80% yield). 1H NMR (400 MHz, DMSO-d6): δ 8.74 (t, 1H, J= 1.2 Hz, 
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H2), 8.60 (d, 1H, J= 8.8 Hz, H8), 8.14 (t, 1H, J= 1.2 Hz, H5), 8.04 (d, 2H, J= 8.8 Hz, 
H7/H10), 7.99 (d, 1H, J= 8.8 Hz, H13), 7.84-7.80 (ddd, J= 8.4, 6.8, 1.6 Hz, 1H, H12), 
7.64-7.60 (ddd, J= 8.0, 6.8, 1.2 Hz, 1H, H11), 7.19 (t, 1H, J= 1.2 Hz, H4). In a 
pressure flask, a mixture of III-4b (300 mg, 1.54 mmol) and 1-(2-bromoethyl)-1H- 
pyrrole (267.45 mg, 1.54 mmol) was dissolved in 10 mL of dry MeCN. The mixture 
was stirred at 80 °C for 72 h. After cooling to room temperature, the solvent was 
removed by vacuum to give a brown paste. The paste was dissolved in CH2Cl2 and 
precipitated with Et2O. The precipitate was filtered, washed with Et2O and dried 
under vacuum to give III-5c as a yellow solid (180 mg, 32% yield). Anal. Calcd. For 
C18H17BrN4: C, 58.55; H, 4.64; N, 15.17. Found: C, 58.73; H, 4.36; N, 15.08. 
1H 
NMR (400 MHz, DMSO-d6): δ 9.98 (t, 1H, J= 2 Hz, H2), 8.84 (d, 1H, J= 8.8 Hz, H8), 
8.64 (t, 1H, J= 2 Hz, H5), 8.17 (d, 1H, J= 8.0 Hz, H7), 8.11 (d, 1H, J= 8.8 Hz, H10), 
8.07 (d, 1H, J= 8.4 Hz, H13), 7.95 (ddd, 1H, J= 8.8, 7.2, 1.6 Hz, H12), 7.77 (ddd, 1H, 
J= 8.4, 7.2, 1.2 Hz, H11), 7.67 (t, 1H, J= 2 Hz, H4), 6.76 (t, 2H, J= 2 Hz, H19), 6.01 
(t, 2H, J= 2 Hz, H20), 4.72 (t, 2H, J= 6 Hz, H16), 4.49 (t, 2H, J= 6 Hz, H17). 13C 
NMR (100 MHz, DMSO-d6): δ 145.9 (1C, C6), 145.6 (1C, C14), 141.9 (1C, C8), 
136.2 (1C, C2), 132.3 (1C, C12), 128.8 (1C, C13), 128.6 (1C, C10), 128.5 (1C, C9), 
128.3 (1C, C11), 124.2 (1C, C5), 121.3 (2C, C19), 119.8 (1C, C4), 112.9 (1C, C7), 
109.0 (2C, C20), 51.1 (1C, C16), 48.4 (1C, C17). HRMS (ES+): calcd. for C18H17N4 
289.1453; found 289.1454. 
 
2.1.8. 3-(2-(Piperidin-1-yl)ethyl)-1-(quinolin-2-yl)-1H-imidazol-3-ium chloride 
hyrdrochloride (III-5d) 
  
  In a pressure flask, a mixture of III-4b (400 mg, 2.05 mmol) and 
1-(2-chloroethyl)piperidine hydrochloride (377 mg, 2.05 mmol) was dissolved in 10 
mL of dry MeCN. The mixture was stirred at 80 °C for 72 h. After cooling to room 
temperature, the precipitate formed was filtered, washed with CH2Cl2 and dried under 
vacuum to obtain III-5d as a white solid (150 mg, 20% yield). Anal. Calcd. For 
C19H24Cl2N4: C, 60.16; H, 6.38; N, 14.77. Found: C, 60.18; H, 6.10; N, 14.92. 
1H 
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NMR (400 MHz, DMSO-d6): δ 11.26 (s, 1H, HCl), 10.05 (s, 1H, H2), 8.86 (d, 1H, J= 
8.8 Hz, H8), 8.71 (t, 1H, J= 2 Hz, H5), 8.22-8.17 (m, 3H, H4/ H7/H10), 8.09 (d, 1H, 
J= 8.8 Hz, H13), 7.96 (ddd, 1H, J= 8.8, 7.2, 1.6 Hz, H12), 7.78 (ddd, 1H, J= 8.4, 7.2, 
1.2 Hz, H11), 4.86 (t, 2H, J= 5.6 Hz, H16), 3.73-3.54 (m, 4H, H19), 2.97 (m, 2H, 
H17), 1.92-1.69 (m, 6H, H20/H21). 13C NMR (100 MHz, DMSO-d6): δ 146.0 (1C, 
C6), 145.8 (1C, C14), 141.8 (1C, C8), 137.3 (1C, C2), 132.3 (1C, C12), 128.9 (1C, 
C13), 128.6 (1C, C10), 128.5 (1C, C9), 128.3 (1C, C11), 124.1 (1C, C5), 119.9 (1C, 
C4), 113.1 (1C, C7), 54.7 (1C, C16), 52.8 (2C, C19), 44.1 (1C, C17), 22.4 (2C, C20), 
21.7 (1C, C21). HRMS (ES+): calcd. for C19H23N4 307.1923; found 307.1919. 
 
2.2.  Preparation of gold(I) complexes 
2.2.1. Complex III-3a 
  
  In a Schlenk tube, III-2a (100 mg, 0.32 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (74 mg, 0.32 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (27 mg, 0.16 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 10 h. Finally, 
Au(SMe2)Cl (47 mg, 0.15 mmol) was added and after stirring for 1 h, the mixture was 
filtered through a pad of celite. The solvent was evaporated under reduced pressure 
and the residue was purified by column chromatography on silica gel with a mixture 
of CH2Cl2 and MeOH (20:1) as eluent to give complex III-3a as a yellow solid (52 
mg, 40% yield). Anal. Calcd. For C36H38AuN7O3: C, 53.14; H, 4.71; N, 12.05. Found: 
C, 53.20; H, 4.58; N, 12.13. 1H NMR (400 MHz, CD3OD): δ 7.49 (d, 2H, J = 2.0 Hz, 
H5), 7.45 (d, 4H, J = 9.2 Hz, H8), 7.43 (d, 2H, J = 2.0 Hz, H4), 7.34-7.31 (m, 6H, 
benzyl), 7.22-7.19 (m, 4H, benzyl), 6.67 (d, 4H, J = 9.2 Hz, H9), 5.28 (s, 4H, H6), 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
152 
 
2.87 (s, 12H, H11). 13C NMR (100 MHz, CD3OD): δ 182.8 (2C, C2), 150.9 (2C, C10), 
136.0 (2C, benzyl), 128.6 (4C, benzyl), 128.1 (2C, C7), 128.1 (2C, benzyl), 127.5 (4C, 
benzyl), 125.5 (4C, C8), 123.1 (2C, C5), 121.6 (2C, C4), 111.9 (4C, C9), 54.1 (2C, 
C6), 39.1 (4C, C11). HRMS (ES+): calcd. for C36H38AuN6 751.2823; found 751.2817. 
 
2.2.2. Complex III-3b 
  
  In a Schlenk tube, III-2b (140 mg, 0.41 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (94 mg, 0.41 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (35 mg, 0.21 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 10 h. Finally, 
Au(SMe2)Cl (60 mg, 0.21 mmol) was added and after stirring for 1 h, the mixture was 
filtered through a pad of celite. The solvent was evaporated under reduced pressure 
and the residue was purified by column chromatography on silica gel with a mixture 
of CH2Cl2 and MeOH (20:1) as eluent to give complex III-3b as a yellow solid (110 
mg, 62% yield). Anal. Calcd. For C40H46AuN7O3: C, 55.23; H, 5.33; N, 11.27. Found: 
C, 55.16; H, 5.34; N, 11.25. 1H NMR (400 MHz, CD3OD): δ 7.48 (d, 2H, J = 2.0 Hz, 
H5), 7.46-7.42 (m, 6H, H4/H8), 7.34-7.30 (m, 6H, benzyl), 7.24-7.19 (m, 4H, benzyl), 
6.64 (d, 4H, J = 9.2 Hz, H9), 5.27 (s, 4H, H6), 3.30 (q, 8H, J = 7.2 Hz, H11), 1.07 (t, 
12H, J = 7.2 Hz, H12). 13C NMR (100 MHz, CD3OD): δ 182.7 (2C, C2), 148.1 (2C, 
C10), 136.0 (2C, benzyl), 128.6 (4C, benzyl), 128.1 (2C, benzyl), 127.7 (4C, benzyl), 
127.2 (2C, C7), 125.7 (4C, C8), 123.0 (2C, C5), 121.5 (2C, C4), 111.2 (4C, C9), 54.1 
(2C, C6), 44.0 (4C, C11), 11.3 (4C, C12). HRMS (ES+): calcd. for C40H46AuN6 
807.3450; found 807.3447. 
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2.2.3. Complex III-3c 
  
  In a Schlenk tube, III-2c (200 mg, 0.60 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (138 mg, 0.60 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (50 mg, 0.30 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 10 h. Finally, 
Au(SMe2)Cl (88 mg, 0.30 mmol) was added and after stirring for 1 h, the mixture was 
filtered through a pad of celite. The solvent was evaporated under reduced pressure 
and the residue was purified by column chromatography on silica gel with a mixture 
of CH2Cl2 and MeOH (20:1) as eluent to give a yellow solid (150 mg, 60 % yield). 
Anal. Calcd. For C40H34AuN7O3: C, 56.01; H, 4.00; N, 11.43. Found: C, 56.12; H, 
3.89; N, 11.52. 1H NMR (400 MHz, CD3CN): δ 7.70 (d, 4H, J = 8.8 Hz, H8), 7.50 (d, 
2H, J = 2.0 Hz, H5), 7.45 (d, 4H, J = 8.8 Hz, H9), 7.40 (d, 2H, J = 2.0 Hz, H4), 
7.32-7.28 (m, 6H, benzyl), 7.21-7.19 (m, 4H, benzyl), 7.09 (t, 4H, J = 2.4 Hz, H11), 
6.34 (t, 4H, J = 2.4 Hz, H12), 5.32 (s, 4H, H6). 13C NMR (100 MHz, CD3CN): δ 
182.7 (2C, C2), 140.7 (2C, C10), 136.1 (2C, benzyl), 136.0 (2C, C7), 128.9 (4C, 
benzyl), 128.4 (2C, benzyl), 127.5 (4C, benzyl), 126.5 (4C, C8), 123.3 (2C, C5), 
122.5 (2C, C4), 120.2 (4C, C9), 119.0 (4C, C11), 111.1 (4C, C12), 54.4 (2C, C6). 
HRMS (ES+): calcd. for C40H34AuN6 795.2510; found 795.2515. 
 
2.2.4. Complex III-3d 
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  In a Schlenk tube, III-2d (108 mg, 0.30 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (70 mg, 0.30 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (26 mg, 0.15 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 10 h. Finally, 
Au(SMe2)Cl (45 mg, 0.30 mmol) was added and after stirring for 1 h, the mixture was 
filtered through a pad of celite. The solvent was evaporated under reduced pressure 
and the residue was purified by column chromatography on silica gel with a mixture 
of CH2Cl2 and MeOH (20:1) as eluent to give a yellow solid (70 mg, 52% yield). Anal. 
Calcd. For C40H42AuN7O5: C, 53.51; H, 4.72; N, 10.92. Found: C, 53.65; H, 4.70; N, 
10.87. 1H NMR (400 MHz, CD3OD): δ 7.54-7.51 (m, 6H, H5/H8), 7.46 (d, 2H, J = 
2.0 Hz, H4), 7.36-7.32 (m, 6H, benzyl), 7.23-7.20 (m, 4H, benzyl), 6.92 (d, 4H, J = 
9.2 Hz, H9), 5.28 (s, 4H, H6), 3.78 (t, 8H, J = 4.8 Hz, H12), 3.03 (t, 8H, J = 4.8 Hz, 
H11). 13C NMR (100 MHz, CD3OD): δ 182.7 (2C, C2), 151.8 (2C, C10), 135.9 (2C, 
benzyl), 130.9 (2C, C7), 128.7 (4C, benzyl), 128.2 (2C, benzyl), 127.6 (4C, benzyl), 
125.6 (4C, C8), 123.0 (2C, C5), 121.8 (2C, C4), 115.2 (4C, C9), 66.3 (4C, C12), 54.2 
(2C, C6), 48.3 (4C, C11). HRMS (ES+): calcd. for C40H42AuN6O2 835.3035; found 
835.3055. 
 
2.2.5. Complex III-6a 
 
  In a Schlenk tube III-5a (100 mg, 0.27 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (63.6 mg, 0.27 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (23.3 mg, 0.14 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 10 h. Finally, 
Au(SMe2)Cl (40.4 mg, 0.14 mmol) was added and after stirring for 1 h, the mixture 
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was filtered through a pad of celite. The solvent was evaporated under reduced 
pressure and the residue was purified on silica gel with a mixture of CH2Cl2 and 
MeOH (20:1) as eluent to give a pale-yellow solid (32 mg, 28 % yield). Anal. Calcd. 
For C32H34AuN7O3S2: C, 46.54; H, 4.15; N, 11.87. Found: C, 46.36; H, 4.27; N, 11.97. 
1H NMR (400 MHz, CD3OD): δ 7.52 (d, 2H, J= 2 Hz, H5), 7.43 (d, 4H, J= 8.4 Hz, 
HSMePh), 7.31 (d, 4H, J= 8.4 Hz, HSMePh), 7.26 (d, 2H, J= 2 Hz, H5), 6.38 (t, 4H, J= 
2.0 Hz, H9), 5.97 (t, 4H, J= 2.0 Hz, H10), 4.48 (t, 4H, J= 5.6 Hz, H6), 4.36 (t, 2H, J= 
5.6 Hz, H7), 2.55 (s, 6H, HSMePh). 
13C NMR (100 MHz, CD3OD): δ 183.1 (2C, C2), 
140.9 (2C, CSMePh), 135.9 (2C, CSMePh), 126.1 (4C, CSMePh), 125.2 (4C, CSMePh), 122.6 
(2C, C5), 121.8 (2C, C4), 120.3 (4C, C9), 108.4 (4C, C10), 52.3 (2C, C6), 49.3 (2C, 
C7), 13.9 (2C, CSMePh). HRMS (ES
+): calcd. for C32H34N6S2Au 763.1952; found 
763.1962. 
 
2.2.6. Complex III-6b 
  
  In a Schlenk tube III-5b (100 mg, 0.27 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (61.9 mg, 0.27 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (22.7 mg, 0.13 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 1 h. Finally, 
Au(SMe2)Cl (39.3 mg, 0.13 mmol) was added and after stirring for 1 h, the mixture 
was filtered through a pad of celite. The solvent was evaporated under reduced 
pressure to give a pale-yellow solid (90 mg, 78% yield). Anal. Calcd. For 
C34H46AuN7O3S2: C, 47.38; H, 5.38; N, 11.38. Found: C, 47.13; H, 5.28; N, 11.50. 
1H 
NMR (400 MHz, CD3OD): δ 7.61-7.56 (m, 8H, H5/H4/HSMePh), 7.40 (d, 4H, J= 8.4 
Hz, HSMePh), 4.29 (t, 4H, J= 6.4 Hz, H6), 2.69 (t, 4H, J= 6.4 Hz, H7), 2.58 (s, 6H, 
HSMePh), 2.34 (t, 8H, J= 4.8 Hz, H9), 1.54-1.49 (m, 8H, H10), 1.46-1.41 (m, 4H, H11). 
13C NMR (100 MHz, CD3OD): δ 182.4 (2C, C2), 140.9 (2C, CSMePh), 136.1 (2C, 
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CSMePh), 126.3 (4C, CSMePh), 125.2 (4C, CSMePh), 122.5 (2C, C5), 122.3 (2C, C4), 58.9 
(2C, C6), 54.2 (4C, C9), 48.1 (2C, C7), 25.4 (4C, C10), 23.7 (2C, C11), 13.9 (2C, 
CSMePh). HRMS (ES
+): calcd. for C34H46N6S2Au 799.2891; found 799.2889. 
 
2.2.7. Complex III-6c 
 
  In a Schlenk tube III-5c (100 mg, 0.27 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (63 mg, 0.27 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (23 mg, 0.14 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 10 h. Finally, 
Au(SMe2)Cl (40 mg, 0.14 mmol) was added and after stirring for 1 h, the mixture was 
filtered through a pad of celite. The solvent was evaporated under reduced pressure 
and the residue was purified on silica gel with a mixture of CH2Cl2 and MeOH (20:1) 
as eluent to give a pale-yellow solid (55 mg, 51% yield). Anal. Calcd. For 
C36H32AuN9O3: C, 51.74; H, 3.86; N, 15.09. Found: C, 51.95; H, 3.60; N, 15.18. 
1H 
NMR (400 MHz, CD3OD): δ 8.03-8.01 (m, 4H, H5/H8), 7.92 (d, 2H, J= 8.8 Hz, H7), 
7.85 (d, 2H, J= 8.4 Hz, H10), 7.74-7.67 (m, 4H, H13/H12), 7.53 (ddd, 2H, J= 8.4, 7.2, 
1.6 Hz, H11), 7.40 (d, 2H, J= 2 Hz, H4), 6.48 (t, 2H, J= 2 Hz, H19), 5.91 (t, 2H, J= 2 
Hz, H20), 4.71 (t, 4H, J= 5.6 Hz, H16), 4.49 (t, 4H, J= 5.6 Hz, H17). 13C NMR (100 
MHz, CD3OD): δ 183.0 (2C, C2), 149.2 (2C, C6), 146.1 (2C, C14), 139.1 (2C, C8), 
130.8 (2C, C12), 128.0 (2C, C13), 127.6 (2C, C10), 127.5 (2C, C9), 127.3 (2C, C11), 
122.1 (2C, C5), 121.3 (2C, C4), 120.3 (4C, C19), 115.6 (2C, C7), 108.5 (4C, C20), 
53.3 (2C, C17), 49.3 (2C, C18). HRMS (ES+): calcd. for C36H32N8Au 773.2415; 
found 773.2417. 
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2.2.8. Complex III-6d 
  
  In a Schlenk tube III-5d (100 mg, 0.26 mmol) was suspended in 10 mL of dry 
MeOH and Ag2O (61 mg, 0.26 mmol) was added. The mixture was stirred at room 
temperature for 3 h under nitrogen in the dark. A solution of AgNO3 (22.4 mg, 0.13 
mmol) in 2 mL of MeCN was added and the mixture was stirred for 1 h. Finally, 
Au(SMe2)Cl (38.8 mg, 0.13 mmol) was added and after stirring for 1 h, the mixture 
was filtered through a pad of celite. The solvent was evaporated under reduced 
pressure to give a pale-yellow solid (88 mg, 77% yield). Anal. Calcd. For 
C38H44AuN9O3: C, 52.35; H, 5.09; N, 14.46. Found: C, 52.54; H, 4.97; N, 14.34. 
1H 
NMR (400 MHz, CD3OD): δ 8.35 (d, 2H, J= 8.8 Hz, H8), 8.17 (d, 2H, J= 8.8 Hz, H7), 
8.08 (d, 2H, J= 2 Hz, H5), 7.94-7.88 (m, 4H, H10/H13), 7.76 (ddd, 2H, J= 8.4, 7.2, 
1.6 Hz, H12), 7.69 (d, 2H, J= 2 Hz, H4), 7.61 (ddd, 2H, J= 8.4, 7.2, 1.2 Hz, H11), 
4.45 (t, 4H, J= 6.8 Hz, H16), 2.74 (t, 4H, J= 6.8 Hz, H17), 2.26 (t, 8H, J= 4.8 Hz, 
H19), 1.44-1.38 (m, 8H, H20), 1.32-1.28 (m, 4H, H21). 13C NMR (100 MHz, 
CD3OD): δ 182.4 (2C, C2), 149.4 (2C, C6), 146.3 (2C, C14), 139.7 (2C, C8), 130.9 
(2C, C12), 128.2 (2C, C13), 127.8 (2C, C10), 127.7 (2C, C9), 127.4 (2C, C11), 122.9 
(2C, C5), 120.9 (2C, C4), 115.6 (2C, C7), 58.8 (2C, C17), 54.1 (4C, C19), 49.0 (2C, 
C18), 25.3 (4C, C20), 23.6 (2C, C21). HRMS (ES+): calcd. for C38H44N8Au 809.3354; 
found 809.3338. 
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3. Neutral gold(I) mono(NHC) complexes 
 
Fig 3.1 General numbering for NMR attribution. 
3.1.  Complex V-2e 
  
  Under nitrogen and in the dark, a Schlenk tube was charged with II-2c (100 mg, 
0.29 mmol) in 6 mL of MeCN and Ag2O (67.3 mg, 0.29 mmol). The reaction mixture 
was stirred at 40 °C for 24 h. After that, Au(SMe2)Cl (102.5 mg, 0.348 mmol) was 
added and the mixture was stirred for 4 h. The solution was filtered through a pad of 
celite and the solvent was removed under reduced pressure to give a pale-yellow solid 
(140 mg, 90% yield). Anal. Calcd. For C16H21AuClN3O: C, 38.15; H, 4.20; N, 8.34. 
Found: C, 38.21; H, 4.26; N, 8.28. 1H NMR (400 MHz, CD3CN): δ 7.43-7.35 (m, 5H, 
benzyl), 7.26 (s, 1H, H5), 7.18 (s, 1H, H4), 5.39 (s, 2H, H6), 4.31 (t, 2H, J= 5.6 Hz, 
H7), 3.63 (t, 4H, J= 4 Hz, H11), 2.84 (s, 2H, H8), 2.57 (t, 4H, J= 4 Hz, H10). 13C 
NMR (100 MHz, CD3CN): δ 170.5 (1C, C2), 136.7 (1C, Bn), 128.8 (2C, Bn), 128.2 
(1C, Bn), 127.6 (2C, Bn), 122.1 (1C, C5), 121.1 (1C, C4), 66.2 (2C, C11), 58.1 (1C, 
C6), 54.3 (1C, C7), 53.4 (2C, C10), 47.8 (1C, C8). HRMS (ES+): calcd. for 
C16H21AuN3O 468.1350; found 468.1351. 
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3.2.  Complex V-2f 
  
  Under nitrogen and in the dark, a Schlenk tube was charged with II-2b (100 mg, 
0.30 mmol) in 6 mL of MeCN and Ag2O (69.7 mg, 0.30 mmol). The reaction mixture 
was stirred at 40 °C for 24 h. After that, Au(SMe2)Cl (106.4 mg, 0.36 mmol) was 
added and the mixture was stirred for 4 h. The solution was filtered through a pad of 
celite and the solvent was removed under reduced pressure to give a grey solid (105 
mg, 72% yield). Anal. Calcd. For C16H17AuClN3: C, 39.73; H, 3.54; N, 8.69. Found: 
C, 39.81; H, 3.56; N, 8.58. 1H NMR (400 MHz, CD3CN): δ 7.41-7.36 (m, 3H, benzyl), 
7.29-7.27 (m, 2H, benzyl), 7.06 (s, 1H, H5), 6.79 (s, 1H, H4), 6.53 (t, 2H, J= 2 Hz, 
H10), 6.02 (t, 2H, J= 2 Hz, H11), 5.33 (s, 4H, H6), 4.49 (t, 2H, J= 6 Hz, H7), 4.35 (t, 
2H, J= 6 Hz, H8). 13C NMR (100 MHz, CD3CN): δ 170.7 (1C, C2), 136.5 (1C, 
benzyl), 128.8 (2C, benzyl), 128.2 (1C, benzyl), 127.5 (2C, benzyl), 121.6 (1C, C5), 
120.6 (1C, C4), 117.3 (2C, C10), 108.5 (2C, C11), 54.3 (1C, C6), 52.2 (1C, C7), 49.3 
(1C, C8). HRMS (ES+): calcd. for C16H17AuN3 448.1088; found 448.1097. 
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4. Iridium(III) NHC complexes 
 
Fig 4.1 General numbering for NMR attribution. 
 
4.1. Preparation of imidazolium salts 
4.1.1. 1,1'-Methylenebis(3-isopropyl-1H-imidazol-3-ium) bromide (VI-3a) 
 
  A three-necked flask was charged with a mixture of imidazole (1.36 g, 20 mmol), 
tetrabutylammonium bromide (193 mg, 0.6 mmol), and powdered potassium 
hydroxide (2.24 g, 40 mmol) and stirred for 1 h at room temperature. To the resulting 
liquid was slowly added dibromomethane (0.7 mL, 10 mmol). After 5 hours, a solid 
was obtained. Purification of the crude product was performed by sublimation at 180 
oC to yield a white product (885 mg, 60 % yield). 1H NMR (400 MHz, CDCl3): δ 7.67 
(s, 2H, H2), 7.14 (s, 2H, H5), 7.14 (s, 2H, H4), 6.02 (s, 2H, H6). 1,1’-Methylene 
bis(1H-imidazole) (50 mg, 0.34 mmol) was dissolved in 2 mL of 2-bromopropane, 
and the reaction mixture was refluxed for 48 h. After cooling down to room 
temperature, the precipitate formed was filtered, washed with Et2O and dried under 
vacuum to obtain a white solid (50 mg, 38% yield). Anal. Calcd. For C13H22Br2N4: C, 
39.61; H, 5.63; N, 14.21. Found: C, 39.45; H, 5.54; N, 14.05. 1H NMR (400 MHz, 
DMSO-d6): δ 9.68 (s, 2H, H2), 8.12 (s, 2H, H5), 8.06 (s, 2H, H4), 6.67 (s, 2H, H6), 
4.74-4.68 (m, 2H, H7), 1.51 (d, 12H, J= 6.4 Hz, H8). 
13C NMR (100 MHz, DMSO-d6): 
δ 137.0 (2C, C2), 122.9 (2C, C5), 121.8 (2C, C4), 58.5 (1C, C6), 53.3 (2C, C7), 22.6 
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(4C, C8). MS (ES
+): calcd. for C13H22BrN4 313.10; found m/z = 312.92 [M-Br
-]+. 
Calcd. for C13H21N4 233.18; found 233.17 [M-2Br
--H+]+. 
 
4.1.2. 1,1'-Methylenebis(3-isobutyl-1H-imidazol-3-ium) bromide (VI-3b) 
 
  1,1’-Methylene bis(1H-imidazole) (100 mg, 0.67 mmol) was dissolved in 2 mL of 
1-bromo-2-methylpropane, and the reaction mixture was refluxed for 48 h. After 
cooling down to room temperature, the precipitate formed was filtered, washed with 
Et2O and dried under vacuum to obtain a white solid (195 mg, 69% yield). Anal. 
Calcd. For C15H26Br2N4: C, 42.67; H, 6.21; N, 13.27. Found: C, 42.64; H, 6.13; N, 
13.10. 1H NMR (400 MHz, DMSO-d6): δ 9.62 (s, 2H, H2), 8.11 (s, 2H, H5), 7.90 (s, 
2H, H4), 6.74 (s, 2H, H6), 4.09 (d, 4H, J= 7.2 Hz, H7), 2.16-2.07 (m, 2H, H8), 0.89 (d, 
12H, J= 6.4 Hz, H9) 
13C NMR (100 MHz, DMSO-d6): δ 138.1 (2C, C2), 124.0 (2C, 
C5), 122.7 (2C, C4), 58.7 (1C, C6), 56.4 (2C, C7), 29.0 (2C, C8), 19.6 (4C, C9). MS 
(ES+): calcd. for C15H26BrN4 341.13; found 341.25 [M-Br
-]+. Calcd. for C15H25N4 
261.21; found 261.25 [M-2Br--H+]+. 
 
4.1.3. 1,1'-Methylenebis(3-benzyl-1H-imidazol-3-ium) chloride (VI-3c) 
  
  A mixture of 1,1’-methylene bis(1H-imidazole) (100 mg, 0.67 mmol) and benzyl 
chloride (188 mg, 1.48 mmol) was refluxed in 5 ml of MeCN for 10 h. After cooling 
to room temperature, the precipitate formed was filtered, washed with Et2O and dried 
under vacuum to obtain a pale-yellow solid (190 mg, 71% yield). Anal. Calcd. For 
C21H22Cl2N4: C, 62.85; H, 5.53; N, 13.96. Found: C, 62.56; H, 5.34; N, 13.72. 
1H 
NMR (400 MHz, DMSO-d6): δ 9.98 (s, 2H, H2), 8.26 (s, 2H, H5), 7.92 (s, 2H, H4), 
7.52-7.34 (m, 10H, benzyl), 6.83 (s, 2H, H6), 5.51 (s, 4H, H7). 
13C NMR (100 MHz, 
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DMSO-d6): δ 138.4 (2C, C2), 134.7 (2C, benzyl), 129.5 (4C, benzyl), 129.4 (2C, 
benzyl), 129.0 (4C, benzyl), 123.5 (2C, C5), 123.1 (2C, C4), 58.5 (1C, C6), 52.7 (2C, 
C7). MS (ES
+): calcd. for C21H21N4 329.18; found 329.42 [M-2Br
--H+]+. 
 
4.1.4. 1,1'-Methylenebis(3-(2-(piperidin-1-yl)ethyl)-1H-imidazol-3-ium) chloride 
hydrochloride (VI-3d) 
  
  A mixture of 1,1’-methylene bis(1H-imidazole) (50 mg, 0.34 mmol) and 
1-(2-chloroethyl)piperidine hydrochloride (136.7 mg, 0.74 mmol) was refluxed in 5 
ml of toluene for 24 h. After cooling to room temperature, the solvent was evaporated 
and MeCN was used to make the precipitation. Then the desired solid was filtered off 
and dried under vaccum to give a yellow solid (60 mg, 34% yield). Anal. Calcd. For 
C21H38Cl4N6: C, 48.85; H, 7.42; N, 16.28. Found: C, 48.55; H, 7.34; N, 16.05. 
1H 
NMR (400 MHz, DMSO-d6): δ 11.03 (s, 2H, HCl), 9.84 (s, 2H, H2), 8.19 (s, 2H, H5), 
7.95 (s, 2H, H4), 6.79 (s, 2H, H6), 4.77 (t, 4H, J= 6 Hz, H7), 3.63-3.47 (m,8H, H10), 
2.97-2.87 (m, 4H, H8), 1.86-1.66 (m, 12H, H11/H12). 
13C NMR (100 MHz, DMSO-d6): 
δ 139.4 (2C, C2), 123.3 (2C, C5), 123.0 (2C, C4), 58.6 (1C, C6), 54.7 (2C, C7), 52.7 
(4C, C10), 43.7 (2C, C8), 22.3 (4C, C11), 21.7 (2C, C12). MS (ES
+): calcd. for 
C21H36ClN6 407.27; found 407.17 [M-Cl
--2HCl]+. Calcd. for C21H35N6 371.55; found 
371.42 [M-2Cl--2HCl-H+]+. 
 
4.1.5. 1,1'-Methylenebis(3-(4-(methylthio)phenyl)-1H-imidazol-3-ium) bromide 
(VI-3e) 
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  Imidazole (3.24 g, 47.6 mmol), 4-bromothioanisole (4.83 g, 23.8 mmol), K2CO3 
(3.29 g, 23.8 mmol) and a catalytic amount of CuSO4 were stirred in a closed pressure 
flask at 205 °C for 10 h. After cooling to room temperature, the crude product was 
extracted by CH2Cl2, filtered and evaporated to dryness. The resulting residue was 
washed three times with Et2O (20 mL) to give 1-(4-methylthiophenyl)-1H-imidazole 
as a grey solid (3.6 g, 80% yield). 1H NMR (400 MHz, CDCl3): δ 7.84 (t, 1H, J= 1.2 
Hz, H2), 7.38-7.32 (m, 4H, HSMePh), 7.27 (t, 1H, J= 1.2 Hz, H5), 7.22 (t, 1H, J= 1.2 
Hz, H4), 2.54 (s, 3H, HSMePh). 1-(4-(methylthiophenyl)-1H-imidazole (200 mg, 1.05 
mmol) was dissolved in 2 mL of dibromomethane, and the reaction mixture was 
refluxed for 10 h. After cooling down, the precipitate formed was filtered, washed 
with Et2O and dried under vacuum to obtain a white solid (255 mg, 44% yield). Anal. 
Calcd. For C21H22Br2N4S2: C, 45.50; H, 4.00; N, 10.11. Found: C, 45.29; H, 3.93; N, 
10.50. 1H NMR (400 MHz, DMSO-d6): δ 10.31 (s, 2H, H2), 8.42 (s, 2H, H5), 8.38 (s, 
2H, H4), 7.76 (d, 4H, J= 8.8 Hz, HSMePh), 7.56 (d, 4H, J= 8.8 Hz, HSMePh), 6.90 (s, 2H, 
H6), 2.56 (s, 6H, HSMePh). 
13C NMR (100 MHz, DMSO-d6): δ 141.9 (2C, CSMePh), 
137.6 (2C, C2), 131.6 (2C, CSMePh), 127.2 (4C, CSMePh), 123.4 (2C, C5), 122.9 (4C, 
CSMePh), 122.1 (2C, C4), 58.9 (1C, C6), 14.9 (2C, CSMePh). MS (ES
+): calcd. for 
C21H22BrN4S2 473.05; found 473.25 [M-Br
-]+. Calcd. for C21H21N4S2 393.12; found 
393.33 [M-2Br-H+]+. 
 
4.1.6. 1-Benzyl-3-[3-(3-benzyl-1H-imidazol-3-ium-1-yl)propyl]-1H-imidazol-3
-ium dibromide (VI-3f) 
  
  A mixture of imidazole (6.201 g, 91 mmol), K2CO3 (15.420 g, 112 mmol) in 60 mL 
of DMF was strirred for 20 min, then benzyl chloride (12.6 mL, 109 mmol) was 
slowly added to the solution. The reaction mixture was stirred at 50 °C for 2 h. After 
cooling to room temperature, water (100 mL) was added. The aqueous layer was 
extracted twice with EtOAc (100 mL) and the combined organic layers were washed 
with water and brine and dried over Na2SO4. The solvent was evaporated to give 
1-benzyl-1H-imidazole as a beige solid (7.910 g, 55% yield). 1H NMR (400 MHz, 
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CD3Cl): δ 7.57 (s, 1H, H2), 7.40 – 7.33 (m, 3H, HBn), 7.17 (ddd, J = 7.2, 1.6, 0.8 Hz, 
2H, HBn), 7.11 (dd, J = 1.3, 1.3 Hz, 1H, H5), 6.92 (dd, J = 1.3, 1.3 Hz, 1H, H4), 5.14 (s, 
2H, H7). A mixture of 1-benzyl-1H-imidazole (105 mg, 0.64 mmol) and 
1,2-dibromoethane (63.6 mg, 0.34 mmol) in 5 ml of toluene was stirred under reflux 
for 24 h. After cooling to room temperature, the solvent was evaporated, the crude 
was washed with Et2O, filtered and dried under vacuum to obtain a beige solid (1.027 
g, 90% yield). 1H NMR (400 MHz, DMSO-d6): δ 9.32 (s, 2H, H2), 7.83 (dd, J = 1.8, 
1.8 Hz, 2H, H5), 7.72 (dd, J = 1.8, 1.8 Hz, 2H, H4), 7.48 – 7.36 (m, 10H, HBn), 5.44 (s, 
4H, H6), 4.75 (s, 4H, H7). 
13C NMR (100 MHz, DMSO-d6): δ 137.2 (2C, C2), 135.0 
(2C, CBn), 129.5 (4C, CBn), 129.3 (2C, CBn), 128.8 (4C, CBn), 123.4 (2C, C5), 123.3 
(2C, C4), 52.5 (2C, C6), 48.9 (2C, C7). MS (ES
+): calcd. for C22H24BrN4 423.12; found 
423.42 [M-Br-]+. Calcd. for C22H23N4 343.46; found 343.75 [M-2Br
--H+]+. 
 
4.1.7. 3,3’-(Ethane-1,2-diyl)bis[1-(2-methylpropyl)-1H-imidazol-3ium] 
dihexafluorophosphate (VI-3g) 
  
  A mixture of imidazole (500 mg, 7.3 mmol) and potassium hydroxyde (618.4 mg, 
11 mmol) was dissolved in 5 ml of DMSO and stirred for 30 min at 19 °C. Then 
isobutyl bromide (100.8 mg, 0.7 mmol) was slowly added at 0 °C. After 2 h stirring at 
room temperature, the mixture was diluted with water and EtOAc. The organic layer 
was washed with brine and dried over Na2SO4. The solvent was evaporated to give 
1-(2-methylpropyl)-1H-imidazole as a white solid (547 mg, 60% yield). 1H NMR (400 
MHz, CDCl3): δ 7.46 (s, 1H, H2), 7.09 – 7.05 (dd, J = 1.3, 1.3 Hz, 1H, H5), 6.89 (dd, J 
= 1.3, 1.3 Hz, 1H, H4), 3.74 (d, J = 7.2 Hz, 2H, H7), 2.04 (dt, J = 13.4, 6.7 Hz, 1H, H8), 
0.93 (d, J = 6.7 Hz, 6H, H9). A mixture of 1-(2-methylpropyl)-1H-imidazole (123.5 
mg, 1 mmol) and 1,2-dibromoethane (93.4 mg, 0.5mmol) in 5 ml of toluene was 
stirred in a closed pressure flask at 110 °C for 72 h. After cooling to room temperature, 
the solvent was evaporated and the crude was dissolved in 10 mL of MeCN. The 
mixture was filtered and the solvent was removed. The solid was washed with a 
mixture of MeCN and Et2O (1:5) and dried under vaccum to afford a white solid. (170 
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mg, 60% yield). 1H NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H, H2), 7.80 (s, 2H, H5), 
7.70 (s, 2H, H4), 4.71 (s, 4H, H6), 3.98 (d, J = 7.1 Hz, 4H, H7), 2.04 (dt, J = 13.6, 6.8 
Hz, 2H, H8), 0.83 (d, J = 6.6 Hz, 12H, H9). 
13C NMR (100 MHz, DMSO-d6): δ 137.1 
(2C, C2), 123.8 (2C, C5), 123.0 (2C, C4), 56.1 (2C, C6), 48.9 (2C, C7), 29.1 (2C, C8), 
19.5 (4C, C9). MS (ES
+): calcd. for C16H28F6N4P 421.20; found 421.17 [M-PF6
-]+. 
Calcd. for C16H27N4; found 275.17 [M-2PF6
--H+]+. 
 
4.1.8. 3-Mesityl-1-(quinolin-2-yl)-1H-imidazol-3-ium chloride (VI-3h) 
  
  This compound was prepared according to the literature procedure.113a 1H NMR 
(400 MHz, CDCl3): δ 12.15 (s, 1H, H2), 9.43 (d, J = 8.8 Hz, 1H, H8), 9.07 (d, J = 1.7 
Hz, 1H, H5), 8.59 (d, J = 8.8 Hz, 1H, H7), 8.08 (d, J = 8.4 Hz, 1H, H13), 7.97 (d, J = 
8.2 Hz, 1H, H10), 7.88 – 7.79 (m, 1H, H12), 7.70 – 7.64 (m, 1H, H11), 7.38 (d, J = 1.7 
Hz, 1H, H4), 7.07 (s, 2H, HMes), 2.37 (s, 3H, CH3), 2.24 (s, 6H, CH3).
 13C NMR (100 
MHz, CDCl3): δ 146.0 (1C, C6), 144.9 (1C, C14), 141.8 (1C, C8), 141.5 (1C, CMes), 
138.0 (1C, C2), 134.0 (2C, CMes), 131.3 (1C, C12), 130.7 (2C, CMes), 130.1 (2C,CMes), 
128.7 (1C, C13), 128.6 (1C, C9), 128.2 (1C, C10), 128.1 (1C, C11), 123.7 (1C, C7), 
119.8 (1C, C5), 114.1 (1C, C4), 21.2 (1C, CMes), 17.9 (2C, CMes). 
 
4.2. Synthesis of iridium(III) complexes 
The precursor of iridium complex ([IrCl(ppy)2]2) was prepared according to the 
literature procedure.86 
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4.2.1. Complex VI-4a 
  
  A mixture of VI-2a (35 mg, 0.09 mmol), silver oxide (20.6 mg, 0.09 mmol) and 
[IrCl(ppy)2]2 (43 mg, 0.04 mmol) in 10 mL of MeCN was refluxed for 10 h. After 
cooling down to room temperature, an aqueous solution of NH4PF6 (200 mg in 10 mL 
deionized water) was slowly added into the reaction mixture under stirring, resulting 
in a yellow suspension. The suspension was then filtered and the resulting precipitate 
was washed with deionized water and dried under vacuum at 70 oC for 12 h. The 
crude product was purified by column chromatography on silica gel with 
CH2Cl2/MeOH (20:1) as the eluent, yielding a yellow solid (40 mg, 57% yield). Anal. 
Calcd. For C35H36F6IrN6P: C, 47.89; H, 4.13; N, 9.57. Found: C, 47.45; H, 4.04; N, 
9.79. 1H NMR (400 MHz, CD3CN): δ 8.33 (d, 2H, J= 5.6 Hz, Hb), 8.09 (d, 2H, J= 7.6 
Hz, He), 7.91 (ddd, 2H, J= 7.6, 7.6, 1.2 Hz, Hd), 7.74 (d, 2H, J= 7.6 Hz, Hk), 7.37 (d, 
2H, J= 2.4 Hz, H5), 7.13-7.09 (m, 4H, Hc/H4), 6.89 (ddd, 2H, J= 7.6, 7.6, 1.2 Hz, Hj), 
6.79 (ddd, 2H, J= 7.6, 7.6, 1.2 Hz, Hi), 6.30 (d, 2H, J= 7.6 Hz, Hh), 5.98 (s, 2H, H6), 
4.16-4.10 (m, 2H, H7), 1.02 (d, 6H, J= 6.4 Hz, H8), 0.27 (d, 6H, J= 6.4 Hz, H8’). 
13C 
NMR (100 MHz, CDCl3): δ 169.7 (2C, Cf), 162.7 (2C, C2), 162.2 (2C, Cl), 153.0 (2C, 
Cb), 143.9 (2C, Cg), 136.7 (2C, Cd), 131.0 (2C, Ch), 129.6 (2C, Ci), 124.4 (2C, C5), 
123.9 (2C, Ck), 121.9 (2C, Cc), 121.4 (2C, C4), 119.8 (2C, Ce), 116.6 (2C, Cj), 61.5 
(1C, C6), 49.9 (2C, C7), 22.7 (2C, C8), 22.6 (2C, C8’). HRMS (ES
+): calcd. for 
C35H36N6Ir 731.2607; found 731.2606 [M-PF6
-]+. 
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4.2.2. Complex VI-4b 
 
  A mixture of VI-3b (43.3 mg, 0.10 mmol), silver oxide (23.8 mg, 0.10 mmol) and 
[IrCl(ppy)2]2 (50 mg, 0.05 mmol) in 10 mL of MeCN was reluxed for 10 h. After 
cooling down to room temperature, an aqueous solution of NH4PF6 (200 mg in 10 mL 
deionized water) was slowly added into the reaction mixture under stirring, resulting 
in a yellow suspension. The suspension was then filtered and the resulting precipitate 
was washed with deionized water and dried under vacuum at 70 oC for 12 h. The 
crude product was purified by column chromatography on silica gel with 
CH2Cl2/MeOH (30:1) as the eluent, yielding a yellow solid (40 mg, 47% yield). Anal. 
Calcd. For C37H40F6IrN6P: C, 49.05; H, 4.45; N, 9.28. Found: C, 49.50; H, 4.14; N, 
9.33. 1H NMR (400 MHz, CDCl3): δ 8.13 (d, 2H, J= 6.0 Hz, Hb), 7.95 (d, 2H, J= 8.0 
Hz, He), 7.81 (dd, 2H, J= 7.2, 7.2 Hz, Hd), 7.65-7.58 (m, 4H, Hk/H5), 7.05 (dd, 2H, J= 
7.2, 7.2 Hz, Hc), 6.89 (dd, 2H, J= 7.2, 7.2 Hz, Hj), 6.84 (s, 2H, H4), 6.78 (dd, 2H, J= 
7.2, 7.2 Hz, Hi), 6.24 (d, 2H, J= 8.0 Hz, Hh), 6.20 (s, 2H, H6), 3.31 (dd, 2H, J= 8.0, 
5.2 Hz, H7), 3.07 (dd, 2H, J= 8.0, 5.2 Hz, H7’), 1.25-1.20 (m, 2H, H8), 0.47 (d, 6H, J= 
6.4 Hz, H9), 0.12 (d, 6H, J= 6.4 Hz, H9’). 
13C NMR (100 MHz, CDCl3): δ 169.7 (2C, 
Cf), 163.6 (2C, C2), 162.8 (2C, Cl), 152.7 (2C, Cb), 143.9 (2C, Cg), 136.7 (2C, Cd), 
131.4 (2C, Ch), 129.7 (2C, Ci), 124.6 (2C, C5), 123.5 (2C, Ck), 122.2 (2C, Cc), 121.5 
(2C, C4), 120.4 (2C, Ce), 119.8 (2C, Cj), 61.5 (1C, C6), 54.9 (2C, C7), 28.3 (2C, C8), 
19.1 (2C, C9), 18.5 (2C, C9’). HRMS (ES
+): calcd. for C37H40N6Ir 759.2920; found 
759.2913 [M-PF6
-]+. 
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4.2.3. Complex VI-4c 
  
  A mixture of VI-3c (41.2 mg, 0.10 mmol), silver oxide (23.8 mg, 0.10 mmol) and 
[IrCl(ppy)2]2 (50 mg, 0.05 mmol) in 10 mL of MeCN was reluxed for 10 h. After 
cooling down to room temperature, an aqueous solution of NH4PF6 (200 mg in 10 mL 
deionized water) was slowly added into the reaction mixture under stirring, resulting 
in a yellow suspension. The suspension was then filtered and the resulting precipitate 
was washed with deionized water and dried under vacuum at 70 oC for 12 h. The 
crude product was purified by column chromatography on silica gel with 
CH2Cl2/MeOH (20:1) as the eluent, yielding a yellow solid (55 mg, 60% yield). Anal. 
Calcd. For C43H36F6IrN6P: C, 53.03; H, 3.73; N, 8.63. Found: C, 53.01; H, 3.49; N, 
8.15. 1H NMR (400 MHz, CDCl3): δ 8.25 (d, 2H, J= 5.6 Hz, Hb), 7.68 (d, 2H, J= 7.6 
Hz, He), 7.64-7.58 (m, 4H, H5/Hd), 7.52 (d, 2H, J= 7.6 Hz, Hk), 7.15-7.04 (m, 6H, 
benzyl), 6.98 (ddd, 2H, J= 6.0, 6.0, 1.6 Hz, Hc), 6.79 (ddd, 2H, J= 7.2, 7.2, 1.2 Hz, Hj), 
6.71 (d, 2H, J= 2.0 Hz, H4), 6.67 (ddd, 2H, J= 7.2, 7.2, 1.2 Hz, Hi), 6.34 (d, 4H, J= 
7.2 Hz, benzyl), 6.30 (s, 2H, H6), 6.23 (d, 2H, J= 7.6 Hz, Hh), 4.81 (d, 2H, J= 15.6 Hz, 
H7), 4.49 (d, 2H, J= 15.6 Hz, H7’). 
13C NMR (100 MHz, CDCl3): δ 169.3 (2C, Cf), 
164.3 (2C, C2), 161.8 (2C, Cl), 152.4 (2C, Cb), 143.9 (2C, Cg), 136.6 (2C, Cd), 135.9 
(2C, benzyl), 131.2 (2C, Ch), 129.6 (2C, Ci), 128.3 (4C, benzyl), 127.3 (2C, benzyl), 
126.2 (4C, benzyl), 124.5 (2C, C5), 124.0 (2C, Ck), 122.2 (2C, Cc), 121.6 (2C, C4), 
121.4 (2C, Ce), 119.8 (2C, Cj), 61.7 (1C, C6), 52.2 (2C, C7). HRMS (ES
+): calcd. for 
C43H36N6Ir 827.2607; found 827.2606 [M-PF6
-]+. 
 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
169 
 
4.2.4. Complex VI-4d 
  
  A mixture of VI-3d (43 mg, 0.08 mmol), silver oxide (19.3 mg, 0.08 mmol) and 
[IrCl(ppy)2]2 (40.6 mg, 0.04 mmol) in 10 mL of MeCN was reluxed for 10 h. After 
cooling down to room temperature, an aqueous solution of NH4PF6 (200 mg in 10 mL 
deionized water) was slowly added into the reaction mixture under stirring, resulting 
in a yellow suspension. The suspension was then filtered and the resulting precipitate 
was washed with deionized water and dried under vacuum at 70 oC for 12 h. The 
crude product was purified by column chromatography on silica gel with 
CH2Cl2/MeOH (10:1) as the eluent, yielding a yellow solid (8 mg, 11% yield). Anal. 
Calcd. For C43H50F6IrN8P: C, 50.83; H, 4.96; N, 11.03. Found: C, 50.97; H, 5.07; N, 
11.27. 1H NMR (400 MHz, CDCl3): δ 8.16 (d, 2H, J= 5.6 Hz, Hb), 8.13 (d, 2H, J= 2.0 
Hz, H5), 7.94 (d, 2H, J= 7.6 Hz, He), 7.79 (ddd, 2H, J= 7.6, 7.6, 1.6 Hz, Hd), 7.62 (d, 
2H, J= 7.6 Hz, Hk), 7.05-6.98 (m, 4H, H4/Hc), 6.90 (ddd, 2H, J= 7.6, 7.6, 1.6 Hz, Hj), 
6.83-6.74 (m, 4H, Hi/H6), 6.28 (d, 2H, J= 7.6 Hz, Hh), 3.56-3.50 (m, 2H, H7), 
3.39-3.34 (m, 2H, H7’), 2.12-2.01 (m, 4H, H10), 1.97-1.86 (m, 4H, H10’), 1.55-1.32 (m, 
16H, H8/H11/H12). 
13C NMR (100 MHz, CDCl3): δ 169.6 (2C, Cf), 162.8 (2C, C2), 
162.7 (2C, Cl), 152.7 (2C, Cb), 143.9 (2C, Cg), 136.7 (2C, Cd), 131.2 (2C, Ch), 129.6 
(2C, Ci), 124.5 (2C, C5), 123.0 (2C, Ck), 122.3 (2C, Cc), 122.1 (2C, C4), 121.4 (2C, 
Ce), 112.0 (2C, Cj), 61.7 (1C, C6), 58.2 (2C, C7), 54.2 (4C, C10), 46.1 (2C, C8), 25.6 
(4C, C11), 24.0 (2C, C12). HRMS (ES
+): calcd. for C43H50N8Ir 869.3764; found 
869.3741 [M-PF6
-]+. 
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4.2.5. Complex VI-4e 
  
  A mixture of VI-3e (56.9 mg, 0.10 mmol), silver oxide (23.8 mg, 0.10 mmol) and 
[IrCl(ppy)2]2 (50 mg, 0.05 mmol) in 10 mL of MeCN was reluxed for 10 h. After 
cooling down to room temperature, an aqueous solution of NH4PF6 (200 mg in 10 mL 
deionized water) was slowly added into the reaction mixture under stirring, resulting 
in a yellow suspension. The suspension was then filtered and the resulting precipitate 
was washed with deionized water and dried under vacuum at 70 oC for 12 h. The 
crude product was purified by column chromatography on silica gel with 
CH2Cl2/MeOH (20:1) as the eluent, yielding a yellow solid (35 mg, 36% yield). Anal. 
Calcd. For C43H36F6IrN6PS2: C, 49.75; H, 3.50; N, 8.10. Found: C, 50.05; H, 3.42; N, 
7.86. 1H NMR (400 MHz, CD3CN): δ 8.54 (d, 2H, J= 5.2 Hz, Hb), 7.82 (ddd, 2H, J= 
7.2, 7.2, 1.6 Hz, Hd), 7.72 (d, 2H, J= 7.6 Hz, He), 7.51 (d, 2H, J= 2.0 Hz, H5), 7.23 (d, 
2H, J= 7.6 Hz, Hk), 7.12 (ddd, 2H, J= 6.4, 6.4, 1.6 Hz, Hc), 6.96 (d, 2H, J= 2.0 Hz, 
H4), 6.59 (ddd, 2H, J= 7.2, 7.2, 1.2 Hz, Hj), 6.54 (d, 4H, J= 8.8 Hz, HSMePh), 6.34-6.24 
(m, 8H, H6/Hi/HSMePh), 5.44 (d, 2H, J= 7.6 Hz, Hh), 2.44 (s, 6H, HSMePh). 
13C NMR 
(100 MHz, CDCl3): δ 169.8 (2C, Cf), 164.9 (2C, C2), 162.9 (2C, Cl), 153.1 (2C, Cb), 
142.7 (2C, Cg), 138.4 (2C, CSMePh), 136.6 (2C, Cd), 135.6 (2C, CSMePh), 130.0 (2C, Ch), 
129.2 (2C, Ci), 126.2 (4C, CSMePh), 125.3 (4C, CSMePh), 124.6 (2C, C5), 124.0 (2C, Ck), 
122.8 (2C, Cc), 121.5 (2C, C4), 120.2 (2C, Ce), 119.7 (2C, Cj), 61.8 (1C, C6), 15.2 (2C, 
CSMePh). HRMS (ES
+): calcd. for C43H36N6S2Ir 891.2049; found 891.2030 [M-PF6
-]+. 
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4.2.6. Complex VI-4f 
 
  Under a nitrogen atmosphere and protection of the light, a flask was charged with 
VI-3f (52.3mg, 0.10 mmol), [IrCl(ppy)2]2 (53.5 mg, 0.05 mmol) and Ag2O (24.5 mg, 
0.10 mmol) in 10 mL of MeCN and the mixture was stirred under reflux for 24 h. 
After cooling to room temperature, NH4PF6 (200 mg) was added to the reaction 
mixture under stirring. The suspension was then filtered over a pad of celite, the 
resulting precipitate was washed with MeOH and the solvent was evaporated form the 
filtrate. The crude product was purified by two columns chromatography on silica gel 
with CH2Cl2/MeOH (30:1) and (200:1), respectively, as the eluent. The product was 
still not pure so it was solubilized in CH2Cl2 and precipitated with Et2O. After drying 
under vacuum, a yellow solid was obtained (49 mg, 49% yield). Anal. Calcd. for 
C44H38F6IrN6P: C, 53.49; H, 3.88; N, 8.51. Found: C, 53.34; H, 3.32; N, 8.77.
 1H 
NMR (500 MHz, CDCl3): δ 8.50 (d, J = 5.5 Hz, 2H, Hb), 7.60-7.57 (m, 4H, Hd/He), 
7.47 (d, J = 6.5 Hz, 2H, Hh), 7.11 (d, J = 2.0 Hz, 2H, H4), 7.10 (d, J = 1.5 Hz, 2H, H11), 
7.05 (dd, J = 8.5, 6.5 Hz, 6H, H10), 6.97 (ddd, J = 7.0, 7.0, 2.5 Hz, 2H, Hc), 6.76 (ddd, 
J = 7.0, 7.0, 1.0 Hz, 2H, Hi), 6.55 (d, J = 2.0 Hz, 4H, H5), 6.53 (dd, J = 7.0, 1.0 Hz, 
2H, Hj), 6.21 (d, J = 7.5 Hz, 4H, H9), 6.13 (d, J = 6.5 Hz, 2H, Hk), 4.80 (d, J = 16.0 
Hz, 2H, H7), 4.61 (s, 4H, H6), 4.51 (d, J = 16.0 Hz, 2H, H7). 
13C NMR (125 MHz, 
CDCl3): δ 168.8 (2C, Cf), 164.5 (2C, C2), 160.7 (2C, Cl), 154.9 (2C, Cb), 143.8 (2C, 
Cg), 136.8 (2C, C8), 136.5 (2C, Cd), 131.4 (2C, Ck), 129.1 (2C, Cj), 128.3 (2C, C10), 
127.2 (2C, C11), 126.0 (2C, C9), 125.6 (2C, C5), 125.1 (2C, C4), 124.6 (2C, Ch), 122.2 
(2C, CC), 121.3 (2C, Ci), 119.8 (2C, Ce), 53.7 (2C, C7), 51.3 (2C, C6). HRMS (ES
+): 
calcd. for C44H38N6Ir m/z = 841.2764; found m/z = 841.2783 [M-PF6
-]+. 
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4.2.7. Complex VI-4g 
  
  Under a nitrogen atmosphere, a flask was charged with VI-3g (52.8 mg, 0.10 
mmol), [IrCl(ppy)2]2 (50 mg, 0.05 mmol) and K2CO3 (13 mg, 0.10 mmol) in 10mL of 
MeCN was stirred under reflux for 24 h. After cooling to room temperature, the 
solvent was evaporated and the solid was dissolved in CH2Cl2. The solution was 
washed with water and brine, then dried with Na2SO4. The solution was filtered and 
the solvent was evaporated to obtain a yellow solid. The solid was treated with a 
mixture of CH2Cl2/Et2O (3:20) to give a yellow solid (55 mg, 60% yield). Anal. Calcd. 
for C38H42F6IrN6P: C, 49.57; H, 4.57; N, 9.13. Found: C, 49.17; H, 4.27; N, 9.33. 
1H 
NMR (400 MHz, CDCl3): δ 8.43 (d, J = 5.6 Hz, 2H, Hb), 7.91 (d, J = 8.0 Hz, 2H, He), 
7.81 (ddd, J = 7.2, 7.2, 1.6 Hz, 2H, Hd), 7.57 (d, J = 8.0 Hz, 2H, Hh), 7.15 (d, J = 2.0 
Hz, 2H, H4), 7.06 (ddd, J = 7.2, 7.2, 1.6 Hz, 2H, Hc), 6.83 (ddd, J = 7.2, 7.2, 1.2 Hz, 
2H, Hi), 6.77 (d, J = 2.0 Hz, 2H, H5), 6.69 (ddd, J = 7.2, 7.2, 1.2 Hz, 2H, Hj), 6.21 (d, 
J = 8.0 Hz, 2H, Hk), 4.55 (s, 4H, H6), 3.21 (dd, J = 13.4, 8.4 Hz, 2H, H7), 2.87 (dd, J = 
13.4, 8.4 Hz, 2H, H7), 1.58 (s, 2H, H8), 0.49 (d, J = 6.4 Hz, 6H, H9), 0.17 (d, J = 6.4 
Hz, 6H, H9’). 
13C NMR (100 MHz, CDCl3): δ 169.4 (2C, Cf), 163.7 (2C, C2), 161.3 
(2C, Cl), 154.9 (2C, Cb), 143.9 (2C, Cg), 136.7 (2C, Cd), 134.0 (2C, Ck), 128.9 (2C, 
Cj), 124.7 (2C, Ch), 124.6 (2C, C4), 122.2 (2C, Cc), 121.3 (2C, Ci), 120.8 (2C, C5), 
119.7 (2C, Ce), 55.8 (1C, C7), 50.6 (2C, C6), 28.3 (2C, C8), 18.7 (2C, C9), 18.4 (2C, 
C9’). HRMS (ES
+): calcd. for C38H42N6Ir 773.3077; found 773.3077 [M-PF6
-]+. 
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Fig 4.2 General numbering for NMR attribution. 
 
4.2.8. Complex VI-4h 
  
  Under a nitrogen atmosphere and protection of the light, a flask was charged with 
VI-3h (51.5mg, 0.15 mmol), [IrCl(ppy)2]2 (70,8 mg, 0.07 mmol) and Ag2O (18.8 mg, 
0.08 mmol) in 10 mL of MeCN and the resulting mixture was stirred under reflux for 
24 h. After cooling to room temperature, the mixture was filtered over a pad of celite 
and the solvent was evaporated from the filtrate. The product was dissolved in CH2Cl2, 
precipited by Et2O, filtered and dried under vacuum, yielding a yellow solid (65 mg, 
51% yield). Anal. Calcd. for C43H35IrN5Cl: C, 60.74; H, 4.12; N, 8.24. Found: C, 
60.54; H, 4.22; N, 8.42. 1H NMR (400 MHz, CDCl3): δ 10.00 (s, 1H, H5), 9.55 (J = 
8.4 Hz, 1H, H7), 8.72 (d, J = 8.4 Hz, 1H, H8), 8.09 (d, J = 8.4 Hz, 1H, H13), 8.05 (d, J 
= 5.6 Hz, 1H, Hb), 7.87 (d, J = 5.6 Hz, 1H, Hn), 7.84 (dd, J = 8.4, 1.6 Hz, 1H, H10), 
7.81-7.75 (m, 2H, He/Hd), 7.72 (d, J = 8.4 Hz, 1H, Hq), 7.65 (dd, J = 8.0, 8.0 Hz, 1H, 
Hp), 7.55-7.51 (m, 1H, Hx), 7.41 (ddd, J = 8.0, 8.0, 1.2 Hz, 1H, H11), 7.14 (ddd, J = 
8.0, 6.8, 1.2 Hz, 1H, H12), 7.09 (dd, J = 8.0, 1.2 Hz, 1H, Hh), 6.98 (s, 1H, H4), 
6.97-6.90 (m, 4H, Hc/Hv/Hw/Ho), 6.62 (ddd, J = 8.0, 8.0, 1.2 Hz, 1H, Hi), 6.46-6.40 (m, 
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2H, Hj/H20), 6.27-6.23 (m, 2H, Hu/H19), 5.90 (dd, J = 8.0, 1.2 Hz, 1H, Hk), 1.95 (s, 6H, 
H18/H24), 0.93 (s, 3H, H21). 
13C NMR (100 MHz, CDCl3): δ 180.4 (1C, C2), 169.3 (1C, 
Cr), 167.9 (1C, Cf), 165.6 (1C, Ct), 154.2 (1C, C6), 151.8 (1C, Cn), 150.7 (1C, Cb), 
146.3 (1C, Cl), 145.2 (1C, C14), 144.0 (1C, C8), 143.6 (1C, Cs), 141.4 (1C, Cg), 139.0 
(1C, C16), 137.7 (1C, Cp), 136.8 (1C, Cd), 133.9 (1C, C23), 133.7 (1C, C12), 133.6 (1C, 
C19), 131.5 (1C, Cv), 130.8 (1C, Cj), 130.6 (1C, C20), 129.5 (1C, C17), 129.5 (1C, Cu), 
129.0 (1C, Ck), 128.7 (1C, C10), 128.0 (1C, C22), 127.6 (1C, C9), 127.6 (1C, C13), 
127.1 (1C, C11), 125.5 (1C, C4), 124.7 (1C, Cx), 123.7 (1C, Ch), 123.0 (1C, Co), 122.5 
(1C, Cw), 122.5 (1C, Cc), 122.4 (1C, C5), 120.2 (1C, Ci), 119.6 (1C, Cq), 119.5 (1C, 
Ce), 113.9 (1C, C7), 20.9 (1C, C21), 18.7 (1C, C24), 15.9 (1C, C18). HRMS (ES
+): calcd. 
for C43H35N5Ir 812.2498; found 812.2490 [M-Cl
-]+. 
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Materials and methods 
1. X-ray measurements 
All data were collected at low temperature using oil-coated shock-cooled crystals at 
100(2) K on a Bruker-AXS APEX II diffractometer with MoKa radiation (λ = 0.71073 
Å). The structures were solved by direct methods123 and all non hydrogen atoms were 
refined anisotropically using the least-squares method on F2.124 The absolute structure 
parameters have been refined using the Flack-method.125 
Crystallographic data for II-3a, II-3b, II-3c, II-3d, III-3a, III-3b, III-3c, V-2e, 
V-2f, VI-4a, VI-4b, VI-4c, VI-4f and VI-4g: 
II-3a: C34H46.5AuN7O3.5, Mr = 806.25, crystal size = 0.40 x 0.10 x 0.02 mm
3, 
triclinic, space group P1, a = 10.684(2) Å, b = 16.145(2) Å, c = 21.292(2) Å, α = 
79.396(3)°, β = 77.511(3)°, γ = 77.607(3)°, V = 3465.6(7) Å3, Z = 4, 48878 reflections 
collected, 9811 unique reflections (Rint = 0.0526), R1 = 0.0538, wR2 = 0.1089 
[I>2σ(I)], R1 = 0.0674, wR2 = 0.1140 (all data), residual electron density = 2.641 e 
Å-3. 
II-3b: C32H34AuN7O3, Mr = 761.63, crystal size = 0.20 x 0.10 x 0.05 mm
3, triclinic, 
space group P1, a = 10.835(1) Å, b = 11.485(1) Å, c = 12.716(1) Å, α = 76.585(4)°, 
β = 77.134(4)°, γ = 84.412(4)°, V = 1498.7(2) Å3, Z = 2, 48878 reflections collected, 
9811 unique reflections (Rint = 0.0526), R1 = 0.0491, wR2 = 0.1271 [I>2σ(I)], R1 = 
0.0586, wR2 = 0.1338 (all data), residual electron density = 2.345 e Å-3. 
II-3c: C32H42AuN7O5, Mr = 801.69, crystal size = 0.30 x 0.30 x 0.20 mm
3, 
monoclinic, space group P21, a = 10.984(1) Å, b = 30.847(3) Å, c = 19.590(2) Å, β = 
90.277(2)°, V = 6637.4(9) Å3, Z = 8, 110310 reflections collected, 56863 unique 
reflections (Rint = 0.0363), R1 = 0.0538, wR2 = 0.1220 [I>2σ(I)], R1 = 0.0630, wR2 = 
0.1265 (all data), absolute structure factor x = 0.245(7), residual electron density = 
6.675 e Å-3. 
II-3d: C30H42AuN7O3, Mr = 745.67, crystal size = 0.30 x 0.20 x 0.20 mm
3, 
monoclinic, space group C2/c, a = 17.575(1) Å, b = 21.290(1) Å, c = 9.851(1) Å, β = 
121.108(2)°, V = 3155.7(2) Å3, Z = 4, 31004 reflections collected, 4798 unique 
reflections (Rint = 0.0480), R1 = 0.0173, wR2 = 0.0359 [I>2σ(I)], R1 = 0.0338, wR2 = 
0.0402 (all data), residual electron density = 0.692 e Å-3. 
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III-3a: C36H38AuN7O3, Mr = 813.7, crystal size = 0.40 x 0.10 x 0.02 mm
3, 
monoclinic, space group Cc, a = 17.300(1) Å, b = 8.384(1) Å, c = 23.168(2) Å, β = 
101.883(2)°, V = 3288.2(3) Å3, Z = 4, 31546 reflections collected, 10626 unique 
reflections (Rint = 0.0511), R1 = 0.0457, wR2 = 0.1095 [I>2σ(I)], R1 = 0.0535, wR2 = 
0.1141 (all data), Flack x refined to 0.001(7), residual electron density = 1.553 e Å-3. 
III-3b: C40.5H48AuN7O3.5, Mr = 885.82, crystal size = 0.40 x 0.40 x 0.30 mm
3, 
triclinic, space group P1, a = 12.989(1) Å, b = 13.120(1) Å, c = 22.637(2) Å, α = 
89.475(2)°, β = 84.108(2)°, γ = 79.203(2)°, V = 3769.0(4) Å3, Z = 4, 108465 
reflections collected, 22101 unique reflections (Rint = 0.0298), R1 = 0.0249, wR2 = 
0.0448 [I>2σ(I)], R1 = 0.0384, wR2 = 0.0486 (all data), residual electron density = 
1.408 e Å-3. 
III-3c: C40H34AuN7O3, Mr = 857.71, crystal size = 0.50 x 0.30 x 0.05 mm
3, 
monoclinic, space group C2/c, a = 15.119(2) Å, b = 14.404(2) Å, c = 32.326(4) Å, β = 
101.172(3)°, V = 6906.1(13) Å3, Z = 8, 37635 reflections collected, 4910 unique 
reflections (Rint = 0.0713), R1 = 0.0730, wR2 = 0.1436 [I>2σ(I)], R1 = 0.1020, wR2 
= 0.1538 (all data), residual electron density = 3.517 e Å-3. 
III-6c: C38H35AuN10O3.5, Mr = 884.72, crystal size = 0.30 x 0.30 x 0.20 mm
3, 
triclinic, space group P1, a = 12.2507(8) Å, b = 12.4973(8) Å, c = 12.9060(7) Å, α = 
63.086(3)°, β = 83.924(3)°, γ = 86.093(3)°, V = 1751.55(19) Å3, Z = 2, 79333 
reflections collected, 13932 unique reflections (Rint = 0.0460), R1 = 0.0265, wR2 = 
0.0514 [I>2σ(I)], R1 = 0.0387, wR2 = 0.0547 (all data), residual electron density = 
1.582 e Å-3. 
III-6d: C39H48AuN9O4, Mr = 903.83, crystal size = 0.50 x 0.30 x 0.10 mm
3, 
triclinic, space group P1, a = 12.5761(5) Å, b = 12.8909(6) Å, c = 13.4962(6) Å, α = 
114.471(2)°, β = 100.927(2)°, γ = 98.673(2)°, V = 1889.85(15) Å3, Z = 2, 39630 
reflections collected, 9353 unique reflections (Rint = 0.0754), R1 = 0.0416, wR2 = 
0.0765 [I>2σ(I)], R1 = 0.0667, wR2 = 0.0855 (all data), residual electron density = 
1.588 e Å-3. 
V-2e: C16H21AuClN3O, Mr = 503.77, crystal size = 0.20 x 0.20 x 0.05 mm
3, 
monoclinic, space group P21/n, a = 10.616(2) Å, b = 7.603(2) Å, c = 21.040(3) Å, β = 
102.438(4)°, V = 1658.4(4) Å3, Z = 4, 21943 reflections collected, 3487 unique 
reflections (Rint = 0.0763), R1 = 0.0413, wR2 = 0.0937 [I>2σ(I)], R1 = 0.0661, wR2 = 
0.1074 (all data), residual electron density = 2.673 e Å-3. 
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V-2f: C16H17AuClN3, Mr = 48374, crystal size = 0.50 x 0.40 x 0.10 mm
3, triclinic, 
space group P1, a = 9.3339(6) Å, b = 9.4041(6) Å, c = 9.9960(6) Å, α = 104.115(2)°, 
β = 101.187(2)°, γ = 104.407(2)°, V = 793.3(1) Å3, Z = 2, 15105 reflections collected, 
5605 unique reflections (Rint = 0.0416), R1 = 0.0308, wR2 = 0.0755 [I>2σ(I)], R1 = 
0.0382, wR2 = 0.0794 (all data), residual electron density = 3.468 e Å-3. 
VI-4a: C35H36F6IrN6P, Mr = 877.87, crystal size = 0.20 x 0.10 x 0.10 mm
3, 
orthorhombic, space group P212121, a = 10.5858(2) Å, b = 17.6393(3) Å, c = 
17.8473(3) Å, V = 3332.6(1) Å3, Z = 4, 25742 reflections collected, 15373 unique 
reflections (Rint = 0.0285), R1 = 0.0263, wR2 = 0.0553 [I>2σ(I)], R1 = 0.0303, wR2 = 
0.0568 (all data), Flack x refined to -0.021(3), residual electron density = 1.720 e Å-3. 
VI-4b: C37H41Br0.25Cl0.75IrN6O, Mr = 824.52, crystal size = 0.20 x 0.20 x 0.10 mm
3, 
monoclinic, space group C2/c, a = 39.743(2) Å, b = 8.954(1) Å, c = 22.453(2) Å, β = 
121.284(2)°, V = 6827.9(6) Å3, Z = 8, 51077 reflections collected, 8390 unique 
reflections (Rint = 0.0465), R1 = 0.0290, wR2 = 0.0524 [I>2σ(I)], R1 = 0.0421, wR2 = 
0.0554 (all data), residual electron density = 0.961 e Å-3. 
VI-4c: C43.5H37ClF6IrN6O, Mr = 1016.41, crystal size = 0.40 x 0.30 x 0.20 mm
3, 
monoclinic, space group P21, a = 11.03(2) Å, b = 24.53(4) Å, c = 14.32(2) Å, β = 
92.13(2)°, V = 3873(10) Å3, Z = 4, 64391 reflections collected, 16738 unique 
reflections (Rint = 0.0314), R1 = 0.0325, wR2 = 0.0694 [I>2σ(I)], R1 = 0.0378, wR2 = 
0.0750 (all data), Flack x refined to 0.482(6), residual electron density = 1.360 e Å-3. 
VI-4f: C47H45.5F6IrN6O0.75P, Mr = 1043.56, crystal size 0.2 x 0.1 x 0.02 mm
3, 
triclinic, space group P1, a = 14.94(2) Å, b = 15.06(2) Å, c = 20.52(3) Å, α = 
107.64(2)°, β = 107.73(2)°, γ = 94.99(3)°, V = 4108(10) Å3, Z = 4, 53646 reflections 
collected, 15235 unique, Rint = 0.0737, R1 = 0.0522, wR2 = 0.0980 [I > 2σ(I)], R1 = 
0.1021, wR2 = 0.1156 (all data), residual electron density = 1.562 eA-3. 
VI-4g: C38H42F6IrN6P, Mr = 919.94, crystal size 0.4 x 0.2 x 0.2 mm
3, orthorhombic, 
P212121, a = 10.806(1) Å, b = 17.084(2) Å, c = 19.875(2) Å, V = 3669.1(4) Å
3, Z = 4, 
54609 reflections collected, 11153 unique, Rint = 0.0326, R1 = 0.0142, wR2 = 0.0322 
[I > 2σ(I)], R1 = 0.0162, wR2 = 0.0328 (all data), Flack x refined to 0.497(3), residual 
electron density = 0.635 eA-3. 
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2. Photophysical measurements 
UV/Vis absorption spectra were recorded at RT on solutions contained in quartz 
cuvettes (optical pathlength 1 cm, Hellma®) with a PerkinElmer®, UV/VIS/NIR 
spectrophotometer Lambda 950 and a PerkinElmer® ditector; UV/VIS/NIR 
Accessory 2D Detector Module. 
Fluorescence and phosphorescence emission spectra were obtained with a HORIBA 
JOBIN YVON, fluromax-4 and spectrofluorometer. 
Luminescence quantum yields were measured according to the method of Demas 
and Crosby,126 on solution samples at RT. The quantum yield is defined as: 
Φ𝑆 =  Φ𝑅 ∗  
(𝐴𝑠)
(𝐴𝑟)
∗  
(𝜂𝑠)
(𝜂𝑟)2
2
 
Where Φ𝑆  is the quantum yield of the sample, Φ𝑅 is the know quantum yield of 
the reference standard. At the area subtended by the emission band (on a wavelength 
scale) and η is the refractive index of the solvent used for the preparation of the 
solution. As (related to the sample) and Ar (related to the reference) must be excitation 
wavelength. Different standards were selected depending on the spectral region of the 
interest: POPOP in hexane (Φ = 0.97) and QUININNE in water (Φ = 0.54). 
Fluorescence lifetime measurements were performed by an Edinburgh FLS920 
spectrofluorimeter equipped with a TCC900 card for data acquisition in 
time-correlated single-photon counting experiments (0.5 ns time resolution) with a D2 
lamp and an LDH-P-C-405 pulsed diode laser. The estimated experimental error is 2 
nm on the band maximum. (5% on the lifetime, 10% on the fluorescence quantum 
yield). 
 
3. Measure of lipophilicity 
The octanol-water partition coefficients (P) of all the complexes were determined 
using a shake-flask method.95 Water (100 mL, distilled after milli-Q purification) and 
n-octanol (100 mL, Sigma Aldrich, ACS spectrophotometric grade, ≥ 99%) were 
shaken together for 24 h to allow saturation of both phases. Stock solutions of the 
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compounds (50 µM) were prepared in the aqueous phase. Aliquots (2 mL) of each of 
these stock solutions were then added to an equal volume of the n-octanol phase. The 
resultant biphasic solution was mixed for 15 min and then centrifuged (3000 tr/min, 5 
min) to separate the phases. The concentrations of the complex in the organic and 
aqueous phases were then determined using UV absorbance spectroscopy (260 nm). 
The blank is the water saturated to n-octanol. Log P was defined as logarithm of the 
ratio of the concentrations of the complex in the organic and aqueous phases (values 
reported are the means of at least three separated determinations). 
𝐿𝑜𝑔 𝑃 =
[𝐼𝑟](𝑜𝑟𝑔)
[𝐼𝑟](𝑎𝑞)
 
 
4. Confocal microscopy 
The fluorescence of the complexes was evaluated using a Zeiss LSM 710 
NLO-Meta Confocal microscope. PC-3 cells were cultured in 6-well plates and on 
glass slides (180,000 cells per well) for 18 h before treated with complexes at 
different concentrations (0.25 μM, 0.5 μM and 1 μM). After 24 hours, a MitoTracker 
deep red probe was incubated on live cells at a final concentration of 200 nM during 
15 min at 37 oC in a 5 % CO2 humidified incubator and then observed in two channels 
440-544 nm for complex VI-4a (two-photon excitation at 720 nm) and 644-700 nm 
for MitoTracker (excitation at 633 nm) at the same time. 
 
5. Biology 
5.1. Cell lines 
Human prostate cancer PC-3 and lung carcinoma A549 cell lines were obtained 
from DSMZ (Braunschweig, Germany). Human bladder cancer T24, osteosarcoma 
U-2 OS, breast cancer MCF-7, hepatocarcinoma HepG-2, mouse osteoblast MC3T3 
and fibroblast NIH3T3 cell lines were from ATCC-LGC Standards (Molsheim, 
France). PC-3, HepG-2 and A549 cells were cultured in RPMI 1640, T24, MCF-7, 
U-2 OS and NIH3T3 in DMEM, and MC3T3 in MEM containing 10% fetal bovine 
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serum and 1% antibiotics (100 U/mL penicillin and 100 μg/mL streotimycin) at 37 oC 
in 5% CO2 humidified incubators. 
 
5.2. Cell viability assay 
The MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
was used to determine cell death as originally described by Mosmann93 and modified 
by Cuvillier et al.127 Briefly, cells were seeded 5000 cells/well in 24-well plates for 
various cell lines (PC-3, T24, A549, MCF-7, HepG-2, U-2 OS, MC3T3 and NIH3T3) 
and allowed to attach overnight. All of the complexes were dissolved in DMSO. The 
concentration of the complexes was calculated according to the elemental 
composition of the complexes determined by the elemental analyses. Media in the 
presence of the tested complexes were added and serially diluted to various 
concentrations (from 5 μM to 0.01 μM). The maximum concentration of DMSO in 
media did not exceed 0.5 % (v/v). After 24 h, 48 h or 72 h of treatment, cells were 
incubated at 37 oC and 5% CO2 with 25 μL MTT solution (5 mg/mL; Sigma-Aldrich) 
in 24-well plates for approximately 3 h. After solubilization with 500 μL of lysis 
buffer (DMSO), formazan was quantified by spectrophotometry with a microplate 
reader at 570 nm absorbance. The GI50 values corresponding to the concentration that 
caused 50% inhibition of cell proliferation were calculated from dose-response curves 
obtained by nonlinear regression analysis (Prism 5, Graphpad Software). All the 
results were calculated from data obtained in three independent experiments. 
 
5.3. Clonogenic assay 
PC-3 and T24 cells were counted and seeded (500 cells/well) to 6-well plates. Cells 
were allowed to attach overnight and then treated with different concentrations of 
gold complexes (0.01 μM，0.1 μM, 0.25 μM, 0.5 μM, 1 μM, 5 μM). After incubation 
for an additional 6 days for T24 and 8 days for PC-3, the cells were washed with PBS 
(2 mL), fixed with methanol (1 mL) for 20 min and stained with 0.5% crystal violet (2 
mL) for 30 min. The relative survival was calculated from the number of single cells 
that formed colonies of more than 50 cells. 
 
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
181 
 
5.4. Cellular uptake studies 
The cellular metal uptake was determined as described according to a previously 
described method.43 Briefly, for the cellular uptake into HepG-2 human liver cancer 
cells, the cells were cultured until at least 80% confluence in 75 cm2 flasks. Stock 
solutions of gold complexes in sterile DMSO were prepared and diluted with cell 
culture medium to a final concentration of 2 μM (freshly prepared, final DMSO 
concentration of 0.1 % v/v). The cell culture medium was replaced by the fresh 
medium containing the gold complexes, and the flasks were incubated at 37 °C and 5% 
CO2 for 1, 2 and 4 h. After the desired incubation period, the cellular uptake was 
stopped by removing the cell culture medium. The cells were washed with PBS (10 
mL), and then the pellets were collected after 10 min of trypsinization (0.05% 
trypsin-EDTA solution (10 mL) and centrifugation (room temperature; 1,500 rpm, 5 
min). Cells were resuspended in Mili-Q water (1 mL) and lysed by sonication for 30 s. 
The protein contents of lysates were determined by the Bradford method. 100 μL of 
samples were digested in 300 μL of 70 % HNO3 at 70 °C for 2 h and room 
temperature overnight, then diluted 1:100 in ultrapure water for inductively coupled 
plasma atomic emission spectroscopy (ICP-AES) analysis. Results were calculated 
from the data obtained from three independent experiments and are expressed as 
microgram of gold per milligram of protein. 
 
5.5. Inhibition of mammalian TrxR 
To determine the inhibition of mammalian TrxR, an established microplate 
reader-based assay was performed with minor modifications.101b For this propose, 
commercially available rat liver TrxR (from Sigma-Aldrich) was used and diluted 
with distilled water to achieve 3.5 U/mL. Gold complexes were freshly dissolved as 
stock solution in sterile DMSO. 25 μL aliquot of the enzyme and either 25 μL 
potassium phosphate buffer (pH 7.0) containing gold complexes in graded 
concentrations or 25 μL buffer without the complex but DMSO (positive control) 
were added. The resulting solution (final DMSO concentration of 0.5 % v/v) was 
incubated at 37 °C for 75 min with moderate shaking in a 96-well plate. To each well, 
225 μL of the reaction mixture (1.0 mL reaction mixture consists of 500 μL 100 mM 
potassium phosphate buffer pH 7.0, 80 μL 100 mM EDTA solution pH 7.5, 20 μL 0.2 % 
BSA, 100 μL of a 20 mM NADPH and 300 μL distilled water) was added and the 
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reaction was initiated immediately by adding 25 μL of 20 mM DTNB solution. After 
thorough mixing, the formation of TNB was monitored by a microplate reader at 405 
nm at 1 min intervals for 10 measurements. The increase of TNB concentration over 
time followed a linear tendency (r2 ≥ 0.99), and the enzymatic activities were 
calculated as the slopes (increase in absorbance per second) thereof. Non-interference 
with the assay components was confirmed by a negative control experiment using an 
enzyme-free test compound. IC50 values were calculated as the concentration of the 
compound decreasing the enzymatic activity of the untreated control by 50%. 
 
5.6. Cellular activity of reducing agents present in cells 
The cellular activity of reducing agents present in the cell was determined 
according to a previously described method.128 Cells were counted and seeded at 
2x105 per well in 6-well plates and incubated for 24 h. Gold complexes were freshly 
dissolved as stock solution in sterile DMSO, and the stock solution was diluted with 
cell culture medium to graded concentrations (final DMSO concentration of 1 % v/v). 
The cell culture medium was replaced by fresh medium containing gold complexes, 
and the plates were incubated for 1 h at 37 °C and 5% CO2. Afterwards, the cells were 
washed with PBS for three times, and 100 μL of cold lysis buffer (50 mM phosphate 
buffer, pH 7.4, 1 mM EDTA, 0.1 % Triton-X 100) were added to the plates. Cell lysis 
was carried out on ice for 5 min and the cell lysates were collected and stored at 
-80 °C. The protein contents of lysates were determined by the Bradford method. 
Then cell lysates (10 μg) were added to 100 μL of reaction buffer (50 mM phosphate 
buffer, pH 7.4, 1 mM EDTA and 0.2 mM NADPH). Finally, 5,5’-dithiobis 
(2-nitrobenzoic acid) (DTNB, final concentration of 3 mM) was added to initiate the 
reaction and the cellular activity of reducing agents was determined as increases in 
O.D. 410 nM in 10 min. All the results were calculated from data obtained in three 
independent experiments. 
 
5.7. Measurement of intracellular reactive oxygen species (ROS) 
For N-acetyl-cysteine (NAC) and reduced glutathione (GSH) treatment, the cells 
were pre-treated with different concentrations of NAC and GSH (2, 5 and 10 mM) for 
1 h, then gold complexes (1 μM) were added for an additional 24 h. After incubation, 
cells were incubated at 37 °C and 5% CO2 with 25 μL MTT solution (5 mg/mL; 
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Sigma-Aldrich) in 24-well plates for approximately 3 h. The cytotoxicity was 
determined as described above. 
The cellular ROS generation was shown by the increase of fluorescence intensity of 
DCF according to a previously reported protocol.129 Briefly, PC-3, T24 and HepG-2 
cells were seeded at a density of 50,000 cells/well in 24-well plates for 24 h. Cells 
were washed with PBS buffer and stained with DCFH-DA (final concentration 20 μM) 
for 45 min. Then cells were washed with PBS buffer and the culture medium without 
phenol red containing gold complexes was added to the cells. The fluorescence 
intensity of DCF (excitation/emission, 485/535 nm) was measured by fluorescence 
microplate reader at different time points. Data are presented as means ± SEM of 
three independent experiments. *p<0.05, **p<0.005, ***p<0.001, compared with 
ROS generation at 0 h. 
 
5.8. Measurement of intracellular superoxide anion (O2
-.) 
To determine reactive oxygen species (ROS) generation, an established 
microplate-reader-based assay was performed with minor modifications.130 Cells were 
counted and seeded at 50,000 per well in 24-well plates. The compounds were freshly 
dissolved as stock solution in sterile DMSO, and the stock solution was diluted with 
cell culture medium to graded concentrations. (final DMSO concentration of 0.5 % 
v/v). After 24 h of incubation at 37 oC and 5% CO2, the cell culture medium was 
replaced by fresh medium containing gold complexes, and the plates were incubated 
for different period of time (0 h, 3 h, 6 h and 24 h). 250 μL of nitroblue tetrazolium 
solution (NBT, 1 mg/mL) in PBS were added to the plates after removal of medium. 
After 4 h of incubation, the supernatant NBT solution was discarded. Then the 
reduced formazan was dissolved by 360 μL of 2 M KOH followed by 400 μL of 
DMSO and quantified by spectrophotometry with a microplate reader at 620 nm 
absorbance using KOH/DMSO as a blank. All the results were calculated from data 
obtained in three independent experiments.  
 
5.9. Measurement of intracellular hydrogen peroxide (H2O2) 
Cells were counted and seeded at 50,000 per well in 24-well plates. The compounds 
were freshly dissolved as stock solution in sterile DMSO, and the stock solution was 
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diluted with cell culture medium to graded concentrations. (final DMSO concentration 
of 0.5 % v/v). After 24 h of incubation at 37 oC and 5% CO2, the cell culture medium 
was replaced by fresh medium containing gold complexes, and the plates were 
incubated for different period of time (0 h, 3 h, 6 h and 24 h). 500 μL of 
3,3’-diaminobenzidine solution (DAB, 2.5 mM) in potassium phosphate buffer were 
added to the plates after removal of medium. After 4 h of incubation, ROS generation 
was quantified by spectrophotometry with a microplate reader at 405 nm absorbance. 
All the results were calculated from data obtained in three independent experiments. 
 
5.10. Antileishmanial evaluation 
Leishmania species used in this study were Leishmania infantum 
MHOM/MA/67/ITMAP-263 (CNR Leishmania, Montpellier, France) expressing 
luciferase activity. 
 
5.10.1. Antileishmanial activity on promatisgotes 
The effects of the tested compounds on the growth of L. infantum promastigotes were 
assessed by Luciferase Assay like previously described.113a Briefly, promastigotes in 
log-phase in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 
2 mM l-glutamine and antibiotics (100U/mL penicillin, 100 μg/mL streptomycin and 
50 μg/mL geneticin), were incubated at a density of 106 parasites/mL in sterile 96-well 
plates with various concentrations of compounds dissolved in DMSO (final 
concentration less than 0.5% v/v), in duplicate. Appropriate controls treated by DMSO, 
amphotericin B, miltefosine and pentamidine (reference drugs purchased from Sigma 
Aldrich) were added to each set of experiments. After a 72 h of incubation period at 
24 °C, each plate-well was then microscope-examined for detecting possible 
precipitate formation. To estimate the luciferase activity of promastigotes, 80 μl of each 
well are transferred in white 96-well plates, Steady Glow reagent (Promega) was added 
according to manufacturer's instructions, and plates were incubated for 2 min. The 
luminescence was measured in Microbeta Luminescence Counter (PerkinElmer). 
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Inhibitory concentration 50% (IC50) was defined as the concentration of drug required 
to inhibit by 50% the metabolic activity of L. infantum promastigotes compared to the 
control. IC50 were calculated by non-linear regression analysis processed on 
dose–response curves, using TableCurve 2D V5 software. IC50 values represent the 
mean value calculated from three independent experiments. 
 
5.10.2. Antileishmanial activity on axenic amastigotes 
Here, we described a new method to generate axenic amastigotes. For this, 
L. Infantum promastigotes in logarithmic phase were centrifuged at 900 g for 10 min, 
the supernatant was removed carefully and was replaced by the same volume of RPMI 
1640 complete medium at pH 5.4 and incubated for 24 h at 24 °C. The acidified 
promastigotes were incubated 24 h at 37 °C in a ventilated flask. Then promastigotes 
were altered to amastigotes form. 
The effects of the tested compounds on the growth of L. infantum axenic amastigotes 
were assessed in the following way. L. Infantum amastigotes were incubated at a 
density of 1.106 parasites/mL in sterile 96-well plates with various concentrations of 
compounds dissolved in DMSO (final concentration less than 0.5% v/v), in duplicate. 
Appropriate controls treated by DMSO, amphotericin B, miltefosine and pentamidine 
(reference drugs purchased from Sigma Aldrich) were added to each set of experiments. 
After a 48 h incubation period at 37 °C, each plate-well was then microscope-examined 
for detecting possible precipitate formation. To estimate the luciferase activity of 
promastigotes, 80 μl of each well are transferred in white 96-well plates, Steady Glow 
reagent (Promega) was added according to manufacturer's instructions, and plates were 
incubated for 2 min. The luminescence was measured in Microbeta Luminescence 
Counter (PerkinElmer). Inhibitory concentration 50% (IC50) was defined as the 
concentration of drug required to inhibit by 50% the metabolic activity of L. infantum 
amastigotes compared to the control. IC50 were calculated by non-linear regression 
analysis processed on dose–response curves, using TableCurve 2D V5 software. IC50 
values represent the mean value calculated from three independent experiments. 
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5.11. Cytotoxicity evaluation 
The evaluation of the tested molecules cytotoxicity by MTT assay on the J774A.1 
cell line (mouse macrophage cell line, Sigma–Aldrich) was done according like 
previously described.113a Briefly, cells (5 × 104 cells/mL) in 100 μL of complete 
medium, [DMEM high Glucose supplemented with 10% fetal calf serum (FCS), 2 mM 
l-glutamine and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin)] were 
seeded into each well of 96-well plates and incubated at 37 °C and 5% CO2. After a 24 
h incubation, 100 μL of medium with various product concentrations and appropriate 
controls treated by DMSO, amphotericin B, miltefosine, doxorubicine and pentamidine 
(reference drugs purchased from Sigma Aldrich) were added and the plates were 
incubated for 72 h at 37 °C and 5% CO2. Each plate-well was then 
microscope-examined for detecting possible precipitate formation before the medium 
was aspirated from the wells. 100 μL of MTT solution (0.5 mg/mL in RPMI) were then 
added to each well. Cells were incubated for 2 h at 37 °C and 5% CO2. After this time, 
the MTT solution was removed and DMSO (100 µl/well) was added to dissolve the 
resulting formazan crystals. Plates were shaken vigorously (300 rpm) for 5 min. The 
absorbance was measured at 570 nm with a microplate spectrophotometer (Eon 
BioTek). DMSO was used as blank. CC50 were calculated by non-linear regression 
analysis processed on dose–response curves, using TableCurve 2D V5 software. CC50 
values represent the mean value calculated from three independent experiments.  
 
5.12. Photodynamic activity 
A colormetric assay using MTT was used to compare the cytotoxicity of the 
complexes in the dark and upon UV irradiation. T24, PC-3 and non-cancerous 
NIH3T3 cell lines were seeded in 24-well plates at a density of 10,000 cells per well 
in 500 μL, 24 h prior to treatment. The cells were then treated with increasing 
concentrations of iridium complexes (from 0.01 μM to 20 μM) for 48 h. For 
photocytoxicity studies, the cells were treated for 4 h with increasing concentrations 
of the compounds in the dark. After that, the medium was removed and replaced by 
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fresh culture medium prior to 10 min irradiation at 365 nm (4 W). After 44 hours of 
incubation, cells were incubated at 37 oC and 5% CO2 with 25 μL MTT solution (5 
mg/mL; Sigma-Aldrich) in 24-well plates for approximately 3 h. After solubilization 
with 500 μL of lysis buffer (DMSO), formazan was quantified by spectrophotometry 
with a microplate reader at 570 nm absorbance. The GI50 values corresponding to the 
concentration that caused 50% inhibition of cell proliferation were calculated from 
dose-response curves obtained by nonlinear regression analysis (Prism 5, Graphpad 
Software). All the results were calculated from data obtained in three independent 
experiments.131 
  
Metal-NHC Complexes for Anti-Cancer Applications: 
Gold(I) for Antimitochondrial Activity and Iridium(III) for Photodynamic Therapy 
188 
 
Bibliography 
1. Martell, A.; Hancock, R., Modern Inorganic Chemistry; ed. JP Fackler jun. Plenum Press, 
New York: 1996. 
2. (a) Berners-Price, S. J.; Sadler, P. J., Coordination chemistry of metallodrugs: insights 
into biological speciation from NMR spectroscopy. Coord. Chem. Rev. 1996, 151, 1-40; (b) 
Stochel, G.; Wanat, A.; Kuliś, E.; Stasicka, Z., Light and metal complexes in medicine. Coord. 
Chem. Rev. 1998, 171, 203-220. 
3. Bertini, I.; Gray, H. B.; Lippard, S. J.; Valentine, J. S., Bioinorganic chemistry. 
University Science Books: 1994. 
4. Rosenberg, B.; Vancamp, L.; Trosko, J. E.; Mansour, V. H., Platinum compounds: a new 
class of potent antitumour agents. Nature 1969, 222 (5191), 385-386. 
5. Wheate, N. J.; Walker, S.; Craig, G. E.; Oun, R., The status of platinum anticancer drugs 
in the clinic and in clinical trials. Dalton Trans. 2010, 39 (35), 8113-8127. 
6. Eastman, A., The formation, isolation and characterization of DNA adducts produced by 
anticancer platinum complexes. Pharmacol. Ther. 1987, 34 (2), 155-166. 
7. Sadler, P. J.; Guo, Z., Metal complexes in medicine: design and mechanism of action. 
Pure Appl. Chem. 1998, 70 (4), 863-871. 
8. (a) Liu, W.; Gust, R., Metal N-heterocyclic carbene complexes as potential antitumor 
metallodrugs. Chem. Soc. Rev. 2013, 42 (2), 755-773; (b) Oehninger, L.; Rubbiani, R.; Ott, I., 
N-Heterocyclic carbene metal complexes in medicinal chemistry. Dalton Trans. 2013, 42 (10), 
3269-3284; (c) Aher, S. B.; Muskawar, P. N.; Thenmozhi, K.; Bhagat, P. R., Recent 
developments of metal N-heterocyclic carbenes as anticancer agents. Eur. J. Med. Chem. 2014, 
81, 408-419; (d) Liu, W.; Gust, R., Update on metal N-heterocyclic carbene complexes as 
potential anti-tumor metallodrugs. Coord. Chem. Rev. 2016, 329, 191-213. 
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